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ABSTRACT
Transcription factor (TF) proteins act as molecular mechanisms that modulate the
initiation of the first step in the expression of genes, gene transcription. Currently,
knowledge of the DNA-binding specificities and genes regulated by many TFs, including
those of well-studied model organisms such as Escherichia coli and Thermus
thermophilus, remains incomplete or lacking which renders gaps in the understanding of
the regulatory networks and systems biology of many organisms. Cyclic-AMP receptor
protein (CRP) regulators and fumarate and nitrate reduction regulator (FNR) proteins
compose the CRP/FNR superfamily of TFs, a diverse subgroup of TFs in bacteria which
regulate various gene expression programs. In the present work, a reverse-genetic
technique involving the combinatorial selection technique Restriction Endonuclease
Protection, Selection, and Amplification (REPSA) has been applied to study TTHA1359,
one of the four CRP/FNR superfamily TFs in the model organism T. thermophilus HB8.
A TTHA1359-binding consensus, 5’-A(T/A)TGT(G/A)A(N6)T(C/T)ACA(A/T)T-3’, was
identified using REPSA to select DNA sequences that TTHA1359 preferentially binds,
massively parallel sequencing to acquire the sequence information of these selections,
and bioinformatics to discover TTHA1359-binding motifs from the acquired sequence
information. TTHA1359-binding to the identified consensus was biophysically
characterized, and TTHA1359 was found to bind the identified consensus with high
affinity, KD of ~ 3.4 nM. Several potential regulatory binding sites for TTHA1359 were
identified bioinformatically by mapping the TTHA1359-binding consensus to the T.
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thermophilus HB8 genome. The findings of the present work should not only contribute
to the knowledge of the DNA-binding specificity and genes regulated by TTHA1359 but
also provide insight into the functionality of the applied reverse-genetic technique that
should guide its future application to study other TFs.
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CHAPTER 1. INTRODUCTION
Chapter 1.1 Bacterial Transcription Factors
Gene expression in prokaryotic and eukaryotic organisms begins with gene
transcription, and in most prokaryotes and eukaryotes, substantial regulation of gene
expression transpires during the initiation, elongation, and termination steps of gene
transcription. Although many molecular mechanisms mediate this regulation,
transcription factor (TF) proteins act as a major mechanism of regulating transcription
initiation, binding to DNA and changing rates of gene transcription initiation from
promoters, the sequences positioned upstream of genes where transcription initiation
transpires.
Bacterial TFs function as critical constituents of signal transduction networks,
sensing cellular and environmental conditions and appropriately altering the
transcriptional program. Most bacterial TFs possess two structural domains: a DNAbinding domain that recognizes specific DNA sequences and a second domain that
regulates the activity of the DNA-binding domain.1,2 For some TFs, the secondary
domain directly perceives cellular or environmental conditions through the binding of
ligands, perhaps small molecules or metabolites, and adjusts the activity of the DNAbinding domain accordingly.3 For other TFs, the secondary domain indirectly senses this
information through an interaction with a partner protein.3
Bacterial TFs act as global or local regulators depending on several aspects
associated with their activities including the number of genes and the functional diversity
1

of the genes they regulate.4 Generally, global TFs regulate the expression of many genes
while local TFs regulate the expression of one to a few genes.4 Some TFs solely function
as activators, upregulating gene transcription, or as repressors, downregulating gene
transcription. Other TFs function as both, up- or downregulating gene transcription
depending on different promoter contexts. Mechanistically, repressors can downregulate
transcription by inhibiting RNA polymerase holoenzymes, the transcriptional machinery,
from binding at promoters by inducing structural changes in DNA to block access to
promoters or by binding promoter sequences overlapping those the holoenzymes
recognize such as the -35 and -10 core promoter sequence elements.5 Activators can
upregulate transcription by distorting promoter sequences to improve suboptimal spacing
between core promoter elements or by interacting directly with both promoter sequences
and RNA polymerase holoenzymes to recruit the transcriptional machinery to promoters.6
In addition to these mechanisms, repressors can counter activators to downregulate
transcription, and conversely, activators can antagonize repressors to upregulate
transcription.7
Knowledge of the DNA-binding specificities and the genes regulated by bacterial
TFs provides insight into not only the regulatory and biological roles of TFs but also the
transcriptional regulatory networks and systems biology of bacteria. This knowledge,
however, remains incomplete or lacking for many TFs in most, even model, bacteria. For
example, ~ 100 of the ~ 300 encoded TFs within the ~ 4,300 genes of the well-studied
model bacteria Escherichia coli K-12 lack as little evidence as a single TF binding
site.1,8-10 Even for Thermus thermophilus HB8, a model thermophilic bacteria with as few
as ~ 2,200 genes and ~ 70 encoded TFs, DNA-binding specificities, genes regulated, and
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biological functions have been discovered for only a handful.11-22 Therefore, continuing
to study bacterial TFs, discovering the DNA sequences they recognize, genes they
regulate, and their regulatory as well as biological functions, is essential if the
transcriptional regulatory networks and systems biology of E. coli, T. thermophilus, and
other bacteria is to be fully comprehended.
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Chapter 1.2 Functional Characterization of Bacterial Transcription Factors
Genomic screens and bioinformatic analyses initially identify and classify
bacterial TFs into families based on primary sequence similarities with previously
characterized DNA-binding domains, the helix-turn-helix motif being the most common.1
Typically, each family is named after its founding family member, and the functions of
TFs assigned to a family are inferable from the function of the founding member or other
characterized members of the family. However, not every family member behaves or
regulates the same biological processes as the founding member or other members of the
family. Therefore, an experimental exploration of their DNA-binding specificities and the
genes they regulate is required to understand their regulatory and biological roles.
Many in vivo and in vitro methods have been developed or adapted for such
purposes, identifying DNA-binding specificities and regulated genes from various
genetic, biological, biochemical, or biophysical perspectives. For example, in vitro
techniques can identify the DNA-binding affinity and specificity of a TF, how tightly a
single DNA sequence is bound and how effectively DNA sequences are differentiated by
a TF respectively.23 This specificity is frequently modeled as a position weight matrix
(PWM) which in turn is often graphically depicted as a sequence logo.24,25 This logo
illustrates a TF’s relative preference for each base at positions within its binding site and
provides a tool to search a genome and identify potential regulatory binding sites and the
genes the TF regulates. Alternatively, in vivo techniques attempt to identify the genes a
TF regulates using more straightforward approaches such as directly isolating TFs bound
4

at promoters. They are particularly useful when the regulatory activity of a TF is to be
studied during defined developmental stages or under various environmental conditions
since they can indicate which binding sites are occupied by the TF under these
conditions. Here, several classical and contemporary techniques applied to study the
DNA-binding specificities and the genes regulated by TFs have been summarized.
The electrophoretic mobility shift assay (EMSA) is one of the oldest techniques
applied to study protein-DNA interactions, probing these interactions by taking
advantage of the impeded electrophoretic mobility of DNA complexed with protein
compared to free DNA.26,27 In a traditional EMSA, labeled DNA is incubated with
protein to attain chemical equilibrium before native, or non-denaturing, polyacrylamide
gel electrophoresis (PAGE) is performed followed by detection of the labeled DNA.28
Binding interactions between the DNA and protein slows DNA movement through the
gel which yields an observable gel band shift.28 The traditional EMSA tolerates a
spectrum of experimental parameters, and variations on the traditional EMSA further
extend its applicational scope.28 However, EMSA is not without drawbacks which
include the effects of the gel matrix environment on the stability of protein-DNA
complexes and the discontinuity of binding equilibrium upon electrophoresis.28
Footprinting, another classic in vitro technique, investigates the DNA-binding
specificities of ligands such as TFs by taking advantage of the local cleavage protection
ligands confer to the DNA sequences they bind compared to those they do not.29-31 In a
typical footprinting assay, test and control reactions are performed in which a cleavage
agent digests a singly end-labeled DNA probe containing potential ligand-binding sites in
the presence and absence of a DNA-binding ligand respectively.30,31 The DNA probe in
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the control reaction is randomly digested, but the DNA probe in the test reaction is
selectively cleaved because the ligand shields bound sites from cleavage.30,31
Consequently, after resolving test and control reaction products by PAGE, bound sites are
identified by comparing the gel band pattern of the two reactions for bands that are
missing in the test reaction pattern.30,31 The sequences of these missing bands are then
determined by comparing missing band locations with sequencing reaction products.30,31
In contrast to EMSA, footprinting assays permit ligand-DNA interactions to be studied at
binding equilibria, but EMSA is typically less difficult to perform since footprinting
requires optimizing both ligand-binding and DNA-cleavage reactions to acquire the
footprint signal.28,30,31 Additionally, gel resolution restricts the size of the footprinting
DNA probe, affecting the number of potential binding sites screened during a single
assay.30
In some bacteria, straightforward genetic approaches involving the manipulation
of TF genes can be applied to identify the potential genes regulated by TFs.11-14,17,32
These approaches rely on gene expression level changes, measured as changes in RNA
transcript levels, caused by the overexpression, deletion, or inactivation of TF genes to
identify the genes that TFs regulate. Genetic engineering techniques are initially applied
to manipulate the genes that encode a TF, creating a mutant bacterial strain.11,12,32 Mutant
and wild-type strains are then cultured, and the RNA transcripts expressed by each strain
are extracted.11,12,32 These transcript samples are reverse transcribed to form
complementary DNA (cDNA) sequences and uniquely labeled.11,12,32 Equivalent
concentrations of labeled RNA or cDNA from each strain are exposed to a DNA
microarray which has been spotted with single-stranded DNA sequences representing
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individual genes from the wild-type strain and are permitted to hybridize with these
spotted DNA microarray sequences.11,12,32 Hybrid cDNA-DNA complexes are then
detected and compared for each strain to reveal the changes in gene expression caused by
manipulating the genes encoding the TF and the potential genes regulated by the
genetically manipulated TF (Figure 1).11,12,32 These approaches provide in vivo views into
the regulatory activity of TFs and are applicable to studying the genes regulated by TFs
during specific developmental stages or under different environmental growth conditions.
However, several factors complicate the results obtained using these approaches.
Overexpressing TFs can yield indiscriminate gene regulation due to nonspecific DNAbinding. Deleting or inactivating TF genes can lead to the detection of false positives,
resulting from the manipulated TF regulating one or more other TFs, and false negatives,
resulting from minor changes in RNA transcript levels or from genes coregulated by
multiple TFs. Additionally, not all bacteria have the required genetic tools to apply these
approaches, and in bacteria with multiple genome copies, deleting or inactivating all
genes encoding TFs can be challenging.
Chromatin immunoprecipitation (ChIP) is an alternative in vivo technique that can
be applied to identify the binding sites of bacterial TFs and the genes they regulate by
directly isolating genomic TF-DNA complexes for analysis.33,34 In a typical ChIP assay,
bacteria are cultivated then chemically treated with formaldehyde to reversibly cross-link
genomic TF-DNA complexes.33 After extracting and fragmenting genomic DNA by
sonication, TF-specific antibodies are utilized to immunoprecipitate TF-DNA complexes
of interest.33,34 Genomic DNA sequences bound to the TF are freed by reversing TF-DNA
complex cross-linkages and are subsequently sequenced along with genomic control
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Figure 1. Identifying the genes regulated by a TF through a genetic approach. Steps in a genetic approach involving the inactivation of the genes

encoding a TF to identify the genes it regulates have been depicted. These steps include (i) cultivation of bacteria, (ii) isolation of RNA transcripts,
(iii) reverse transcription and fluorescent labeling, (iv) microarray hybridization, and (v) scanning and data analysis. Spots considered significant
or those with differential gene expression, green and red spots, are used to identify the genes regulated by the TF. Green spots, genes with higher
expression in wild-type bacteria, indicate the genes potentially upregulated by the TF, and red spots, genes with higher expression in mutant

bacteria, indicate the genes potentially downregulated by the TF.
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DNA by microarray (ChIP-chip) or high-throughput sequencing (ChIP-seq).33,34 Similar
to the previous genetic approaches, ChIP assays can capture snapshots of the genes that
TFs regulate during distinct developmental stages or under specific environmental
conditions, but they can also provide a robust in vivo indication of the genes actually
regulated by a TF since isolated DNA sequences contain TF-binding sites. While ChIP
assays possess limitations, including the required quantity of cells for experiments and
the poor resolution of TF-binding sites, ChIP techniques continue to be developed that
improve upon the aspects of the standard assay, reducing these experimental
limitations.35,36 However, being an immunoprecipitation technique, ChIP assays require
TF-specific antibodies or genetically tagging the genes of TFs with epitopes for which
specific antibodies exist which often requires additional time and expense.33,34
Protein-binding microarray (PBM) assays offer a high-throughput in vitro method
for identifying the DNA-binding specificities of TFs and other DNA-binding
proteins.37,38 A PBM assay, as its name suggests, utilizes a DNA microarray spotted with
double-stranded DNA sequences. Purified TF, native or epitope-tagged, is exposed to
microarray sequences, enabling the formation of TF-DNA complexes.37,38 These TFDNA interactions are detected and quantified using TF- or epitope-specific antibodies
linked to single fluorophores, revealing the DNA sequences preferentially bound by a TF
as a measure of fluorescence intensity.37,38 Currently, a universal PBM is available for
screening TF sequence specificity, encompassing the variation of every predicted 10-base
pair (bp) sequence.38,39 While extensive, some TFs recognize DNA sequences longer than
10 bp, rendering it difficult to comprehensively identify their DNA-binding specificities
using PBMs.39 Additionally, some TFs require cofactors, post-translational modifications,
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or interactions with partner proteins to bind DNA specifically which complicates using
PBMs to identify their specificities.39
Combinatorial in vitro selection methods, including systematic evolution of
ligands by exponential enrichment (SELEX), selected and amplified binding (SAAB),
and cyclic amplification and selection of targets (CASTing), can also be applied to
identify the DNA-binding specificities of TFs.40-43 These techniques typically use ligands
such as TFs in repetitive nucleic acid selection, isolation, and amplification cycles to
elucidate ligand-nucleic acid specificity.40-43 In these methods, a ligand is initially
incubated with a nucleic acid selection template library containing randomized nucleic
acid sequences for probing preferred ligand binding.40-43 An affinity- or physical-based
technique is then applied to separate ligand-nucleic acid complexes formed during the
incubation from unbound sequences.40-43 These complexed nucleic acids are then
amplified and utilized as the input nucleic acid for a subsequent cycle.40-43 Repeating
these steps enriches for nucleic acid sequences preferentially bound by the ligand (Figure
2).40-43 These techniques have yielded useful binding information for an assortment of
ligands, and additional adaptations and variations, SELEX serial analysis of gene
expression (SELEX-SAGE) and high-throughput SELEX (HT-SELEX) for example,
have expanded the utility of these techniques as research tools in biochemistry and
molecular biology.44,45 However, the affinity- or physical-based steps used to separate
complexed from free nucleic acid present potential obstacles when studying some ligand-
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Figure 2. Selecting preferred ligand-binding DNA sequences by cyclic amplification and
selection of targets (CASTing). Steps in CASTing have been depicted as a representative
illustration of general combinatorial selection technique methodology. These include (i) complex
formation, (ii) antibody association, (iii) complex purification, (iv) PCR amplification, and (v)

repetition steps to not only select but also enrich for sequences that a ligand preferentially binds.
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nucleic acid interactions, particularly when minute differences in physical properties exist
between complexed and free sequences and when ligands lack the amenability of an
affinity-based separation approach.
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Chapter 1.3 Identifying Preferred DNA-binding by Restriction Endonuclease
Protection, Selection, and Amplification
Pioneered by the Van Dyke Laboratory, restriction endonuclease protection,
selection, and amplification (REPSA) is an alternative in vitro combinatorial selection
method that can be applied to identify the binding specificities of TFs.46 REPSA selects
the DNA sequences a ligand preferentially binds using a methodology like that of other
combinatorial selection techniques, but this technique relies on ligand-dependent
protection of bound DNA sequences from cleavage by type IIS restriction endonucleases
(IISREs) to select preferred DNA-binding sequences and eliminate rejected sequences.46
Independent DNA recognition and cleavage domains enable IISREs to recognize
DNA with sequence specificity yet non-specifically cleave DNA at a defined distance
and, typically, in an asymmetric direction from the recognition site.47 REPSA exploits
these distinctive cleavage properties by utilizing a double-stranded DNA selection
template containing a randomized internal DNA core and defined flanking sequences
with IISRE recognition sites that are oriented so that cleavage occurs within the
randomized core (Figure 3).46 Thus, unlike other combinatorial selection techniques,
REPSA does not require a physical- or affinity-based step to separate selected and
rejected template sequences because IISREs are used to eliminate rejected sequences
which remain vulnerable to cleavage due to lack of ligand binding.46
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Figure 3. Type IIS restriction endonucleases and selection template ST2R24 structure in REPSA. (A) Selected IISREs used in
REPSA with respective asymmetric distances to cleavage sites. (B) Structure of the selection template ST2R24 used in REPSA

containing standard template 2 (ST2) flanks and a randomized 24-bp (R24) core. Brackets indicate respective IISRE recognition
sequences within ST2 flanks. Arrows indicate corresponding IISRE cleavage sites within the randomized template core.
Horizontal arrows represent primer sequences used to PCR amplify templates. Asterisks indicate the presence of a single IRDye
700 fluorophore label at the 5’-end of primer ST2R and selection template ST2R24. N represents a random nucleotide.
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A round of REPSA involves several steps: the incubation of a DNA selection
template library with a ligand to form ligand-DNA complexes, IISRE cleavage of
unbound selection templates, and amplification of ligand-bound templates by PCR for the
subsequent round of REPSA (Figure 4).46 Repetition of REPSA continues until the
detected enrichment of ligand-preferred DNA-binding sequences.46 Highlighting its
utility as a research tool, REPSA has been applied to identify the DNA-binding
specificities for ligands including small molecules, oligonucleotides, and proteins
including TFs.19-22,48-53 However, selecting low and high affinity sequences as well as
intermediate affinity sequences to inclusively identify ligand-binding specificity using
REPSA requires the optimization of both ligand-binding and IISRE cleavage reaction
parameters.46 Additionally, REPSA often requires switching from the use of one IISRE to
another between rounds to reduce the selection of sequences recognized by IISREs.46,48
Due to differences in the DNA-binding kinetics and cleavage efficiencies of IISREs, this
typically requires optimizing REPSA reaction parameters at least twice if not more.
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Figure 4. Selecting preferred ligand-binding DNA sequences by restriction endonuclease
protection, selection, and amplification (REPSA). REPSA involves (i) complex formation, (ii)
IISRE cleavage, (iii) PCR amplification, and (iv) repetition steps to select and enrich for
sequences that a ligand preferentially binds.
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Chapter 1.4 The CRP/FNR Transcription Factor Superfamily
Cyclic adenosine monophosphate (cAMP) receptor protein (CRP) regulators and
fumarate and nitrate reductase regulatory (FNR) proteins together compose the CRP/FNR
superfamily of TFs that primarily activate gene expression programs in response to a
spectrum of cellular and environmental signals.54 Members of the superfamily are
structurally characterized by a C-terminal domain with a helix-turn-helix DNA-binding
motif and large N-terminal domain that typically binds a ligand or cofactor.54
Currently, most insight into the CRP/FNR superfamily derives from research on the
founding and representative members of the superfamily, E. coli CRP (CRPEc) and FNR
(FNREc).
CRPEc is a two hundred and nine residue protein with a C-terminal helix-turnhelix DNA-binding domain and an N-terminal domain with a binding site for cAMP.55,56
This site functions as the primary cAMP-binding site while a site that lies between the Nand C-terminal domains functions as a secondary binding site for cAMP.55 These binding
sites possess respective micromolar and millimolar affinity for cAMP.57-59 The active
DNA-binding form of CRPEc is a dimer with cAMP bound at the primary binding site of
each monomer.57-59 By comparison, cAMP-free CRPEc dimer and CRPEc dimer with
cAMP bound at both primary and secondary binding sites have significantly reduced
DNA-binding activity.57-59 CRPEc acts primarily as a global activator in E. coli that binds
and directly upregulates the transcription initiation rate of hundreds of genes generally
associated with the movement and metabolism of alternative carbon sources.4,60,61
17

Currently, two hundred and seventy-one binding sites are listed for CRPEc in RegulonDB,
a database repository for information on gene expression regulatory networks in E. coli.10
Extracting and submitting these sequences to the online motif analysis program Multiple
Em for Motif Elicitation (MEME) yields the DNA-binding consensus motif of CRPEc
(Figure 5A1).10,62 CRPEc recognizes 22-bp stretches of DNA and exhibits high affinity for
its 22-bp consensus sequence (Figure 5A2).63
FNREc, is a two hundred and fifty residue protein with a C-terminal helix-turnhelix DNA-binding domain and an N-terminal domain that senses intracellular redox
conditions through interactions with iron-sulfur clusters.64-68 FNREc switches between an
inactive conformation as a monomer and an active conformation as a homodimer
depending on the oxidative state of E.coli.65-68 Aerobic conditions promote the inactive
monomer conformation while anaerobic conditions promote the active homodimer
conformation by reducing and oxidizing the state of the associated iron-sulfur cluster
respectively.65-68 Active FNREc functions as a global regulator that primarily activates the
transcription of genes associated with anaerobic energy metabolism and to a lesser extent
represses genes associated with aerobic energy metabolism.4,69-72 Currently, eighty-eight
binding sites are listed in RegulonDB for FNREc.10 Extracting and submitting these
sequences to MEME for motif analysis as with CRPEc yields the DNA-binding consensus
motif of FNREc (Figure 5B1).10,62 Its minimal 14-bp consensus sequence shares
similarities with that of CRPEc (Figure 5B2).73,74
As mentioned previously, TFs can mechanistically activate transcription at
promoters by binding promoter DNA and directly engaging RNA polymerase
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Figure 5. DNA-binding consensus motifs and sequences for the transcription
factors CRPEc and FNREc. (A) CRPEc and (B) FNREc consensus motifs (1) and
consensus sequences (2). Consensus motifs, represented as sequence logos, were
obtained from MEME analysis of the currently listed binding sites for CRPEc and
FNREc in RegulonDB.10
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holoenzymes to recruit the transcriptional machinery. 75 The two simplest forms of the
mechanism, termed Class I and Class II transcriptional activation, require only one TF
bound at a single site for activation.75 This terminology was initially applied to describe
simple CRPEc-dependent activation mechanisms at promoters and now extends to
describe the activation mechanisms of other TFs. 6,75
A TF that promotes transcription from a binding site positioned upstream of the
-35 core promoter element activates through the Class I mechanism, engaging the Cterminal domain of one or both RNA polymerase holoenzyme α-subunits to upregulate
transcription initiation.75,76 Alternatively, a TF that upregulates transcription from a
binding site that overlaps the -35 core promoter element activates through the Class II
mechanism, primarily contacting the RNA polymerase holoenzyme σ subunit to
upregulate transcription initiation.75,77 Class I and Class II activation efficiency appears
dependent to a significant extent on the spacing of binding sites for TFs relative to core
promoter elements due to the helical nature of duplex DNA.78,79 Studies on TF binding
site spacing have demonstrated that an optimal TF binding site aligns a TF with core
promoter elements along the double helix of DNA and that displacing an optimal TF
binding site by even 1 bp is sufficient to reduce the activation efficiency of a TF.78,79 For
Class I activation, a TF bound at a site centrally positioned approximately 51.5, 61.5,
72.5, 82.5, or 92.5 bp upstream, sites separated by integral turns of the helix, can activate
transcription with the greatest activation efficiency transpiring at positions 61.5 and 72.5
bp upstream.78,79 For Class II activation, the optimal TF binding site corresponds to an
upstream central position at 41.5 bp.78
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Chapter 1.5 CRP/FNR Superfamily Transcription Factors in T. thermophilus HB8
Thermophilic organisms, thriving in environments of extreme heat, constitute a
subgroup of extremophilic organisms, flourishing in environments of at least one
extreme. Characteristically, proteins and enzymes expressed by thermophilic organisms,
such as those expressed by T. thermophilus HB8, possess relatively higher intrinsic
thermostability and function optimally at elevated temperatures, and as a result, they are
of significant interest to biotechnology and industry as well as structural biology.80
Discovered in Japanese thermal spas, gram negative T. thermophilus HB8 can
grow at temperatures as relatively cold as 47° to as hot as 85°C with an optimal growth
temperature range of 65°-72°C.81,82 As a polyploid bacterium, T. thermophilus HB8
maintains multiple copies of a 1.85 mega-bp circular chromosome (TTHA); a 257 kilo-bp
megaplasmid, pTT27 (TTHB); and a 9.3 kilo-bp miniplasmid, pTT8 (TTHC).83 This
bacterium is the subject of the Structural and Functional Whole-Cell Project undertaken
by the research institute RIKEN in Japan (http://thermus.org/).84 This structural genomics
project pursues the structural and functional characterization of all highly ordered T.
thermophilus HB8 proteins with the aim of understanding all the biological phenomena
of this bacterium (see previous link).84 Due to its smaller proteome size, the
thermostability of its proteins, the increased aptitude of its proteins to crystalize, and the
ability to genetically manipulate its genome, T. thermophilus HB8 was selected as the
subject of the project.84
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Screening of the T. thermophilus HB8 genome has identified proteins TTHA1359,
TTHA1437, and TTHB099 as CRP family members and protein TTHA1567 as an NtcA
family member, a family of TFs within the CRP/FNR superfamily functioning in global
nitrogen assimilation in cyanobacteria.54 Currently, regulatory and biological functions
have been assigned to only the CRP family members.11-13,16 A review of these roles for
these proteins has been provided here.
TTHA1437 was the first T. thermophilus HB8 CRP family member studied and
was designated T. thermophilus HB8 CRP due to its primary sequence and biochemical
attributes.11-13,16 It is a two hundred and sixteen residue protein that forms a homodimer
in solution and binds cAMP based on the findings of gel filtration chromatography, light
scattering photometry, and protease sensitivity experiments.11 Inactivating the TTHA1437
genes in T. thermophilus HB8 has no apparent effect on T. thermophilus HB8 growth,
and therefore, the TTHA1437 gene is considered dispensable for the train.11 Six T.
thermophilus HB8 gene promoters are activated by TTHA1437 in a mechanism
dependent on cAMP.11 These gene promoters were initially identified using a genetic
approach involving the inactivation of TTHA1437 genes in T. thermophilus HB8 and the
comparison of gene expression levels for wild-type and TTHA1437-inactivated T.
thermophilus HB8 strains.11 They were then validated using in vitro run-off transcription
assays which demonstrated they were upregulated in a TTHA1437-dependent, cAMPdependent mechanism.11 Genes associated with these promoters were found to encode
clustered regularly-interspaced short-palindromic repeat (CRISPR)-associated (Cas)
proteins, proteins with potential roles in DNA replication and transcriptional regulation,
and several proteins with no known function.11 The DNA-binding consensus 5’-
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(C/T)NNG(G/T)(G/T)C(A/C)N(A/T)NNTCACAN(G/C)(G/C)-3’ was predicted for
TTHA1437 from the sequences of these six gene promoters.11
Currently, TTHA1359 is the most extensively studied T. thermophilus HB8 CRP
family member.11-13,16 It is a two hundred and two residue protein with the alternative
name of stationary phase-dependent regulatory protein (SdrP) due to its elevated gene
transcript level in the stationary phase of T. thermophilus HB8 growth and its function as
a transcriptional regulator.12 Its conformation in solution is a homodimer, and its overall
ligand-free dimeric crystal structure closely resembles that of CRPEc with cAMP
complexed at both primary and secondary cAMP-binding sites.12,55 Inactivating the genes
encoding TTHA1359 in T. thermophilus HB8 slightly impairs the growth of T.
thermophilus HB8 and its ability to cope with oxidative stress.12
TTHA1359 activates sixteen T. thermophilus HB8 promoters whose genes encode
proteins that function in redox control, transcriptional regulation, RNA metabolism, DNA
and protein repair, and the supply of energy and nutrients.12,13 Eight of these gene
promoters were initially identified using a genetic approach involving the inactivation of
TTHA1359 genes in T. thermophilus HB8 and the comparison of gene expression levels
for the wild-type and TTHA1359-inactivated T. thermophilus HB8 strains.12 They were
then validated using in vitro run-off transcription assays which demonstrated that they
were upregulated in a TTHA1359-dependent, cAMP-independent mechanism.12 Because
similarities were observed for structures of TTHA1359 and CRPEc, TTHA1359-binding
sites were predicted for these eight promoters based on the consensus DNA-binding
properties of CRPEc and the positions of CRPEc-binding sites associated with Class I and
Class II activation mechanisms.12,55,56,75,85 From these predicted binding sites, the putative
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DNA-binding consensus 5’-(A/T)(A/T)GTGA(N5-7)ACAC(T/A)(T/A)-3’ was derived for
TTHA1359.12 The other eight gene promoters regulated by TTHA1359 were identified
using an alternative genetic approach.13 In this approach, gene expression levels were
collected from experiments with wild-type and gene-inactivated T. thermophilus HB8
strains in which cultivation conditions such as duration, culture medium, and chemical
treatment were varied.13 Expression levels were then analyzed for individual genes whose
expression correlated with the expression of THA1359.13 Of those whose expression
strongly positively correlated with that of TTHA1359, eight genes possessed promoter
sequences resembling the putative TTHA1359-binding consensus site derived
previously.12,13 These eight promoters were upregulated in vitro in a cAMP-independent,
TTHA1359-dependent mechanism as with the eight gene promoters identified
previously.13 From the binding sites of all sixteen promoters, the putative TTHA1359binding consensus 5’-TTGTG(N9)CNC-3’ was derived.12,13
TTHB099 is the most recently studied T. thermophilus HB8 CRP family
member.11-13,16 It is a one hundred and ninety-five residue protein that forms a
homodimer in solution, and its overall ligand-free dimeric crystal structure resembles that
of TTHA1359 and that of CRPEc with cAMP complexed at both primary and secondary
cAMP-binding sites.12,16,55 It is considered to function biologically as a transcriptional
activator of carotenoid biosynthesis in T. thermophilus HB8 based on the function of the
nearly identical protein TT_P0055 encoded in the megaplasmid pTT27 of the closely
related T. thermophilus HB27 strain.16
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Chapter 1.6 Objectives of the Present Work
REPSA has been previously applied in the Van Dyke laboratory as part of a
reverse-genetic technique to study the potential regulatory and biological functions of
TFs.19-22 Initially, REPSA is used in combination with next-generation sequencing and
bioinformatic research tools to discover the DNA-binding specificities of TFs. These
specificities are then bioinformatically mapped to genomes and bioinformatically
characterized to identify potential regulatory binding sites for TFs. These potential sites
are examined for binding by TFs in vitro, and validated binding sites are used to predict
the genes regulated by TFs. Possible biological roles are then described for these TFs
with respect to these validated genes. An end goal in the Van Dyke laboratory is the
implementation of this reverse-genetic technique as an effective alternative approach to
study putative TFs that lack characterization beyond mere family categorizations.
Achieving this end goal requires a series of studies to demonstrate the effectiveness of
this technique regarding the accurate determination of potential regulatory binding sites
for TFs within subject genomes and the possible biological functions of TFs. Several of
these studies have already been performed in which the reverse-genetic technique was
implemented to identify the potential regulatory binding sites and possible biological
roles of four transcriptional repressors from T. thermophilus HB8.19-22 For each of these
TFs, a level of regulatory and biological characterization had already been established,
allowing the accuracy of the reverse-genetic approach to be assessed by comparing its
findings with those previously reported for these repressors.14,15,17-22
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These studies not only corroborated what had been established previously but also
reported additional findings that have contributed to a greater functional understanding of
these TFs.14,15,17-22 In the present work, this reverse-genetic technique has been
implemented to study TTHA1359-binding specificity and the genes that TTHA1359
potentially regulates. This protein is an excellent next-step study subject for evaluating
the effectiveness of the reverse-genetic for several reasons. TTHA1359 has been
previously studied which permits the findings of the present work to be evaluated. 12,13 As
with the four previously studied TFs, TTHA1359 does not require a ligand to bind
DNA.12,13,19-22 However, unlike the TFs studied previously, TTHA1359 functions as a
transcriptional activator.12-15,17-22 Studying TTHA1359 should yield further insight into
the functionality of the reverse-genetic technique and guide its future application to study
other previously characterized TFs and eventually putative TFs.
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CHAPTER 2. MATERIALS AND METHODS
Chapter 2.1 Nucleic Acids and Stock Selection Template Library Preparation
RIKEN kindly supplied plasmid pET11a-TTHA1359 encoding TTHA1359
protein for the project. Oligonucleotide precursors and primers were synthesized and
purified by Integrated DNA Technologies and are listed in Appendix A (Table A1). Stock
library selection template ST2R24 DNAs were prepared by assembling, PCR amplifying,
and subsequently combining the PCR products of five individual 25 μL PCR reactions
containing 1X Standard Taq Reaction Buffer (New England Biolabs®, NEB), 50 μM
each dNTPs, 600 nM each ST2L and IRD7_ST2R primers, 1 ng single-stranded ST2R24
template DNAs, and 25 U Taq DNA Polymerase. Cycling conditions consisted of 5
cycles of 95°C for 30 sec, 60°C for 30 sec, and 68°C for 1 min; 1 cycle of 95°C for 30
sec, 60°C for 30 sec, and 68°C for 1.5 min; and 1 final cycle of 95°C for 30 sec, 60°C for
30 sec, and 68°C for 2 min.
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Chapter 2.2 Expression and Purification of TTHA1359 Protein
Expression and purification of TTHA1359 protein followed a protocol similar to
that previously established.19 Transformation of competent E. coli strain BL21 (DE3)
bacteria with plasmid pET11a-TTHA1359 was followed by cultivation in 50 mL LB
medium containing 100 μg/mL ampicillin at 37°C/250 rpm to an ODA600 of 0.6 before
induction by supplementation of the growth medium with 1 mM IPTG. Induced bacteria
were cultivated 5 hrs further then isolated by centrifugation (4000 x g, 15 min, 4°C). The
obtained bacterial pellet was suspended in 1 mL cold 50 mM Tris-Cl (pH 8.1 at 25°C),
200 mM NaCl, 0.2 mM EDTA, 2 mM DTT, and 1 mM PMSF. Suspended bacteria were
lysed by incubation at 0°C with 0.3 mg/mL supplemented lysozyme for 15 min followed
by sonication (5 cycles, 3 W, 10 sec on/ 10 sec off, 0°C). After centrifugation (21,000 x
g, 15 min, 4°C), soluble cell lysate was aspirated and incubated at 70°C for 15 min before
centrifugation a second time (21,000 x g, 15 min, 4°C). Aspiration and dilution of the
resulting supernatant in an equivalent volume of glycerol, ensuring homogenization by
rocking at 4°C for 1 hr, yielded the purified TTHA1359 stock utilized in downstream
experiments. The purified stock was stored between experiments at -20°C. The
concentration of purified TTHA1359 protein prior to dilution in glycerol was determined
by densitometric quantification against a BSA standard curve and estimated at 2.45
mg/mL, corresponding to a purified TTHA1359 stock of 27.5 μM monomer or 55 μM
dimer as calculated with the 22,317 Dalton molecular weight of TTHA1359 protein
obtained from the UniProtKB database, entry Q5SIL0.86 Samples obtained during the
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expression and purification of TTHA1359 were analyzed alongside PageRuler™
Prestained Protein Ladder (Thermo Fisher Scientific™) by 12% SDS-PAGE analysis
(Figure 6).
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Chapter 2.3 Identification of a DNA-binding Consensus for TTHA1359
Rounds of REPSA were performed following a formerly outlined protocol.19
REPSA selections were performed in 10 μL reaction volumes containing 1X CutSmart®
Buffer (NEB), 4.515 ng (10 nM) selection template ST2R24 DNAs, and 34 nM
monomeric or 17 nM dimeric purified TTHA1359 protein stock. TTHA1359 protein was
diluted in cold 50 mM Tris-Cl (pH 8.1 at 25°C), 200 mM NaCl, 0.2 mM EDTA, 2 mM
DTT, and 200 μg/mL BSA, and 0.2% wt/vol Tween 20 on ice prior to its addition to
reactions. The initial REPSA selection reaction contained stock selection template
ST2R24 DNAs while each subsequent round of REPSA contained the selection template
ST2R24 DNAs that were selected and amplified during the previous REPSA round. The
4.515 ng stock selection template ST2R24 DNAs (100 fmoles or 6.023 x 1010 molecules)
used as the input for round one of REPSA was not considered sufficient to encompass all
random 24-bp sequences possible for the selection template ST2R24 (424⁄2 =1.4 x 1014),
but it was considered sufficient to identify preferred TTHA1359-binding sequences based
on REPSA selections with the four previously studied T. thermophilus HB8 TFs which
were initiated with less than half the input of ST2R24 DNAs reported in the present
work.19-22 During REPSA cycles, selection reactions were incubated at 55°C for 20 min
then 37°C for 10 min with a IISRE, 0.8 U FokI or 2 U BpmI for the initial two or final
three rounds respectively, added to the reactions at the 37°C incubation midpoint.
Selection reactions were terminated by incubation below 0°C. Alongside selection
reactions, two selection control reactions were run which were assembled without
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TTHA1359 protein and IISRE (DNA control) or solely without TTHA1359 (IISRE
control). REPSA selections were PCR amplified for 6, 9, and 12 cycles as before except
the PCR reaction input for each was 1 μL REPSA-selected ST2R24 template DNAs, the
concentrations of ST2L, IRD7_ST2R, and NEB Taq DNA Polymerase were doubled, and
the thermocycling annealing and elongation temperatures were adjusted to 58°C and
68°C respectively.19 REPSA rounds each ended with the assessment of selection and
amplification reactions, performed by native PAGE and IR fluorescence after the
protocol described previously.19 Equivalent 2 μL volumes of reactions and 6X loading
solution prepared with 20% wt/vol dextrose, 0.9% wt/vol Orange G dye, 0.1% wt/vol
SDS, and 66 mM EDTA then loaded on 1X Tris-borate-EDTA (TBE, pH 8.3 at 25°C),
10% wt/vol polyacrylamide (19:1 acryl:bis) gels and electrophoresed at 5 V/cm for 10
min then 15 V/cm for 30 min. REPSA selection and amplification reactions were
visualized by LI-COR instrument IR fluorescence imaging, and quantification of
amplification reactions determined by a Qubit double-stranded DNA high-sensitivity
assay kit (Thermo Fischer Scientific) and Qubit 3 Fluorometer (Thermo Fisher Scientific)
as before.19 REPSA was terminated after round 5 as an apparent population of
TTHA1359-dependent, IISRE cleavage-resistant selection template ST2R24 DNAs was
detected during the assessment of round 5 selection results (Figure 7).
Amplicon library DNAs were prepared from REPSA-selected round five
amplified ST2R24 DNAs for massively parallel semiconductor sequencing by
modification of the method outlined previously.19 A 2 μL aliquot of REPSA round 5
DNAs was added to a 25 μL PCR reaction containing 1X Standard Taq Buffer, 150 μM
each dNTPs, 200 nM each trP1_ST2L and A_BC06_ST2R primers, and 0.08 U Taq
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DNA Polymerase (NEB). Cycling conditions were seven cycles of 95°C for 30 sec, 54°C
for 30 sec, and 68°C for 1 min. Deviating from the previous method, 2 μL aliquots of
PCR product were added to three individual 25 μL PCR reactions containing 1X
Standard Taq Buffer, 150 μM each dNTPs, 200 nM each trP1_uni and A_uni primers,
and 0.08 U Taq DNA Polymerase. Cycling conditions consisted of 6, 9, and 12 cycles of
95°C for 30 sec, 55°C for 30 sec, and 68°C for 1 min. From each reaction, 2 μL aliquots
were removed and assessed as described during rounds of REPSA. Results were
visualized by UV exposure using a Gel Doc™ EZ (BIO-RAD) instrument after staining
in 20 mL water containing 50 μg ethidium bromide. The resulting library of amplicon
DNAs yielded by the 9-cycle PCR reaction, possessing the highest visible concentration
and double-stranded to single-stranded ratio of amplicon DNAs, was selected and
purified using a DNA Clean & Concentrator kit (Zymo Research). Massively parallel
sequencing of the prepared and purified library of amplicon DNAs proceeded as
described.19
Raw sequencing data was initially refined by the Sequencing1.java program as
described while the first one thousand unique sequences of the resulting refined sequence
set were manually identified due to the apparent removal from the web of the program
applied previously to remove duplicate sequences, DuplicatesFinder v 1.1.19 The unique
sequence set was uploaded to MEME v 5.1.1 for non-palindromic and palindromic
consensus discovery.62 Motif discovery parameters were set at default except the
maximum width of discovered motifs was restricted to 24 bp, corresponding to the width
of the randomized core of selection template ST2R24 DNAs, and the palindromic filter
was applied for the palindromic motif search. Resulting motifs with statistical
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significance values, E-values, < 0.01 were analyzed. Data from the discovered, selected
motifs such as statistical significances and number of sites contributing to the motifs were
recorded, and graphical representations of the motifs were exported (Figure 9A, 9B).
From the obtained consensus motifs, a TTHA1359-DNA binding consensus was derived
(Figure 9C).
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Chapter 2.4 TTHA1359-DNA Binding Assays
An EMSA was performed to validate the authenticity of the emergent REPSAselected TTHA1359-binding ST2R24 DNAs which generally followed the protocol that
has been described previously.19 EMSA binding reactions were performed in 5 μL
reaction volumes containing 0.5X Tris-acetate-EDTA (TAE, pH 8.4 at 25°C)
supplemented to 1 mM EDTA, 0.2% wt/vol Tween 20, 2% wt/vol glucose, 0.5 μg BSA,
and 10 nM IRD7-labeled REPSA round one and five PCR-amplified selections incubated
with 0, 1, 10, 100, or 1000 nM TTHA1359 protein dimer. Binding reactions were
assembled and equilibrated at 55°C for 5 min prior to the addition of TTHA1359 protein.
Binding reactions were then incubated at 55°C for 30 min before they were directly
loaded onto a 0.5X TAE, 10% wt/vol polyacrylamide (19:1 acryl:bis) gel. Loaded
reactions were electrophoresed in 0.5X TAE buffer at 10 V/cm for 30 min. Results were
visualized by IR fluorescence as described previously (Figure 8).19
Binding kinetics were determined between TTHA1359 and biotinylated DNAs by
biolayer interferometry (BLI) essentially as described previously but with additional
control reactions.19 TTHA1359-binding control, consensus, mutant consensus, and CRPEc
consensus DNAs were PCR biotinylated and amplified for BLI assays in 50 μL reaction
volumes containing 1X Standard Taq Reaction Buffer, 50 μM each dNTPs, 350 nM
ST2L primer, 300 nM Bio_ST2R primer, 2 ng DNA template precursor, and 2 U Taq
DNA Polymerase (Table A1). Cycling conditions consisted of 30 cycles of 95°C for 30
sec, 58°C for 30 sec, and 68°C for 1 min. BLI assays were performed with an
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OctetQK (FortéBio) instrument at 37°C in 25 mM Tris-Cl (pH 8.1 at 25°C), 100 mM
NaCl, 1 mM EDTA, and 0.05% Tween 20 buffer in 96-well microplates. For each assay,
2 nM biotinylated DNA sequences were immobilized during a 20 min incubation on
Streptavidin Dip and Read Biosensors (FortéBio) which were hydrated in buffer 5-10
minutes at 25°C prior to each assay. Loaded biosensors were rinsed in fresh buffer for 5
min to establish immobilized DNA baselines, then immersed for 5 min in buffer
containing different dimeric TTHA1359 protein concentrations (5.7, 17, 51, 153, and 461
nM), and finally washed for 10 min in fresh buffer. Biosensor data for each assay,
recorded in wavelength shift (nm), was obtained every 1.6 sec. Besides the PCR
amplified biotin-labeled control DNA sequence tested for nonspecific or weak binding,
ST2_1359_ctrl, each assay included controls, assembled without TTHA1359 protein
dimer and biotinylated DNA sequences (biosensor control) or TTHA1359 protein dimer
(biosensor load control). Data from the control was subtracted point-by-point from the
experimental biosensor data prior to data analysis. Binding kinetics were determined for
each assay by non-linear regression analysis of association and dissociation biosensor
data collected using protein concentrations of 5.7, 17, 51, and 153 nM TTHA1359 dimer
using GraphPad Prism software as before (Table 1).19 Representative raw associative and
dissociative step BLI data and calculated best-fit line traces for TTHA1359 and tested
DNA sequences have been provided in the text (Figure 10) while the remaining plots
have been provided in Appendix B (Figure B1).
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Chapter 2.5 Identification of Potential Regulatory TTHA1359-binding Sites in
the T. thermophilus HB8 Genome
Since the top non-palindromic motif discovered by MEME was a truncation of the
consensus suggested by the motif, the motif was not directly imported into the program
Find Identified Motif Occurrences (FIMO) as previously described.19,87 Instead, positiondependent letter-probability matrix data from positions 6-16 of the top non-palindromic
motif discovered by MEME was initially utilized to derive an extended 22-bp positiondependent letter-probability matrix motif. A text file suitable for upload and utilization by
FIMO was then written in MEME minimal motif format, containing the targeted version
number of MEME, the extended motif alphabet and strand information, and the extended
position-dependent letter-probability matrix motif (http://meme-suite.org/doc/memeformat.html?man_type=web) (data not shown). The file was uploaded to FIMO v 5.1.1
and utilized to scan the GenBank Thermus thermophilus HB8 universal identifier 13202
version 210 database for potential binding sites with statistically significant p-values less
than 0.0001. Potential binding sites selected for further bioinformatic analysis were
limited to the identified potential binding sites with p-values less than 6 x 10-5 (Table 2).
Genomic sequence contexts, encompassing -210/+310 bp of these potential
binding sites, were obtained from the Kyoto Encyclopedia of Genes and Genomes
(KEGG) database.88 As explained in the next paragraph, some of these genomic
sequences contexts have been provided in the text (Figure 11) while others have been
provided in Appendix C (Figure C1). Potential binding sites located between or near
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bidirectionally oriented genes were examined individually, extracting the genomic
sequence context in both orientations. Genes positioned near potential TTHA1359binding sites were noted (Table 2), and transcription unit information for these genes,
whether they were transcribed as single units or as one of several genes in an operon, was
ascertained through the BioCyc database collection (Table 2).89 Potential core promoter
elements within the obtained sequence contexts were predicted by sequence context
submission to the online bacterial promoter prediction program BPROM by Softberry
(Figure 11, Figure C1).90
Initially, FIMO-identified potential binding sites with no identifiable core
promoter elements were removed from further consideration. Potential binding sites were
also excluded by limiting the distance between predicted transcription and known
translation start sites of local genes to 100 bp. This was an arbitrary restriction as no
comprehensive transcription start site data is currently available for T. thermophilus HB8.
Of the remaining potential binding sites, those positioned downstream of predicted core
elements were excluded from further consideration. Finally, potential binding sites with
central positions greater than 100 bp upstream of predicted transcription start sites were
excluded. Potential TTHA1359-binding sites which were excluded from further analysis
have been provided in Appendix C (Figure C1). Potential TTHA1359-binding sites which
were investigated for regulatory potential have been provided in the text (Figure 11).
Distances were calculated from transcription start sites to the center of remaining
binding sites overlapping or upstream of predicted -35 core promoter elements (Table 3).
Calculated distances were used to postulate binding site roles in transcriptional activation
and corresponding activation mechanisms, either Class I or Class II, based on CRPEc-
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binding site mutational studies with regard to transcriptional activation.78,79 Roles in
transcriptional repression were also postulated based on potential binding sites for
TTHA1359 overlapping predicted core promoter elements.
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CHAPTER 3. RESULTS
Chapter 3.1 Expression and Purification of TTHA1359
Recombinant expression of TTHA1359 protein from T. thermophilus HB8 by
induction of cultivated E. coli strain BL21 (DE3) transformed with plasmid pET11aTTHA1359 yielded significant TTHA1359 protein production as evidenced by analyzed
culture samples harvested pre- and post-induction (Figure 6, Lanes 2 and 3). Expressed
TTHA1359 protein was initially recovered in the cell lysate together with E. coli proteins
after sonoporation of harvested cells treated with lysozyme (Figure 6, Lane 4).
TTHA1359 protein was then purified from most contaminant E. coli proteins by
subjection of the recovered cell lysate to high-temperature incubation (Figure 6, Lane 5).
The identities of the few contaminant E. coli proteins that remained soluble during heat
treatment have yet to be determined (Figure 6, Lane 5). Further purification to remove
these remaining proteins was deemed unnecessary because previous applications with T.
thermophilus HB8 proteins, expressed and purified similarly to TTHA1359, appeared
unaffected by remaining contaminant proteins.19-22 This likely resulted from the dilutions
of purified T. thermophilus HB8 proteins utilized in previous experiments effectively
rendering remaining contaminant proteins as non-existent.19-22 The identity of the
expressed and purified protein as TTHA1359 monomer was substantiated by the ~ 22
kilodalton molecular weight of the presented protein band, consistent with the molecular
weight of TTHA1359 monomer as determined its UniProtKB database entry, Q5SIL0
(Figure 6, Lanes 3-5).86
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Figure 6. Expression and purification of TTHA1359 protein. Image
depicts samples obtained during TTHA1359 protein expression and
purification as analyzed by 12% SDS-PAGE. Lanes were loaded with
samples of protein ladder (lad), cultivated transformant E. coli in the
exponential growth phase (exp), induced cultivated transformant E. coli
post-incubation (ind), recovered cell lysate following harvested

bacterial cell membrane disruption (lys), and recovered soluble cell
content after high temperature purification (pur). Molecular weights of
the protein ladder are indicated to the left of the figure. The protein band
corresponding to TTHA1359 monomer is indicated to the right of the
figure. Additional E. coli proteins that remained soluble during heat
treatment (pur) have yet to be determined.
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Chapter 3.2 Identification of a DNA-binding Consensus for TTHA1359
REPSA selections of TTHA1359-binding selection template ST2R24 DNAs were
performed for a total five rounds before the detected emergence of an apparent
population of TTHA1359-dependent, IISRE cleavage-resistant ST2R24 template DNAs
(Figure 7). Rounds of REPSA initially relied on the IISRE FokI to interrogate
TTHA1359-binding specificity, but selection of a minor population of ST2R24 DNAs
with cleavage resistance against FokI, observed in the cleavage control and selection
reactions during the assessment of REPSA round two selection results through image
intensification (data not shown), required the switch to BpmI, an alternative IISRE, for
the third round of REPSA. Unlike rounds one through four of REPSA, approximately
half the input ST2R24 template DNAs in the selection reaction of REPSA round five
were not digested by IISRE in the presence of 17 nM TTHA1359 dimer (Figure 7, Round
5, Lane 3), suggestive of an enriched population of ST2R24 template DNAs to which
TTHA1359 preferentially binds. Titration of REPSA round one and five amplified
selections of ST2R24 template DNAs with TTHA1359 in an EMSA validated the
enriched presence of preferred TTHA1359-binding DNAs (Figure 8). No mobility shift
was observed for REPSA round one amplified DNAs across the range of TTHA1359
dimer titrated (Figure 8, Lanes 1-5). However, an increasing mobility shift was observed
for round five amplified DNAs beginning as low as equivalent concentrations of
TTHA1359 dimer and DNAs (Figure 8, Lanes 6-10). Consequently, the cleavage
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Figure 7. REPSA selection of a population of TTHA1359-binding 73-bp template ST2R24 DNAs. Each IR fluorescence image depicts selection
reaction results from individual rounds of REPSA. Reactions in lanes 1-3 in each figure correspond to DNA controls prepared without TTHA1359
or IISRE (-/-), cleavage controls including only IISRE (-/F or -/B representing FokI and BpmI IISRE inclusion respectively), and the selection

reaction prepared with 17 nM dimeric TTHA1359 protein and IISRE (+/F or +F). Band designations: T I, intact ST2R24 template DNAs; TC,
cleaved ST2R24 template DNAs; P, remnant 5’-labeled fluorescent ST2R primer.
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Figure 8. Titration of amplified REPSA-selected 73-bp template ST2R24 DNAs from rounds
one and five with TTHA1359. Reactions in lanes 1-5 and 6-10 contained 10 nM amplified
selections from REPSA rounds 1 and 5 respectively. Reactions were incubated with either 0, 1,
10, 100, or 1,000 (1K) nM dimeric TTHA1359 protein. Band designations: TF, Free ST2R24
template DNAs; TB, bound ST2R24 template DNAs; P, remnant 5’-labeled fluorescent ST2R
primer.

43

resistance of the intact population of ST2R24 template DNAs at REPSA round five was
attributed to TTHA1359-binding as a result of the ST2R24 template DNAs possessing
core sequences preferentially bound by TTHA1359.
Massively parallel sequencing of the synthesized amplicon library DNAs yielded
9,516,545 total base reads with an incorrect base calling quality score, ≥ Q20, of
8,631,131 and 158,313 reads of 60 bp average length. Sequencing runs with the amplicon
library DNAs prepared from the REPSA-selected DNAs of the four previously studied T.
thermophilus HB8 transcriptional repressors yielded 2-5 million total base reads, 1.5-3.5
million ≥ Q20 quality scores, and 40,000-100,000 reads of average length 48-51 bp.19-22
The improved sequencing results reported here were considered to be the result of the
method in which the amplicon library DNAs were prepared for sequencing which
differed than that used in the previous studies.19-22 The obtained 158,313 reads were
reduced to 61,754 sequences of appropriate quality for further investigation by the
applied Sequencing1.java refinement program. Manual examination of the first one
thousand and five refined sequences yielded the first one thousand unique sequences as
five sequences were identified as duplicates and removed. Submission of the identified
unique sequence set to MEME yielded the top three non-palindromic and palindromic
motifs each within the unique sequence set as determined by the program with the top
two motifs discovered during each search possessing E-values, measurements of
statistical significance, < 0.01 (Figure 9A, 9B). The top non-palindromic and palindromic
motifs, corresponding to a 19-bp motif within a lengthier 24-bp pseudo- motif (Figure
9A1) and a 24-bp motif (Figure 9B1), were discovered respectively within seven hundred
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Figure 9. Discovered and derived TTHA1359-DNA binding motifs. The top two
(A) non-palindromic and (B) palindromic motifs discovered by MEME analysis
with statistically significant E-values < 0.01, represented as position-dependent
letter-probability matrices. (C) The minimal TTHA1359-DNA binding consensus

sequence derived from MEME discovered motifs.
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and eighty-nine and eight hundred and ten of the unique one thousand sequence set input
with remarkably high statistical significances as indicated by associated E-values of
1.1x10-2,996 and 4.5x10-1,153. Top secondary non-palindromic and palindromic motifs,
corresponding to a 15-bp (Figure 9A2) and a 16-bp (Figure 9B2) motif, were respectively
identified in one hundred sixty-seven and one hundred thirty-nine of the unique sequence
set input with much lower statistical significances with E-values of 4.2x10-264 and
1.5x10-51. A minimal 20-bp inverted-repeat TTHA1359-binding consensus was derived
primarily from the non-palindromic top motif (Figure 9C). Positions 1-7 and 14-20 of this
THA1359-binding consensus (Figure 9C) were found to share significant similarities
with positions 2-8 and 15-21 of the CRPEc consensus which correspond to twelve of the
fourteen positions that CRPEc demonstrates strong sequence preferences (Figure
5A2).63,91-93 Since TTHA1359 is a homodimer and its derived DNA-binding consensus is
a palindrome, each TTHA1359 dimer subunit is considered to bind half of the
consensus.12
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Chapter 3.3 Biophysical Characterization of TTHA1359-DNA Binding
BLI assays were performed to characterize the DNA-binding affinity of
TTHA1359 for its identified consensus and CRPEc consensus sequences and to
investigate its consensus-binding specificity. In these BLI experiments, real-time binding
kinetics for select TTHA1359-DNA interactions were measured by recording wavelength
shifts in biosensor-reflected, white-light interference patterns brought about by the
interactions of TTHA1359 with biosensor-immobilized DNA.94 Raw wavelength shift
data collected during these experiments at concentrations of 5.7, 17, 51, and 153 nM
TTHA1359 dimer was used to calculate the DNA-binding kinetics between TTHA1359
and the DNA sequences tested (Table 1). Raw data recorded at concentrations of 461 nM
TTHA1359 dimer was excluded from these calculations because no significant or
detectable binding was observed between TTHA1359 and the TTHA1359-binding
control sequence except at 461 nM TTHA1359 dimer (data not shown). Raw associative
and dissociative step BLI data and calculated best-fit line trace plots for TTHA1359 and
its consensus, the CRPEc consensus, and control sequences have been provided here
(Figure 10). The remaining plots for TTHA1359 and other DNA sequences have been
provided in Appendix C (Figure C1).
High-affinity binding was observed between TTHA1359 and its consensus
sequence, having a quick on rate, slow off rate, and a calculated apparent KD of ~ 3.4 nM
with an R2 value > 0.95 (Figure 10A, Table 1). Individual single-point mutants were then
introduced to positions 1-7 of the TTHA1359-binding consensus sequence (Figure 9C) to
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Table 1. TTHA1359-DNA binding parameters
Name

Sequence

kon (M-1 ∙s-1 )

con_wt

ATTGTGACACACATCACAAT

457555

0.001577

con_p1

cTTGTGACACACATCACAAT

con_p2

AgTGTGACACACATCACAAT

317173

0.01166

36.78x10-9

0.01867

-9

koff (s-1 )

KD (M)

R2

0.9572
3.447x10-9
⸺⸺⸺⸺⸺⸺ Ambiguous ⸺⸺⸺⸺⸺⸺

215769

0.9820

con_p3

ATgGTGACACACATCACAAT

con_p4

ATTtTGACACACATCACAAT

0.9793
86.53x10
⸺⸺⸺⸺⸺⸺ Ambiguous ⸺⸺⸺⸺⸺⸺

con_p5

ATTGgGACACACATCACAAT

⸺⸺⸺⸺⸺⸺ Ambiguous ⸺⸺⸺⸺⸺⸺

con_p6

ATTGTtACACACATCACAAT

288341
267033

0.02153
0.006236

74.67x10-9

0.9766

-9

con_p7

ATTGTGgCACACATCACAAT

con _s5

ATTGTGAcacacTCACAAT

0.9843
23.35x10
⸺⸺⸺⸺⸺⸺ Ambiguous ⸺⸺⸺⸺⸺⸺

con _s7

ATTGTGAcacacacTCACAAT

⸺⸺⸺⸺⸺⸺ Ambiguous ⸺⸺⸺⸺⸺⸺

0.0007341 1.011x10-9
0.8979
ATACGAAAAACACACAC
ctrl
⸺⸺⸺⸺⸺⸺ Ambiguous ⸺⸺⸺⸺⸺⸺
Lowercase nucleotides indicate single-point or spacing mutations from the wild-type
consensus. KD, kon, and koff indicate the equilibrium dissociation, association rate, and
dissociation rate constants respectively. Ambiguous indicates the absence of a significant
observable or detectable binding event by BLI.
CRP_Ec

AAATGTGATCTAGATCACATTT

726387

48

Figure 10. Representative BLI association and dissociation step raw data plots of TTHA1359-DNA binding. Graphs depict raw association and
dissociation step data measured during BLI experiments with TTHA1359 and (A) ST2_1359_con_wt, (B) ST2_CRP_Ec, and (C) ST2_1359_ctrl
biotinylated DNAs. These DNAs correspond respectively to wild-type TTHA1359-binding consensus, CRPEc-binding consensus, TTHA1359binding control sequences. Dots represent raw data points for these TTHA359-binding assays, and solid lines depict calculated best-fit lines for the

raw data points. Line colors pink, green, orange, and blue indicate concentrations of TTHA1359 protein corresponding to 5.7, 17, 51, and 153 nM
TTHA1359 dimer.
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characterize consensus sequence binding specificity, having mutated individual base
positions to either the least represented or the non-complementary partner of the most
highly represented base as identified by the top non-palindromic motif (Figure 9A1).
Single-point mutant binding kinetics varied dramatically with single-point mutants
introduced at positions 1, 4, and 5 yielding ambiguous binding under the applied
experimental conditions (Table 1), suggesting a strong sequence preference at these
positions. Results of mutations introduced at positions 2, 3, 6, and 7 were less detrimental
as binding kinetics were actually attainable with observed binding affinity for the wildtype TTHA1359-binding consensus ranging from ~ 6.5- to ~ 25-fold higher than binding
affinities for single point mutants by calculated apparent KD value comparison (Table 1).
Additional mutant consensus sequences, possessing either a truncated 5-bp or extended 7bp spacer sequence instead of the observed 6-bp spacer at positions 8-13 within the
consensus sequence (Figure 9C), were tested and yielded ambiguous binding results,
suggestive of a strict consensus sequence recognition spacing requirement under the
reaction conditions specified (Table 1). Finally, as TTHA1359 and CRPEc were found to
recognize similar sequences, TTHA1359-binding to the CRPEc consensus was
investigated (Figure 5A2, Figure 9C, Figure 10B).63 TTHA1359 was found to have
greater than 3-fold higher affinity for the CRPEc consensus over its identified consensus,
having an apparent KD of ~ 1 nM with an R2 value of ~ 0.9 (Figure 10B, Table 1). This
increased affinity was attributed to a slight difference in the recognition sequences,
corresponding to positions 2 and 19 within the TTHA1359 and 3 and 20 within the
CRPEc consensus sequences, as well as differences in the 6-bp composition of the interior
spacer regions of the two sequences (Figure 5A2, Figure 9C, Table 1).63
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Chapter 3.4 Identification of Potential Regulatory TTHA1359-binding Sites in
the T. thermophilus HB8 Genome
Having investigated TTHA1359-binding to its REPSA-selected consensus to
ascertain the validity of its selected consensus, an extended TTHA1359 consensus motif
which was derived from the top non-palindromic MEME motif discovered (Figure 9A1,
positions 6-16) was submitted to FIMO to identify potential regulatory binding sites. The
FIMO search yielded eighty-eight potential THA1359-binding sites within the T.
thermophilus HB8 genome with p-values less than 0.0001 (data not shown). Selection of
identified potential binding sites with p-values less than 6 x 10-5 narrowed the list of
potential binding sites to the first fifty-nine for further analysis (Table 2). Cursory
inspection of the selected potential sites using the KEGG database extended the list of
sites to investigate to seventy-four, as fifteen of the fifty-nine selected sites were
positioned near or within bidirectionally-oriented genes which were analyzed
individually.
Initially, eleven of the seventy-four FIMO-identified potential binding sites for
TTHA1359 were excluded from further analysis based on the absence of a predicted
promoter, corresponding to potential sites upstream of genes TTHA0843, TTHB243,
TTHA0583, and TTHA1326 (FIMO result nos. 5, 16, 36a, and 44 in Figure C1 and Table
2) and downstream of genes TTHA1836, TTHA1236, TTHA1158, TTHA0486,
TTHA1301, TTHA1352, and TTHA0030 (FIMO result nos. 18, 25, 26, 27, 32, 34a, and 53
in Figure C1 and Table 2). In the absence of available comprehensive transcription start
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site data for T. thermophilus HB8, distances between predicted transcription and known
translation start sites of genes located proximally to potential TTHA1359-binding sites
was restricted to 100 bp. Based on this restriction, potential binding sites downstream of
genes TTHA0974, TTHC001, TTHA0910, TTHA0644, TTHA0030, TTHA0943,
TTHA1848, TTHA0507, TTHB177, TTHA1632, TTHA0910, and TTHA0036 (FIMO result
nos. 1, 3, 12, 13, 20, 23, 33, 35b, 38, 47, 48, and 54 in Figure C1 and Table 2) and
upstream of genes TTHA0784, TTHA1730, TTHA1538, TTHB113, TTHA0055, TTHB088,
TTHB177, TTHA1854, TTHA0303, TTHA0544, TTHA1398, and TTHA0205 (FIMO result
no. 7, 21b, 29b 30, 31a, 37a, 38, 39, 42a, 45, 56a, 57a in Figure C1 and Table 2) were not
investigated further. The limited genomic sequence context prevented the visual
determination of predicted transcription start site distances to nearby translation start sites
for potential binding sites positioned downstream of genes TTHA0910, TTHA0030, and
TTHA0036 (FIMO result nos. 12, 20, and 54 in Figure C1 and Table 2). Returning to the
KEGG database revealed there were no translation start sites within the distance restraint,
and thus, these binding sites were excluded from further analysis. To the resulting thirtyseven, only those potential TTHA1359-binding sites centrally positioned upstream or
overlapping predicted core promoter elements were considered further which lead to the
elimination of ten additional potential binding sites. These ten sites included potential
sites identified upstream of genes TTHA0942, TTHA0936, TTHA1223, TTHA0084,
TTHA0643, TTHA0643, TTHA0532 (FIMO result nos. 19, 22, 24, 41, 46, 49, and 52 in
Figure C1 and Table 2) and downstream of genes TTHA1729, TTHA0344, TTHA1073,
(FIMO result nos. 21a, 28, and 50 in Figure C1 and Table 2). For the remaining sites, an
upstream limit of 100 bp from the central position of potential TTHA1359-binding sites
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to predicted start sites of transcription was imposed based on the previously determined
spacing requirements for CRPEc-dependent transcriptional activation at promoters in E.
coli.78,79 This final restriction excluded potential binding sites upstream of genes
TTHA1537, TTHA0056, TTHA1353, TTHA0304, TTHA1135, and TTHA1133 (FIMO
result nos. 29a, 31b, 34b, 42b, 43, and 59 in Figure C1 and Table 2) from further analysis.
These refinement steps excluded fifty-one potential TTHA1359-binding sites (Figure
C1), yielding a total twenty-three FIMO-identified TTHA1359-binding sites which were
analyzed for potential regulatory functions (Figure 11).
Of the remaining potential TTHA1359-binding sites with central positions
overlapping or upstream predicted -35 core promoter elements, five sites were optimally
positioned for TTHA1359 to bind and upregulate transcription based on calculated
distances to predicted transcription start sites and information on binding site positions
associated with simple CRPEc-dependent activation mechanisms (Table 3).78,79 These
sites corresponded to potential sites centered 41.5 bp from the predicted transcription
start sites of TTHA0425, TTHA0584, and TTHA0770; 61.5 bp from the predicted
transcription start site of TTHA0506; and 82.5 bp from the predicted transcription start
site of TTHA0987 (FIMO result nos. 4, 36b, 58, 35a, and 6 in Figure 11 and Table 3).
Potential TTHA1359-binding sites upstream of TTHA0425, TTHA0584, and TTHA0770
gene promoters were found to correspond to optimal TF-binding positions associated
with transcriptional upregulation by a Class II mechanism (Table 3).75,78,79 Potential
binding sites upstream of TTHA0506 and TTHA0987 gene promoters were observed to
correspond to optimal TF-binding positions associated with transcriptional upregulation
by a Class I mechanism (Table 3).75,78,79 An additional potential regulatory binding site
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for TTHA1359 was noted, centered at 93.5 bp upstream of TTHB089 (Table 3).
However, since the transcriptional activity CRPEc when centrally bound 92.5 bp upstream
of a transcription start site has been demonstrated to be minor, substantial upregulation of
TTHB089 transcription by TTHA1359 at this potential binding site was considered
unlikely to occur (Table 3).79 Potential binding sites were also noted upstream of
TTHA0953, TTHA0446, TTHA0447, TTHA0533, TTHA0606 twice, and TTHA0206
genes, but were considered unlikely to be regulatory due to their orientation on the DNA
double-helix with respect to predicted core promoter elements (Table 3). 78,79
Interestingly, a considerable number of remaining potentially binding sites overlapped
predicted core promoter elements (Table 3). These binding sites included those upstream
of genes TTHA0080, TTHA0081, TTHA0954, TTHA0534, TTHA0109, TTHA0607,
TTHA0607 again, TTHA1026, TTHA1399, and TTHA1133 (FIMO result nos. 9a, 9b, 10,
14b, 17, 40b, 51b, 55, 56b, and 59 in Figure 11 and Table 3). Although a potential role as
transcriptional repressor was not suggested by previous work with TTHA1359, the
positioning of these sites with respect to predicted transcription start sites suggests a
potential role for TTHA1359 as a repressor of these genes by a simple steric hindrance
mechanism.12,13
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Table 2. FIMO-identified potential TTHA1359-binding sites in the T. thermophilus HB8 genome
FIMO
Result

Loci

Start

End

p-Value

Q-value

Sequence

Position

Local Gene(s)

Operon

1

Chromosome

917,761

917,782

1.01x10-8

0.0125

AAATGTGAACATATTCACTTTC

Intragenic

TTHA0974
TTHA0973

1/1
1/6

2

Chromosome

898,965

898,986

1.48x10-8

0.0125

AATCGTGAAGTTTATCACATAT

Intergenic

TTHA0952
TTHA0953

1/1
1/1

3

Miniplasmid

1,503

1,524

1.78x10-8

0.0125

GAAAGTGAGATAACTCACATAT

Intergenic

TTHC001

1/1

4

Chromosome

402,440

402,461

1.01x10-7

0.0532

TAAAGTGCTTTATTTCACAAAA

Intergenic

TTHA0424
TTHA0425

1/1
1/1

5

Chromosome

809,120

809,141

2.64x10-7

0.104

AATTGTGCTGGGCCACACAAAT

Intragenic

TTHA0843
TTHA0842

1/3
2/3

6

Chromosome

931,166

931,187

2.95x10-7

0.104

ATTAGTGAAACTTTTCACGATT

Intragenic

TTHA0986
TTHA0987

1/1
1/1

7

Chromosome

752,613

752,634

3.71x10-7

0.105

GAAGGTAACTTCAAACACTTTC

Intragenic

TTHA0785
TTHA0784

6/6
1/1

8a

Chromosome

418,352

418,373

3.97x10-7

0.105

AATTGTCAACGGGATTACGTAT

Intergenic

TTHA0446

1/1

8b

Chromosome

418,352

418,373

3.97x10-7

0.105

ATACGTAATCCCGTTGACAATT

Intergenic

TTHA0447

1/5

9a

Chromosome

81,405

81,426

5.35x10-7

0.113

CCATGTGTTTTAGTTTACTTTA

Intragenic

TTHA0080

1/2

9b

Chromosome

81,405

81,426

5.35x10-7

0.113

TAAAGTAAACTAAAACACATGG

Intragenic

TTHA0081

1/3

10

Chromosome

899,588

899,609

5.82x10-7

0.113

AATCGTGAATAAAATCACTAGG

Intergenic

TTHA0953
TTHA0954

1/1
1/2

11

Chromosome

932,531

932,552

5.88x10-7

0.113

TCTTGTACTTTTATTCACGATT

Intergenic

TTHA0987

1/1
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12

Chromosome

871,755

871,776

1.69x10-6

0.298

ACTTGTCAGCAAAATTACGATG

Intergenic

TTHA0910

3/3

13

Chromosome

613,187

613,208

2.35x10-6

0.383

CAATGTCCTTTTAAGCTCAATT

Intragenic

TTHA0644
TTHA0643

2/3
3/3

14a

Chromosome

496,704

496,725

3.11x10-6

0.471

GAAAGAGAATGTTAGCACATTT

Intergenic

TTHA0533

1/2

14b

Chromosome

496,704

496,725

3.11x10-6

0.471

AAATGTGCTAACATTCTCTTTC

Intergenic

TTHA0534

1/2

15

Chromosome

1,507,780

1,507,801

5.01x10-6

0.706

ATTTGGACGCAATTTCACTTTT

Intragenic

TTHA1584

3/3

16

Megaplasmid

249,380

249,401

5.72x10-6

0.757

AAATGTGGCTTAGGGCGCAAAA

Intragenic

TTHB244
TTHB243

5/5
1/7

17

Chromosome

109,940

109,961

6.09x10-6

0.758

TTTCGTGCCCTAGTTCACTAAG

Intragenic

TTHA0110
TTHA0109

3/3
1/1

18

Chromosome

1,718,950

1,718, 971

9.54x10-6

1

CAACGTGTTTGAGCTCACCAAG

Intragenic

TTHA1836
TTHA1837

1/1
1/1

19

Chromosome

890,892

890,913

1.05x10-5

1

TATTGTGCTCAATTTCATACTG

Intragenic

TTHA0943
TTHA0942

1/7
2/7

20

Chromosome

32,701

32,722

1.33x10-5

1

GGCTGTGTACGAAATTACAACT

Intragenic

TTHA0030
TTHA0031

1/2
2/2

21a

Chromosome

1,622,533

1,622,554

1.35x10-5

1

AAAGGTGGGCAAAAAGACGTTT

Intragenic

TTHA1729

1/1

21b

Chromosome

1,622,533

1,622,554

1.35x10-5

1

AAACGTCTTTTTGCCCACCTTT

Intragenic

TTHA1730

1/3

22

Chromosome

885,131

885,152

1.37x10-5

1

AACAGTAACCCATCATGCACTT

Intergenic

TTHA0937
TTHA0936

7/7
1/1

23

Chromosome

891,322

891,343

1.42x10-5

1

GAATGTTGGCAGATGTACTGTT

Intragenic

TTHA0943
TTHA0942

1/7
2/7

56

24

Chromosome

1,161,988

1,162,009

1.49x10-5

1

GACTGTAACGGCGTGCACCATC

Intragenic

TTHA1222
TTHA1223

1/1
1/1

25

Chromosome

1,174,082

1,174,103

1.53x10-5

1

CAAGGTGGTCCTGGACACCTTT

Intragenic

TTHA1236
TTHA1235

8/9
9/9

26

Chromosome

1,104,298

1,104,319

1.67x10-5

1

CATCGTGGGCATCGTCACCATG

Intragenic

TTHA1158
TTHA1159

1/3
2/3

27

Chromosome

456,182

456,203

1.69x10-5

1

CTGCGTGAGCTACCTCACCATT

Intragenic

TTHA0486

2/2

28

Chromosome

326,380

326,401

1.72x10-5

1

CAAGGTGAGCCTAGGCACCATC

Intragenic

TTHA0344
TTHA0343

1/2
2/2

29a

Chromosome

1,464,992

1,465,013

1.74x10-5

1

TAATGTGCGCTATTTCCCAACT

Intergenic

TTHA1537

1/1

29b

Chromosome

1,464,992

1,465,013

1.74x10-5

1

AGTTGGGAAATAGCGCACATTA

Intergenic

TTHA1538

1/1

30

Megaplasmid

101,237

101,258

1.96x10-5

1

GACTTTGCCCTAAGGTACAAAC

Intergenic

TTHB114
TTHB113

2/2
1/2

31a

Chromosome

54,523

54,544

2.08x10-5

1

ATCAGTGACATACGTGCCATTT

Intergenic

TTHA0055

1/2

31b

Chromosome

54,523

54,544

2.08x10-5

1

AAATGGCACGTATGTCACTGAT

Intergenic

TTHA0056

1/4

32

Chromosome

1,241,335

1,241,356

2.22x10-5

1

CACTGGGACGTCATCTACATTG

Intragenic

TTHA1301
TTHA1300

8/10
9/10

33

Chromosome

1,733,129

1,733,150

2.32x10-5

1

GATTGTGAGCGGAGCCACGAGC

Intragenic

TTHA1848
TTHA1849

1/1
1/1

34a

Chromosome

1,292,459

1,292,480

2.35x10-5

1

CATGGTGAGCATGATGACCTTG

Intragenic

TTHA1352

1/3

34b

Chromosome

1,292,459

1,292,480

2.35x10-5

1

CAAGGTCATCATGCTCACCATG

Intragenic

TTHA1353

1/2

57

35a

Chromosome

472,200

472,221

2.44x10-5

1

CCCTGTTTTTCAAGATACAAAA

Intragenic

TTHA0506

1/1

35b

Chromosome

472,200

472,221

2.44x10-5

1

TTTTGTATCTTGAAAAACAGGG

Intragenic

TTHA0507

1/1

36a

Chromosome

550,760

550,781

2.62x10-5

1

AAAAGGGGGCCAGGGCACTTTT

Intergenic

TTHA0583

1/1

36b

Chromosome

550,760

550,781

2.62x10-5

1

AAAAGTGCCCTGGCCCCCTTTT

Intergenic

TTHA0584

1/1

37a

Megaplasmid

79,603

79,624

2.84x10-5

1

CAGGGTGAGGGGGAGCACATTC

Intergenic

TTHB088

1/1

37b

Megaplasmid

79,603

79,624

2.84x10-5

1

GAATGTGCTCCCCCTCACCCTG

Intergenic

TTHB089

1/3

38

Megaplasmid

171,682

171,703

2.86x10-5

1

AACTTTATCCCTTTATACAGAT

Intragenic

TTHB177
TTHB176

1/3
2/3

39

Chromosome

1,507,336

1,507,357

3.3x10-5

1

AAGAGTATGTCAAAACCCTTTA

Intragenic

TTHA1583
TTHA1584

2/3
3/3

40a

Chromosome

574,514

574,535

3.32x10-5

1

TAAACTAAGAAAGTTTACGAAA

Intergenic

TTHA0606

1/2

40b

Chromosome

574,514

574,535

3.32x10-5

1

TTTCGTAAACTTTCTTAGTTTA

Intergenic

TTHA0607

1/1

41

Chromosome

83,733

83,754

3.42x10-5

1

CTTCGTGAAGAAAGGCACGAAA

Intergenic

TTHA0083
TTHA0084

3/3
1/17

42a

Chromosome

290,819

290,840

3.58x10-5

1

TATAGTGAGGTATGGTCCGGTT

Intragenic

TTHA0303

1/1

42b

Chromosome

290,819

290,840

3.58x10-5

1

AACCGGACCATACCTCACTATA

Intragenic

TTHA0304

1/3

43

Chromosome

1,075,934

1,075955

3.68x10-5

1

GATCGTCTTCAAGATCACGAGC

Intragenic

TTHA1134
TTHA1135

2/3
3/3

58

44

Chromosome

1,265,643

1,265,664

3.76x10-5

1

CTTTGTGGGCCAGCTCCCTATA

Intergenic

TTHA1325
TTHA1326

1/1
1/2

45

Chromosome

508,691

508,712

3.79x10-5

1

CACCGTGGACTACGACACCATC

Intragenic

TTHA0543
TTHA0544

1/1
1/2

46

Chromosome

612,470

612,491

3.94x10-5

1

TTTGGTAATCTTTGTCTTAATT

Intragenic

TTHA0644
TTHA0643

2/3
3/3

47

Chromosome

1,546,227

1,546,248

4x10-5

1

CATTGACTTTATGCTCACCATC

Intragenic

TTHA1632

2/2

48

Chromosome

871,788

871,809

4.26x10-5

1

CTTTGGGCTTTGAAAAACAAAG

Intergenic

TTHA0910

3/3

49

Chromosome

612,463

612,484

4.63x10-5

1

ATCTTTGTCTTAATTTACATCG

Intragenic

TTHA0644
TTHA0643

2/3
3/3

50

Chromosome

1,022,206

1,022,227

4.69x10-5

1

CATTGAGACCTACTCCACCAAG

Intragenic

TTHA1074
TTHA1073
TTHA1072

1/1
1/1
1/2

51a

Chromosome

574,529

574,550

4.74x10-5

1

GTTCGTAAACCAAAATAAACTA

Intergenic

TTHA0606

1/2

51b

Chromosome

574,529

574,550

4.74x10-5

1

TAGTTTATTTTGGTTTACGAAC

Intergenic

TTHA0607

1/1

52

Chromosome

495,754

495,775

4.89x10-5

1

GTTTGACATCATAGTTACGAAC

Intragenic

TTHA0533
TTHA0532

1/2
2/2

53

Chromosome

32,413

32,434

4.94x10-5

1

CAAGGTGAAGGACGTCACCAAG

Intragenic

TTHA0030

1/2

54

Chromosome

37,707

37,728

4.94x10-5

1

CAAGGTGAAGGACGTCACCAAG

Intragenic

TTHA0036

1/3

55

Chromosome

976,524

976,545

4.95x10-5

1

GTTGGTGAACTTCAGTAAAATC

Intragenic

TTHA1025
TTHA1026

2/2
1/1

56a

Chromosome

1,332,409

1,332,430

5.15x10-5

1

CCATGTGCCCAAGTATACTTAG

Intragenic

TTHA1398

1/1

59

56b

Chromosome

1,332,409

1,332,430

5.15x10-5

1

CTAAGTATACTTGGGCACATGG

Intragenic

TTHA1399

1/1

57a

Chromosome

203,014

203,035

5.48x10-5

1

TTGTGTAAAAATGCGCACCATG

Intragenic

TTHA0205

1/3

57b

Chromosome

203,014

203,035

5.48x10-5

1

CATGGTGCGCATTTTTACACAA

Intragenic

TTHA0206

1/3

58

Chromosome

738,907

738,928

5.71x10-5

1

CATTGTGCCCCGGGGTGCCTTT

Intergenic

TTHA0770

1/2

59

Chromosome

1,075,413

1,075,434

5.75x10-5

1

AAATGTCCCAAAAAGTCCCTTT

Intergenic

TTHA1133

1/3

P-value indicates the FIMO calculated probability of random sequence of input motif length fitting the identified potential binding
site sequence equally well or better than the input motif. Q-value indicates the rate of false discovery for potential binding sites
considered important. Operon indicates the position of the gene within its transcribed unit.
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2. Chromosome (898755...899296); TTHA0952 and TTHA0953

10. Chromosome (899378...899919); TTHA0953 and TTHA0954

GTGGGGACCCTCTTGGGGGAGGCGGGGGTGAACATCGCCGGGATGCAGCTCGGGCGGGACGTG
CCGGGCGGCCGGGCCCTCTTCGTACTCACCGTGGACCAGAAGCCCTCCCCCGAGGTCCTGGAG
GCCTTGAGGGCCCTTCCCGTCTTGGAGCGGGTGGACCTGGTGGAGCTGTAGCCGCAAGGGGAG
AGAAAAAGCACGAGCGGGAGTAATCGTGAAGTTTATCACATATCGCCCCTCTGAGTTCCGAGT
GTTCACACTTGACCAAACTTTCCGAACCTTCTATCCTGCGGGCGTGGACCCTCACCTCGCCCG
CTGGGTGGAAGAGGCGGCCCGCCTCTTTGAGGCCGGGGGCGTACCCCGGATGGCGGGCCGGGC
CCTGGCCTTCCTCCTGGTGGCCGACCCCCCCGAGCCCACGGCCAAGGAGGTGGCCCAGGCCCT
GGGGGTGAGCAAAGGGGCCCTGAGCCCGGCCCTGGGCTATTTGGTGCGCCTTCACCTCGTGGA
GCGGTTCCGCCGCCCGGGGGAGCGGGCCGACCGCTACA

GCCTGGCCCTCGTCGGGGAGAACCCCCGGTTGCGGGAGGTGCGGGACCTCTACGCCTTTTTGG
AGAGGGAGTTTCCCCTCCTGCTCGCCAAGCTGGAGGAAGGATGACCCTTCTCGGGCTTGCCTG
GCGCAACCTCCTCCGCACCCCGGGGCGGAGCCTCACCACCGGGTGCGCGGGCGTTTAGCGGGG
AGAGAAGTCACAAGCCGAATAAATCGTGAATAAAATCACTAGGAGAGCCTTGTACACTGGGGG
CATGCGTCTGGAGATTCCCAACCACACCGAGCGCTTCGGCGTCGTCCGGCTCCACGAGGTGCA
ACGCATTTTGGAGCTGGACTCCGGGCGCGTGCGGGACGAGTCCCCGGCCGTGGGGCTCCGCCG
GCTGGACGACGCCGACCTCAGGGACGTCCTGGAGCAGACGGCCATCGTGGTGCCCACGCGGAA
CGAGCGCCTGAAGCTCCTGGAAGGCGTCCTCTCCGGGATCCCCCACGAGGCCCTCATCCTCGT
GGCCTCCAACAGCAGCCCCGACCGCTTCCAGATGGAGC

4. Chromosome (402230...402771); TTHA0424 and TTHA0425

14a. Chromosome, compl. (496394...496935); TTHA0534 and TTHA0533

GCGGCCGCGGTGGAAGCGAGGGCCAAGGCCAAGGGGCTTCCCCTCTTCCGGGCAGGGAGGGTG
GTGGCGGGGGAAGGGGTTTACCTCCGGGGGGCGCCCCTTCCCCGGAAGGGGTATGCCCACTTT
TGACACTGCTCCACAAAGCGGGAGCTCTGAGCGCTCCCCGGCTTTCGGACGGGAGGGGCGCAA
GGGCAGGGGGCTTTTGCTTTGTAAAGTGCTTTATTTCACAAAACTGTCCCTCCCCCCGGGTTA
GACTCCCCGGCGTATGGAGGCGACCCTTCCCGTTTTGGACGCGAAGACGGCGGCCCTAAAGAG
GCGTTCCATCCGGCGTTACCGGAAGGACCCCGTACCCGAGGGGCTTCTCCGGGAAATCCTCGA
GGCCGCCCTCCGGGCGCCCTCGGCCTGGAACCTCCAGCCCTGGCGGATCGTGGTGGTGCGGGA
CCCCGCCACCAAACGGGCCCTGAGGGAGGCGGCCTTCGGCCAGGCCCACGTGGAGGAGGCCCC
CGTGGTCCTGGTCCTCTACGCCGACCTCGAGGACGCTC

CGGGTTCACCCGCTTGGCCAAGGCGATGAGCTCGTCGGTGGTGTGCCCCATGGCCGAGACCAC
CACCGCAAGCCGATGCCCCTTCTCGCGGTAGTGGGCGATGCGCTGGGCCACCTTGTGGATGCG
CTCCAGGTCGCCCACGGAGGTGCCGCCGTACTTCTGAACCACCAGGGCCACGCTTCCCTCCTT
CCCCGCCCCCCCGGGCGGTTTGAAAGAGAATGTTAGCACATTTGCCCCCTCCGCCCAAGGCCC
TTATCCTGGGAGGACGTGAGCCTGACGCGGGAAGCCTACCACCGCCTCACCCCCCTTCCCCAC
CCCGGGGGCCGGCTCTTCATCAAGCCCGGGGCCCGGGGGTACCGGGACCCGGTCCACGACCTC
CTGCAGAAGACGGTGGAGCCCTTCGGCGAGCGGGCCCTGGACCTGAACCCCGGGGTGGGCTGG
GGAAGCCTCCCCTTGGAGGGGAGGATGGCGGTGGAGCGGCTGGAGACCTCCCGGGCCGCCTTC
CGCTGCCTCACGGCGAGCGGCCTCCAGGCCCGGCTCGC

6. Chromosome (930956...931497); TTHA0986 and TTHA0987

14b. Chromosome (496494....497035); TTHA0533 and TTHA0534

GCACGGAACTTGCCCTGCCCCTGCCCTCCCCTCTCCTCGAGGCCGCAAGGGGGGCCTTCCTGC
CCCTCACCCAGCTGGTCCTGGGGCCCGCCGGGGCGCTTCCCGCCCTCGAGGGGCGGGAAGCGG
GGAAGGCCTACGTGTGCCGGAGGGGGGTCTGCCTCCTCCCGGTGGACCGGTGGGAGGAGGTGG
AGGCCCGGGTGCGGGGGGATGATTAGTGAAACTTTTCACGATTACACCCGCTTGTGCGTTCTT
TCTCCCCCTAGTCGCTTGACCCCGCCCCCGCCTTCCGGCTAAGCTACTACCGACCGTTCGGTA
AGGAGGACCCCATGCCCGAAGCCTGGATCGTGGAAGCGGTTAGGACCCCCATCGGCAAGCACG
GAGGGGCGCTGGCCTCGGTGCGCCCCGACGACCTCCTCGCCCACGCCCTCTCCGCCCTCGTGG
ACCGCTCCGGCGTCCCCAAAGAGGAAGTGGAGGACGTCTACGCCGGCTGCGCCAACCAGGCGG
GCGAGGACAACCGCAACGTGGCCCGCATGGCCCTCCTC

CCCAGCCCACCCCGGGGTTCAGGTCCAGGGCCCGCTCGCCGAAGGGCTCCACCGTCTTCTGCA
GGAGGTCGTGGACCGGGTCCCGGTACCCCCGGGCCCCGGGCTTGATGAAGAGCCGGCCCCCGG
GGTGGGGAAGGGGGGTGAGGCGGTGGTAGGCTTCCCGCGTCAGGCTCACGTCCTCCCAGGATA
AGGGCCTTGGGCGGAGGGGGCAAATGTGCTAACATTCTCTTTCAAACCGCCCGGGGGGGCGGG
GAAGGAGGGAAGCGTGGCCCTGGTGGTTCAGAAGTACGGCGGCACCTCCGTGGGCGACCTGGA
GCGCATCCACAAGGTGGCCCAGCGCATCGCCCACTACCGCGAGAAGGGGCATCGGCTTGCGGT
GGTGGTCTCGGCCATGGGGCACACCACCGACGAGCTCATCGCCTTGGCCAAGCGGGTGAACCC
GAGACCTCCCTTTCGCGAGCTGGACCTCCTCACCACCACCGGGGAGCAGGTCTCCGTGGCCCT
CCTCTCCATGCAGCTTTGGGCCATGGGGATCCCCGCCA

8a. Chromosome, compl. (418042...418583); TTHA0447 and TTHA0446

17. Chromosome, compl. 109630...110171); TTHA0110 and TTHA0109

AAAAGCCGGAGATGCAGTTCAAGAGGCTCGTCTTCCCCGCCCCGTTGGGGCCGATGATGGAGA
CGAGCTCCCCAGCCTCCACCCGCATGGACACCCCGGAAAGGGCGGCCACGCCGCCGAAGGTAA
GGGTCACGCCTTCCACGTCAAGCTGCGCCACCTACGCCTCCTCAGGGATGCGACTTGGCGTGA
AGTATACCGGGCGGGGCGGCAAATTGTCAACGGGATTACGTATGGGTGTAAAAAACCGTCAGC
CTTTGTTTCCCCTGCTCTATGCTACACTCTTAGAGGCATGGGGGGCCATGGCCCCAGGGAGGG
AGATGGATGAAAAGGACGTGGCAACCCAACCGCAGGAAACGGGCCAAAACCCACGGCTTTCGG
GCCAGGATGAGGACCCCGGGCGGCCGGAAGGTGCTGAAGCGCCGCCGTCAGAAGGGGCGCTGG
CGCCTCACGCCCGCCGTTCGGAAGCGGTAGGCCCCAAGCCCCCCGCCCCGGGGGGCAAGCTTC
TTTCCCTCAAAGGCGACCGGGCCTTCCAGAGGCTCCGC

CGAGGCCCGGGCCCTCACCCCCTTCAAGGGGGCCAAGGGGAAGAAGGTCTTCCGCCGGGGGGT
GCTCTCCGTGGCCGAAAAGACGGTGCGGAGCACGGGGAACCAGAGTAGTGGGGTCCTCCGCTC
CATGGCCTTCGGCAACGCCCTGGTGGTCCTTCCCCCGGACCGGGACGCCCGGGAGGGGGAGGA
GGTGGAGGTCATCCCCTTGACTTTCGTGCCCTAGTTCACTAAGCTAGTAAGGTTTACGGGCGC
TACCCCCCTTTTCGGGCGCAGGTGGGCCCGGAAAGGCAGAGCATGGAGTTTAAAGACTTTCCC
CTGAAGCCAGAAATCCTGGAAGCCCTCCACGGGCGCGGCCTCACCACCCCCACCCCCATCCAG
GCGGCGGCGCTCCCCTTGGCCCTGGAGGGCAAGGACCTCATCGGCCAGGCCCGCACCGGCACC
GGCAAGACCCTGGCCTTCGCCCTCCCCATCGCCGAAAGGCTTGCGCCAAGCCAGGAGAGGGGG
CGGAAGCCCCGGGCCCTCGTCCTCACCCCCACGCGGGA

8b. Chromosome (418142...418683); TTHA0446 and TTHA0447

35a. Chromosome, compl. (471890...472431); TTHA0507 and TTHA0506

GCCAGCGCCCCTTCTGACGGCGGCGCTTCAGCACCTTCCGGCCGCCCGGGGTCCTCATCCTGG
CCCGAAAGCCGTGGGTTTTGGCCCGTTTCCTGCGGTTGGGTTGCCACGTCCTTTTCATCCATC
TCCCTCCCTGGGGCCATGGCCCCCCATGCCTCTAAGAGTGTAGCATAGAGCAGGGGAAACAAA
GGCTGACGGTTTTTTACACCCATACGTAATCCCGTTGACAATTTGCCGCCCCGCCCGGTATAC
TTCACGCCAAGTCGCATCCCTGAGGAGGCGTAGGTGGCGCAGCTTGACGTGGAAGGCGTGACC
CTTACCTTCGGCGGCGTGGCCGCCCTTTCCGGGGTGTCCATGCGGGTGGAGGCTGGGGAGCTC
GTCTCCATCATCGGCCCCAACGGGGCGGGGAAGACGAGCCTCTTGAACTGCATCTCCGGCTTT
TACCACCCGGAGCGAGGACGCATCCTCTTTGAGGGACAGGACCTCACCCGGGCAAGCCCCCAC
GAGGTCACCCGGAAGGGCATCGCCCGGGCCTTCCAGAA

CCTCCTCCACGAAGCCCGCCTGGGCCAGGGCCCTGAGGAGGCGGTAGAGGGTGCTCTTGGCGA
GGCCCACCCGTTCGGCCAAGGGGCCCAAGGGGCTTTCCCCCGCCTGGGCCAGGGCCTCGAGGA
CCCGAAGCCCCCTCTCCAGGGTCTTCACCGCCTGGGGCGGCTTCTCCCGAGGACGCGCCATGC
CGCTTAGGGTAACGGGGGCGGCCCTGTTTTTCAAGATACAAAAAATCTTTTTGCTTCTTGACA
ATCCCGCCCCGCCTCCCGTAAGCTCGGACCACCATGAAGGGCGTGGAGATCCGGAAAGACCAC
CCCCTCCTGAAGGAGGTCCTGACGGAGGAGGCCCTGAGGTTCGTGGTGGCGCTGCACCGGGAG
TTCAACCCGGTGCGCAAGGCCCTCCTGGAGCGGCGTCAAGCGCTTTGGGAGCGGTACAAGGCC
GGGGAGAAGCCGGACTTCCTCCAGGAGACCGCCTTCGTCCGGGGCGGGGCGTGGCGGGTGGCC
GAGGCCCCGCCTGACCTCCTGGACCGCCGGGTGGAGAT

9a. Chromosome, compl. (81095...81636); TTHA0081 and TTHA0080

36b. Chromosome (550550...551091); TTHA0583 and TTHA0584

CGTCTTTCACCAGGCGCTCCGCGTCGGAGAGGACCTCGTAGGCGTCGTGCCAGCCCTCCGGGC
CCACCACCTTGTCCAGGCGGTCCAACACGGTGCGGGCGTCCACGTAGGGGACCACCAAGGCCC
GCTTCTTGTCCCGGGAGAGGGCTTCCACGCGCCACTGCACCTCCCCCGGGGGAAAGGGTTCGG
CCAGTTTCCGCCAGACTTCGTCCATGTGTTTTAGTTTACTTTAGGTTGCTCTCACCCCAAAGC
CTTGGGGGAAGGCGAAGATGGGGGCATGAAGCGGTGGCTGGCGTTCCTTCCCTTCCTGGCCCT
GGCCTGGGCTTTGGAGCTCAGGGTCACCGCCTCCTTGGTGGTGGACCTCTTCCCCCAGGCGGT
GGTGGTGGAGCGGGTTACCGAGCCCCAGGGGATCGTGGTGGTTTACCAGGCTTCCCAGGCGGA
GGCCGTTTTCCGCTACCACGACCTGGACCTCCGCCGCCGGGGCTGGGTGCGGGTGAAGTACGA
GGTCAAGAAGGGCGAGTGGAAGGCGGAGTACCGCAAGG

CCCTTTCCAGGAGGGGCGGGAGGAGGCCTTCCAGGACGGCGTGGGCGGCCTCGAGGCTCGGCC
TCGTCCCCACCCTCTCCCCCAGGACCTCGCTGGTGGAGCCCCCGAGGACGAAGAGGCTCCCGG
GCGCCATGGGGAAGGCCTGAAGAAACTCTTCCGCGGCCCGCTGCGCCGCGCGCCGGATGCCCT
CCATGCCTCCATGGTAGCCGGAAAAGTGCCCTGGCCCCCTTTTCCCCGGGCAGGGCGGGGGTA
CCCTTAAGCCATCCCGACTCAAGGAAGGCCGTTCTGGGTTTCCGCTCCCGCGCCGCACGAAAG
GCAGGGTGAGTACGGTGAAAAAGATCCTGTGGCTGCCCTTCTTGGGCCTCGCCGCCTGTTCCC
AGTGGCAGGGGGCGGACGACTCCAGGTGGCTCCTGGAGCCTGCGGGCCTCTCCTGGGTGGACT
GCGCGCCGGGCCCCAGGGGGGAGGCCCTGGCCTACGACTTCGTCCACGAGGAGGTGCCCGGGC
GAAGCTTCGCCCCGTCCCCGGACGCCTGCGGGGGGCAT

9b. Chromosome (81195...81736); TTHA0080 and TTHA0081

37b. Megaplasmid (79393...79934); TTHB088 and TTHB089

CTCCGCCTGGGAAGCCTGGTAAACCACCACGATCCCCTGGGGCTCGGTAACCCGCTCCACCAC
CACCGCCTGGGGGAAGAGGTCCACCACCAAGGAGGCGGTGACCCTGAGCTCCAAAGCCCAGGC
CAGGGCCAGGAAGGGAAGGAACGCCAGCCACCGCTTCATGCCCCCATCTTCGCCTTCCCCCAA
GGCTTTGGGGTGAGAGCAACCTAAAGTAAACTAAAACACATGGACGAAGTCTGGCGGAAACTG
GCCGAACCCTTTCCCCCGGGGGAGGTGCAGTGGCGCGTGGAAGCCCTCTCCCGGGACAAGAAG
CGGGCCTTGGTGGTCCCCTACGTGGACGCCCGCACCGTGTTGGACCGCCTGGACAAGGTGGTG
GGCCCGGAGGGCTGGCACGACGCCTACGAGGTCCTCTCCGACGCGGAGCGCCTGGTGAAAGAC
GAGAGGGGCGAGAGGCGGGAGCGCCTTTGCGAGGTCAAGTGCCGCCTCACCGTCCTCGGGGTC
ACCAAGGAGGACGTGGGGGAGGGGGACTCCCTGAAGGC

GGACTGGCCGTCGGAGAGGACCACCGCCTGGATCCCCCCTACCCGGAAGCGGTAAAAGCCGCC
CCCGTTCACCCCCTTGGGCGCGCGCCCCTGGGCCCGGCCCAAGGGAAGGCCTCCCGCCGCCAA
AAAAAGCCCCGCACCGGTGAGAAAACGCCTGCGGTCCATGCCCTTACCTCCTTTGGGAGGATG
CTAGGGCCGAAGGTCCCCCGAGAATGTGCTCCCCCTCACCCTGGGTGTGGTCCAGGCTACCTT
GGCGGGAGGTTTATGTGGCCTGCGCCCATTTTGACGGGCAGGCCTCCCTCTAGGCTTTTCCCG
TGGAGGTGAAAAGATGAAACGAGGCCTTTTTGTTCTGGTTCTGGCGGCCCTGGCCGGCCTGGC
CCTGGGCCAAGGCGCCATGGTGCGGGTGGCCCACCTCTCCCCCGACGCCCCGGCGGTGGACGT
CCTGGTGAACGGGCAGCGGGCCATCACGGGCCTGGCCTTCAAGGAGGTGACCCCCTACATCCC
CCTTCCCGCCGCCAAGGTCCGGGTCCAGGTGGTGCCCG
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40a. Chromosome, compl. (574204...574745); TTHA0607 and TTHA0606

56b. Chromosome, (1332199...1332740); TTHA1398 and TTHA1399

TGGGCAGAAGCCGCTTTTAACGTTGAGAAGACGGACCAGCTTGAGCCGCCGTCCGAAAAAGTA
CTCCTTGACCCGGATGGCCGCCTCCGCCAAAGCAGGCAGGGCCTCGGGTGGGGCCTCGAGGAC
AAAAAGGGCTTCCTGTAGGCTCAAGGGCCTTTCGGCCAGGCGAGGAGGGTCCAGATCGGGCCA
CGCCATGTTCGTAAACCAAAATAAACTAAGAAAGTTTACGAAAGCAAGGGGCGCGTTGCCCAA
ATCACGGCCGTGCCCTAAACTTAGACCTCGTGAAGAGGGTGATGTTCCACGCCAAGATCCACC
GGGCCACCGTGACCCAGGCCGACCTCCACTACGTGGGCTCGGTGACGGTGGATCAGGACCTCC
TGGACGCCGCCGGGATCCTTCCTTTTGAGCAGGTGGACATCTACGACATCACCAACGGGGCCC
GGCTCACCACCTACGCCCTTCCCGGGGAACGGGGGTCCGGCGTCATCGGGATCAACGGGGCCG
CGGCCCACCTGGTGAAGCCCGGGGACCTGGTTATCCTC

CTGAGCCTCCCCTCCTCCAGCCTCCCCGAGACCTTCACCTTCAAGGCGTCGTAGAGGCCCGTG
ACCCGGACGGGGTACTCCGCCTCCCCCGTGTACTTCCAGTAGAAGACGGGGAGGAAGGGGGGG
TAGCCCACGGCCAGGCCGTACCGCTCGGCGTACCAGTAGAGGCCCAGGGCCGCCAGGGCCAGA
AAGAGCAGGGTCCGCATTGGCCTAAGTATACTTGGGCACATGGCGGGCACCGGCCACACCCCG
GAAGAGGCCCTGGCCCTCCTCAAGCGGGGGGCCGAGGAGATCGTCCCCGAGGAAGAGCTTCTC
GCCAAGCTCAAGGAGGGGCGGCCCCTCACGGTCAAGCTCGGAGCCGACCCCACGAGGCCCGAC
CTGCACCTGGGCCACGCGGTGGTCCTGAGGAAGATGCGCCAGTTCCAGGAGCTCGGCCACAAG
GTGGTCCTCATCATCGGCGACTTCACCGGGATGATCGGGGACCCTTCGGGCCGTTCCAAGACC
CGGCCCCCCCTCACCCTGGAGGAGACCCGGGAGAACGC

40b. Chromosome (574304...574845): TTHA0606 and TTHA0607

57b. Chromosome, (202804 .. 203345); TTHA0205 and TTHA0206

CGGGCCCCGTTGGTGATGTCGTAGATGTCCACCTGCTCAAAAGGAAGGATCCCGGCGGCGTCC
AGGAGGTCCTGATCCACCGTCACCGAGCCCACGTAGTGGAGGTCGGCCTGGGTCACGGTGGCC
CGGTGGATCTTGGCGTGGAACATCACCCTCTTCACGAGGTCTAAGTTTAGGGCACGGCCGTGA
TTTGGGCAACGCGCCCCTTGCTTTCGTAAACTTTCTTAGTTTATTTTGGTTTACGAACATGGC
GTGGCCCGATCTGGACCCTCCTCGCCTGGCCGAAAGGCCCTTGAGCCTACAGGAAGCCCTTTT
TGTCCTCGAGGCCCCACCCGAGGCCCTGCCTGCTTTGGCGGAGGCGGCCATCCGGGTCAAGGA
GTACTTTTTCGGACGGCGGCTCAAGCTGGTCCGTCTTCTCAACGTTAAAAGCGGCTTCTGCCC
AGAGGACTGCGCCTACTGCGCCCAGTCCGCTAGATCCCAAGCCGCCATCGCCCGGTACCCCCT
GCTCTCCTTGGAGGAGATCTTGGAGAGGGCCGAGGAGG

GGGCAGCCCCGCCCTGCCCTCCAAGGGCCGCGTCCAGCCGGGGGCGAGGAGGAGGGCGGCCAAG
GCCAGGCGCCCCGCGCTCATCACCAGGCTGAAGGCGAGGCTTTGGTCCCCGGAGGCCCGAAGGG
CCAGGCGCACCAGGATGCTCCCGAAGCTTATGGCCAGGATGCCCACGAGAAGGACGGCGGCGAT
CTTCCACCCCGGGGGGCGCATGGTGCGCATTTTTACACAAGGGAAGCCTTCCGGGAAGCGTCAA
AGTAGTGTAGCCCAAGGGAAAACCCGGGGACGGACGCCCCACCCCGCGCTGGTATACTTCCCCC
GAAGGAGGCGCCTATGGTGACCGTCGCGGTTCCCAAGGAAAGGGCCCCAGGGGAAAGGAGGGTG
GCCCTGGTGCCCGAGGTGGTGGCCCGCCTGGTGAAAGGCGGGGCCCGGGTGCGGGTGGAGCGGG
GCGCGGGGGAGGGCGCCTACCACCCCGACGAGGCCTACCAGGAGGCCGGGGCCGAGGTGGTGGA
GCGAGGGGAGCTCCTAAAGGGCGCCCACCT

51a. Chromosome, compl. (574219...574760); TTHA0607 and TTHA0606

58. Chromosome, compl. (738597...739138); TTHA0771 and TTHA0770

GTAGGCGCAGTCCTCTGGGCAGAAGCCGCTTTTAACGTTGAGAAGACGGACCAGCTTGAGCCG
CCGTCCGAAAAAGTACTCCTTGACCCGGATGGCCGCCTCCGCCAAAGCAGGCAGGGCCTCGGG
TGGGGCCTCGAGGACAAAAAGGGCTTCCTGTAGGCTCAAGGGCCTTTCGGCCAGGCGAGGAGG
GTCCAGATCGGGCCACGCCATGTTCGTAAACCAAAATAAACTAAGAAAGTTTACGAAAGCAAG
GGGCGCGTTGCCCAAATCACGGCCGTGCCCTAAACTTAGACCTCGTGAAGAGGGTGATGTTCC
ACGCCAAGATCCACCGGGCCACCGTGACCCAGGCCGACCTCCACTACGTGGGCTCGGTGACGG
TGGATCAGGACCTCCTGGACGCCGCCGGGATCCTTCCTTTTGAGCAGGTGGACATCTACGACA
TCACCAACGGGGCCCGGCTCACCACCTACGCCCTTCCCGGGGAACGGGGGTCCGGCGTCATCG
GGATCAACGGGGCCGCGGCCCACCTGGTGAAGCCCGGG

GACCACGAGTTTCTACTCCGCCCGGGACAGTACCTACTAGAGCTAGGGACCCCAGGGGTAGTC
TCCCTACGCCTACAAGCCTGGGAGACCGCTCCAGGAAACCAAGAAATCCTCGTACCCCTAGAG
ATGACCGAGAGCCTCTAAGCGTTCTCCCGTAGGGACCAATCCCCTCCGCTGGCGGCCGCGGTC
CCCGGCCAAAGCCTGAACGCCCATTGTGCCCCGGGGTGCCTTTGTTTCCTGAAAGGGGGGTAT
CATAGGGGCAGATGAAGGACTTTCTGCGCCTAGAACTCCCCGTGCTCCCTCTCCGGAACACCG
TGGTCCTCCCCCACACCACCACCGGGGTGGACGTGGGGCGCCTCAAGAGCAAGCGGGCGGTGG
AGGAGGCCCTCTCCGCCGACCGGCTCCTCTTCTTGGTGACCCAGAAGGACCCGGAGGTGGACG
ACCCCGCCCCGGAGGACCTTTACGCCGTGGGCACCCTGGCCGTGGTCAAGCAGGCCATGCGCC
TGCCGGACGGCACCCTCCAGGTGATGGTGGAGGCGAGA

51b. Chromosome, (574319..574860), TTHA0606 and TTHA0607

59. Chromosome, (1075203...1075744); TTHA1132, TTHA1133, and TTHA1134

ATGTCGTAGATGTCCACCTGCTCAAAAGGAAGGATCCCGGCGGCGTCCAGGAGGTCCTGATCC
ACCGTCACCGAGCCCACGTAGTGGAGGTCGGCCTGGGTCACGGTGGCCCGGTGGATCTTGGCG
TGGAACATCACCCTCTTCACGAGGTCTAAGTTTAGGGCACGGCCGTGATTTGGGCAACGCGCC
CCTTGCTTTCGTAAACTTTCTTAGTTTATTTTGGTTTACGAACATGGCGTGGCCCGATCTGGA
CCCTCCTCGCCTGGCCGAAAGGCCCTTGAGCCTACAGGAAGCCCTTTTTGTCCTCGAGGCCCC
ACCCGAGGCCCTGCCTGCTTTGGCGGAGGCGGCCATCCGGGTCAAGGAGTACTTTTTCGGACG
GCGGCTCAAGCTGGTCCGTCTTCTCAACGTTAAAAGCGGCTTCTGCCCAGAGGACTGCGCCTA
CTGCGCCCAGTCCGCTAGATCCCAAGCCGCCATCGCCCGGTACCCCCTGCTCTCCTTGGAGGA
GATCTTGGAGAGGGCCGAGGAGGCCCAACGCCTTTCTG

ATGGTCCGGGCCGTGGTGGACCCCGAGGGGAAGTTCCCGGTCCTCGAGGCGGTGGCCACCGAGG
GCAAGGGGGTCTTTGAGACCCTCAAGGAGGTGAGCCGCCTGGTCCTCGCCCGCGTGGCGGGCGG
GTCTTAAGCGGCCCACGCGCCCGGGGGCGGGGCGACCCGCCCCCTTTTTACTCCCCACCCGTAT
TCCGGACTTTATAGGGACAAATGTCCCAAAAAGTCCCTTTGCCAAGGGACAAATGCCCCTCACC
GCAAAGCCCGGTTTCCGCTACCATGGAGGCCGTATACGGCACCTGCCGTTAGGGAGGAGGGGTA
TGGAAGAAAAGCCCAAAGGCGCACTGGCGGTCATCCTGGTCCTGACCCTCACCATCCTGGTCTT
CTGGCTGGGAGTGTACGCCGTCTTCTTCGCTAGGGGGTAGGTATGGTGGACGAGCACAAGGCCC
ACAAGGCGATCCTGGCCTACGAGAAGGGGTGGCTCGCCTTCTCCTTGGCGATGCTCTTCGTCTT
CATCGCCCTCATCGCCTACACCCTGGCCAC

55. Chromosome, (976314...976855); TTHA1025 and TTHA1026
AGGCCCTCTGGGGCCTCCTGGTCGAGGCCATCGCCGACCGCCTCGTGGACGGTTGGGACCGGTA
CGGGGCCCCCAGCGCGGCCCGGGATCCCGAGGGGGGATTCGTGGCCAGCGCCGAGGGGCCAGGG
GAGCCCATCGTGGTTCGGGCCTCCACGAAGCGCGAGGCCTACCGGGAGGCTCGCCGGGAGTGGG
TGAAGCGGCTCCTAAACGGTTGGTGAACTTCAGTAAAATCCCTCTGCTCCGTACCCCTCTTTGG
GGTTCCTTGATACTCTCGAGTCGTGCAAGGAGAAGTCCTGACCGTGGCGGAGGTGGCCAAGCTC
CTCCGGGTTAGCCGCAAGACGGTGGAAAAGCTCATCTACGCCAAGAAGCTCCACGCGGTGAAGG
TGGGCCGGGTTTGGCGCATCCCGAGGGCCGCCGTGGAGGCGTTCTTGGAGGGGAAGGAGTACCG
TGAACCTTAGGAAGCTCTGGTCCTGGCTTCGCTTCGCCAAAGCCCTCTCCCGGGGCCGGGTGGG
CAAGCGGTGGGCCCTACGCCGGGCCCGGTG

Figure 11. Bioinformatically characterized TTHA1359-binding sites in the T. thermophilus
HB8 genome with regulatory potential. Sequences depict the genomic sequence context, 210/+310 bp, of the refined twenty-three FIMO-identified TTHA1359-binding sites
analyzed for potential regulatory functions. Blue, red, green, and black nucleotides represent
genes oriented 5’→ 3’, overlapping genes oriented 5’→ 3’, genes oriented 5’→ 3’ on the
complementary strand, and intergenic regions respectively. Cyan, yellow, and green
highlighting represent predicted core promoter elements, potential TTHA1359-binding sites,
and potential TTHA1359-binding sites overlapping core promoter elements respectively.
Underlined nucleotides indicate translation start sites.
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Table 3. Identification of potential TTHA1359-binding transcriptional activation sites
FIMO
Result

Candidate
Regulated
Gene(s)

Potential Binding Site
Distance to Predicted
Transcription Start
Site

Phase
(bp)

Regulatory

2

TTHA0953

-74.5

3

N

-

4

TTHA0425

-41.5

0

Y

Activating, Class II

6

TTHA0987

-82.5

0

Y

Activating Class I

8a

TTHA0446

-65.5

4

N

-

Mechanism

8b

TTHA0447

-38.5

3

N

-

14a

TTHA0533

-44.5

3

N

-

35a

TTHA0506

-61.5

0

Y

Activating, Class I

36b

TTHA0584

-41.5

0

Y

Activating, Class II

37b

TTHB089

-93.5

1

Y

Activating, Class I

40a

TTHA0606

-58.5

3

N

-

51a

TTHA0606

-73.5

2

N

-

57b

TTHA0206

-99.5

3

N

-

58

TTHA0770

-41.5

0

Y

Activating, Class II

Phase indicates the alignment of potential binding sites in relation to predicted core
promoter elements. A phase of 0 indicates sites are aligned. Other phase numbers
indicate sites are unaligned and by how many bp they are out of alignment. Potential
sites were considered likely (Y) or unlikely (N) to function as regulatory sites based
on phase alignment.78,79 Potential mechanisms associated with identified potential
regulatory TTHA1359-binding sites were described as Activating, Class I if sites
were positioned upstream of predicted -35 elements and Activating, Class II if sites
overlapped predicted -35 elements.
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CHAPER 4. DISCUSSION
In the Van Dyke laboratory, a reverse-genetic technique involving the
combinatorial selection technique REPSA has been applied to study the possible
regulatory and biological roles of TFs by identifying their DNA-binding specificities and
the potential genes they regulate.19-22 Since many TFs lack a level of characterization
beyond a mere family categorization, an end goal in the Van Dyke laboratory is to
implement this reverse-genetic technique as an effective alternative to other methods
used to study putative TFs. Previously, this reverse-genetic technique had been applied
to study the DNA-binding specificities and potential genes regulated by four T.
thermophilus HB8 transcriptional repressors.19-22 These TFs were specifically selected to
study using this reverse-genetic technique because they possessed a pre-existing level of
regulatory and biological characterization.14,15,17,18 This allowed the findings from the
reverse-genetic studies of these TFs to be compared to previously reported findings to
evaluate the effectiveness of the reverse-genetic technique.14,15,17-22 In general, the
reverse-genetic studies with these four TFs not only corroborated previous findings but
also reported additional findings which further characterized these TFs. 14,15,17-22 In the
present work, several steps in the application of this reverse-genetic technique to identify
the possible regulatory and biological roles of the previously studied T. thermophilus
HB8 transcriptional activator TTHA1359 have been described as part of yet another
study to evaluate the effectiveness of this reverse-genetic technique.12,13
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The DNA-binding consensus 5’-A(T/A)TGT(G/A)A(N6)T(C/T)ACA(A/T)T-3’
was identified for TTHA1359 using REPSA to select sequences preferentially bound by
TTHA1359, massively parallel sequencing to acquire the sequence information of these
selections, and MEME to elucidate TTHA1359-binding motifs from obtained sequence
information. Previous studies with TTHA1359 initially identified sixteen gene promoters
which were upregulated in the presence of TTHA1359.12,13 Eight of these promoters
were initially identified through differential gene expression levels obtained from wildtype and TTHA1359-inactivated T. thermophilus HB8 strains.12 The other eight gene
promoters were initially identified by analyzing gene expression levels obtained from
various experiments with T. thermophilus HB8 strains for individual genes whose
expression showed strong positive correlations with TTHA1359 expression.13 After
validating that these sixteen gene promoters were upregulated in a TTHA1359dependent mechanisms in run-off transcription assays in vitro, putative TTHA1359binding sites were assigned to these sixteen gene promoter sequences from which the
putative consensus TTHA1359-binding site 5’-TTGTG(N9)CNC-3’ was derived.12,13
Comparing this consensus to the consensus identified for TTHA1359 in the present work
reveals a partial overlap between consensus sequences, particularly in the consensus
composition along the 5’-end of both consensuses.13 While the consensus from the
previous studies was derived from sixteen predicted TTHA1359-binding sites, the
TTHA1359-binding consensus in the present work was derived from a motif, primarily
the top non-palindromic motif, discovered in seven hundred and eighty-nine
experimentally selected unique sequences.12,13 Therefore, greater confidence is placed in
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the REPSA-selected TTHA1359-binding consensus as an accurate representation of the
DNA-binding specificity of TTHA1359.
Prior to bioinformatically applying the TTHA1359-binding consensus identified
in the present work to identify potential regulatory binding sites for TTHA1359 in the T.
thermophilus HB8 genome, the consensus was evaluated biophysically by BLI to assess
its true reflection of intrinsic TTHA1359-DNA binding specificity. This evaluation
included testing not only TTHA1359-binding to the identified consensus but also to
single-point and spacing mutants of the consensus to probe this specificity. TTHA1359
was observed to bind with high affinity, apparent KD of ~ 3.4 nM, to the identified
consensus, and single-point mutations to the consensus were found to lower this high
binding affinity (Table 1). Of the single-point mutations to the consensus tested, some
were found to dramatically reduce this binding affinity with no significant or detectable
binding having transpired under the reaction conditions applied while others were found
to reduce this binding affinity less radically with apparent KD values ranging from ~ 23
to ~ 86 nM (Table 1). These single-point mutations were found to reduce TTHA1359binding affinity in a method that reflected the significance of the positions in the
TTHA1359-binding consensus as indicated by the top MEME non-palindromic motif
(Figure 9A1, Table 1). Additionally, consensus spacing mutations were observed as
having no significant or observable binding which suggests that TTHA1359 possesses a
stringent consensus spacing requirement for recognition (Table 1). Because BLI assays
were limited by the instrument to temperatures considered non-native for the protein,
37°C as opposed to at least 47°C, this consensus spacing requirement might merely
reflect an experimental constraint.81,82 Higher temperatures might introduce a level of
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flexibility within the TTHA1359 dimer which might allow TTHA1359 to recognize
shorter or lengthier consensus spacer sequences. With an apparent KD of ~ 1 nM, the
CRPEc consensus was the only sequence tested that exhibited higher binding affinity than
that of the identified TTHA1359-binding consensus (Table 1). Because of a significant
degree of consensus conservation between the tested TTHA1359-binding and CRPEcbinding consensus sequences, the higher binding affinity observed for the CRPEc-binding
consensus was considered the cumulative result of differences between the two
sequences (Figure 5A2, 9C, Table 1).63 These differences included the 6-bp spacer
sequences of these consensuses, 5’-TCTAGA-3’ in the CRPEc consensus sequence as
opposed to 5’-CACACA-3’ in the TTHA1359 consensus sequence, and single bp
differences in the half-sites between consensus sequences (Figure 5A2, 9C, Table 1).63
Together, these kinetic experiments support an accurate reflection of preferred
TTHA1359-DNA binding in the REPSA-selected TTHA1359-binding consensus.
Curiously, in vitro run-off transcription assays which were performed to
demonstrate TTHA1359-dependent transcriptional upregulation at the promoters
identified in previous studies utilized a concentration of 1 μM TTHA1359 dimer.12,13
Results of these run-off transcription experiments were either black or white with an
observed upregulation of transcription observed in reactions containing TTHA1359.12,13
The relatively high concentration of TTHA1359 protein in these reactions solicited
initial concern as BLI experiments in the present work suggest that TTHA1359 possesses
a low level of binding specificity.12,13 This was suggested by individual single-point
mutant consensus experiments which found that TTHA1359-binding to its consensus
sequence had an apparent KD that was minimally ~ 8-fold higher than that of mutant
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consensus sequences (Table 1). Additionally, a binding event between TTHA1359 and a
control sequence was detected by BLI at 461 nM TTHA1359 dimer, the highest
concentration of TTHA1359 protein used in BLI experiments (data not shown). Whether
this interaction was specific or non-specific was not ascertained. Previously, the
expression level of TTHA1359 in the stationary phase had been reported measuring
minimally ~ 8.5-fold higher than that of TTHA1359 in the exponential phase of wild-type
T. thermophilus HB8 growth during cultivation in different growth media.12 However, a
high concentration of expressed TTHA1359 transcripts might not necessarily correlate
with a high concentration of translated TTHA1359 protein. Based on the present work,
concentrations of 1 μM TTHA1359 dimer used in previous studies to validate
TTHA1359-dependent transcriptional regulation were initially considered excessive,
resulting in false positive indications of regulation by TTHA1359 from non-specific
binding driven by high protein concentrations.12,13
However, results of run-off transcription assays performed with TTHA1359 and
increasingly shorter promoter sequences upstream of genes TTHA0337 and TTHA0634
suggested the presence of specific promoters sequences essential to the TTHA1359dependent transcriptional upregulation of these gene promoters.12 These reported results
were baffling considering the predicted binding sites for TTHA1359 upstream of these
genes, 5’-AGGGGAACCCACGGCACAC-3’ and 5’-TTGTGCCTTTTACCCCT-3’
respectively, were very different from the REPSA-selected TTHA1359-binding
consensus.12 As a result of the observed phenomenon, a hypothesis was formulated with
regard to TTHA1359 transcriptional activity. If TTHA1359-binding conveys insufficient
specificity to discriminately upregulate transcription, then perhaps a second mechanism
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conveys further specificity. Since similarities have been reported for structures of
TTHA1359 and CRPEc and drastically different binding affinities have been reported for
CRPEc and its consensus compared to one of its most well-understood regulatory binding
sites, studies with CRPEc were investigated for a potential answer.12,63
As it happens, simple CRPEc-dependent transcriptional activation at promoters
has been reported to be dependent upon the positioning of binding sites for CRPEc
relative to core promoter elements.78,79 Studies in which a binding site for CRPEc was
displaced at increasingly lengthier distances from the -35 core promoter element
suggested a loss followed by a return of transcriptional activity depending on the
distance introduced from the initial site of activity.78,79 Spacing mutants for which
transcriptional activity was lost corresponded to spacer sequences resulting in partial or
half-turns of the DNA double-helix while activity was returned for spacer sequences
resulting in full or nearly-full turns of the DNA, positioning CRPEc interactions with
RNA polymerase holoenzyme out of or into alignment with core promoter elements
respectively.75,78,79
Provided the importance of spacing for simple CRPEc-dependent transcriptional
activation, a spacing requirement was imposed during the search for potential regulatory
TTHA1359-binding sites based on distances from predicted core promoter elements.
Initially, eighty-eight potential TTHA1359-binding sites within the T. thermophilus HB8
genome were identified. Of these, the first fifty-nine were selected for further
investigation, totaling seventy-four potential binding sites when sites positioned near
bidirectionally-oriented promoters with dual regulatory potential were accounted (Table
2). These potential sites were narrowed down to twenty-three TTHA1359-binding sites
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with regulatory potential based on several criteria including the presence of predicted
core promoter elements, the positioning of these promoter elements relative to translation
start sites of local genes, and positioning of potential TTHA1359-binding sites relative to
these promoter elements (Figure 11). Since the criteria for reducing the number of
potential regulatory TTHA1359-binding sites revolved to a large extent around predicted
core promoter elements, several potential regulatory binding sites for TTHA1359 might
have been missed due perhaps to the inability to predict core promoter elements or the
inaccurate prediction of core promoter element positioning. This is a current limitation of
the reverse-genetic technique resulting from the orientation of promoter prediction
software to predict core promoter elements based on those recognized by the
housekeeping RNA polymerase holoenzyme in E. coli and not that of T. thermophilus.90
While attempts by the Van Dyke laboratory are being made to more accurately predict
and map T. thermophilus core promoter elements, the promoter prediction software used
in this study was currently considered the best option to predict promoters with a userdefined restriction as to the allowable distance between predicted transcription and
translation start sites.
Of the twenty-three refined TTHA1359-binding sites with regulatory potential,
thirteen of the twenty-three were positioned upstream of predicted -35 core promoter
elements with the potential to function as transcriptional activation binding sites for
TTHA1359 (Table 3). However, only five of these thirteen potential TTHA1359-binding
sites were positioned optimally upstream to activate transcription at gene promoters
(Table 3). These five potential binding sites corresponded to those found upstream of
genes TTHA0425, TTHA0506, TTHA0584, TTHA0770, and TTHA0987. A sixth potential
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activating site for TTHA1359 was found upstream of TTHB089, but this site was
considered unlikely to lead to substantial upregulation of TTHB089 by TTHA1359 (Table
3). The eight remaining upstream potential sites were positioned poorly, oriented along
different or opposite faces of the DNA double-helix as core promoter elements (Table 3).
These potential TTHA1359-binding sites were considered unlikely to upregulate
transcription of local downstream gene promoters. As a point of interest, the remaining
ten potential binding sites overlapped the core promoter elements in a manner suggestive
of transcriptional repression. Because previous studies with TTHA1359 only reported its
activity as a transcriptional activator, the role of these sites has yet to be determined.12,13
In contrast to the absence of previous findings supporting a role for TTHA1359
as a transcriptional repressor, ample findings have been reported supporting the role of
TTHA1359 as a transcriptional activator.12,13 TTHA1359 has been demonstrated to
upregulate transcription from promoters upstream of the sixteen genes TTHA0425,
TTHA0654, TTHA0337, TTHA0986, TTHA0770, TTHA1028, TTHA0634, TTHA0570,
TTHA0557, TTHA0029, TTHA1128, TTHA1215, TTHA1625, TTHA1635, TTHA1892,
and TTHB132 in run-off transcriptional assays in vitro.12,13 Comparing these genes to
potentially regulated genes identified in the present work, TTHA0425, TTHA0506,
TTHA0584, TTHA0770, and TTHA0987, suggests the overlapping identification of only
the two genes TTHA0425 and TTHA0770.12,13 A third gene, TTHA0987, would have
overlapped the genes identified in both studies had it not failed to be validated in a
previous study.13 Previous TTHA1359 studies predicted TTHA1359-binding sites within
~ 30-50 bp of transcription start sites, positions suggestive of Class II transcription
activation binding sites for TTHA1359.12,13 However, in the case of the TTHA0987 gene
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promoter as determined in the current study, the TTHA1359 binding site maps to ~ 82 bp
upstream of the transcription start site, indicative of a Class I transcriptional activation
binding site for TTHA1359. Analyzing the run-off transcription template promoter
sequence utilized to test TTHA0987 promoter regulation by TTHA1359 in the previous
study suggested the TTHA1359-binding site identified in the present study had been
occluded by 20 bp.13 This was considered the likely reason why the TTHA0987 gene
promoter failed to be validated in the previous study.13 Interestingly, the TTHA0987 gene
promoter might be coregulated by TTHA1359 and TTHB032, a previously studied
transcriptional repressor in the Van Dyke laboratory, based on potential regulatory
binding sites for both TFs identified in the TTHA0987 gene promoter.17,22
Of the five genes potentially activated by TTHA1359 based on optimally
positioned potential regulatory binding sites in their promoters, the genes TTHA0506 and
TTHA0584 appear to be novel genes which could have been missed in previous
studies.12,13 These sites could have been missed in previous genetic studies due to
occlusion of these binding sites by chromosome organization or the activity of
transcriptional repressors interfering with the activation of TTHA0506 and TTHA0584
gene promoters.12,13 Regarding the remaining fourteen TTHA1359-regulated genes
identified in previous studies with TTHA1359, these sites could have been missed using
the reverse genetic technique due to promoter prediction limitations mentioned in a
preceding paragraph or the limited number of FIMO-identified results investigated.12,13
To test the latter possibility, the extended TTHA1359-binding consensus motif created
should be applied using FIMO to search the promoter sequences of these fourteen genes
used in run-off transcription assays in previous studies.12,13 Identified TTHA1359 motif
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matches within these promoter sequences should then be searched within the list of
potential TTHA1359-binding sites in the T. thermophilus HB8 genome initially
identified by FIMO using the extended TTHA1359-binding consensus motif. The initial
FIMO scan could be expanded, if necessary, by resubmitting the initial search with a
lower p-value threshold for matches to the TTHA1359-binding consensus. Identifiable
since on the list would support that the missed genes reported in previous studies could
have been identified as genes potentially activated by TTHA1359 using the reversegenetic technique if more FIMO-identified sites would have been investigated.12,13
As the present work served as an additional test as to the effectiveness of a
reverse-genetic technique involving REPSA to study TFs, a conclusion of the present
work without evaluating the effectiveness of this reverse-genetic technique would leave
the present work incomplete. Based on the findings of the current study, applying a
reverse-genetic methodology involving REPSA alone to study global transcriptional
activators appears inadequate to the task. A strength of the genetic approach previously
applied to study TTHA1359 was the apparent in vivo identification of genes whose
promoters were potentially regulated by TTHA1359 which allowed run-off transcription
assays to be performed in vitro to validate TTHA1359-dependent regulation of the
identified promoters.12,13 In some instances, a genetic approach such as the approaches
used to study TTHA1359 might miss potentially regulated genes.12,13 Such a case is
demonstrated by the T. thermophilus HB8 gene TTHA0987 which was identified as
potentially regulated by TTHA1359 but not validated for TTHA1359-dependent
transcriptional upregulation previously.13 Additionally, genes, potentially including
TTHA0506 and TTHA0584 identified in the present work, might be missed due to other
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factors complicating genetic approaches to studying TFs which have been mentioned
previously. However, the genetic approaches used to study TTHA1359 identified more
genes under the control of TTHA1359 than the reverse-genetic technique used in the
present work.12,13 Strengths of the reverse-genetic technique include the ability to
characterize the intrinsic DNA-binding specificity of TFs and biophysically characterize
TF-DNA interactions.19-22 However, as suggested in the present work with TTHA1359,
identifying potential regulatory binding sites within genomes based on statistically
significant matches to the DNA-binding consensuses of TFs does not account for
additional mechanisms such as binding site spacing from core promoter elements which
might prove more critical to the regulatory roles of TFs than these matches. A
combinatorial approach, understanding the DNA-binding specificity of TFs and
application of such understanding to validate potentially regulated gene promoters
identified by a genetic approach might prove a more effective method. However, since
TTHA1359 functions as a global activator, it might represent a special case.12,13
Finally, a few future directions for the project have been described. Future work
should seek to validate whether TTHA1359 upregulates the transcription of TTHA0506
and TTHA0584 which were genes not previously identified in previous studies with
TTHA1359.12,13 In vitro run-off transcription assays could be used to validate these
genes as with the genes in previous TTHA1359 studies.12,13 Additionally, an in vitro runoff transcription assay with the TTHA0987 gene promoter should be performed
incorporating both TTHA1359 and TTHB023 to determine whether coregulation of this
gene occurs as suggested by prior work and the present study.22 The fourteen
TTHA1359-regulated genes reported in previous studies but missed in the present work
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should be investigated for potential TTHA1359-binding sites using FIMO and the
extended TTHA1359-binding motif to identify whether these genes would have been
identified if more FIMO-identified matches were investigated.12,13 Potential regulatory
binding sites for TTHA1359 which were found to overlap predicted core promoter
elements should be examined more closely to identify the potential regulatory roles of
these sites. This might be accomplished by obtaining the TTHA1359-inactivated and
wild-type T. thermophilus HB8 gene expression levels collected previously for genes
downstream of these sites to provide insight into their potential regulatory roles.12,13
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APPENDIX A: OLIGONUCLEOTIDES
Table A1. Oligonucleotides
Name

Sequence

Length

Purification

Application

ST2R24

CTAGGAATTCGTGCAGAGGTGAATNNNNNNNNNNNNNNNNNNNNNNNNTTACCATCCCTCCAGAAGCTTGGAC

73

PAGE

Selection Template ST2R24 Precursor

ST2L

CTAGGAATTCGTGCAGAGGTGAAT

24

Desalt

PCR Primer

ST2Ls

CTAGGAATTCGTGCAGAGGTGA

22

Desalt

PCR Primer

IRD7_ST2R

/5IRD700/GTCCAAGCTTCTGGAGGGATGGTAA

25

HPLC

5’-labeled IRDye700 PCR Primer

A_BC06_ST2R

CCATCTCATCCCTGCGTGTCTCCGACTCAGCTGCAAGTTCGATGTCCAAGCTTCTGGAGGGATG

64

PAGE

Fusion PCR Primer

trP1_ST2L

CCTCTCTATGGGCAGTCGGTGATCTAGGAATTCGTGCAGAGGTGA

45

PAGE

Fusion PCR Primer

A_uni

CCATCTCATCCCTGCGTG

18

Desalt

PCR Primer

trP1_uni

CCTCTCTATGGGCAGTCGG

19

Desalt

PCR primer

Bio_ST2R

/5BiodT/GTCCAAGCTTCTGGAGGGATG

22

HPLC

5’-biotinylated PCR primer

ST2_1359_ctrl

CTAGGAATTCGTGCAGAGGTGAATACGAAAAACACACACCATCCCTCCAGAAGCTTGGAC

60

Desalt

TTHA1359 Control Probe Precursor

ST2_1359_con_wt

GGAATTCGTGCAGAGGTGAATTGTGACACACATCACAATCATCCCTCCAGAAGCTTGG

58

Desalt

Wild-type TTHA1359 Consensus Probe Precursor

ST2_1359_con_p1

GGAATTCGTGCAGAGGTGACTTGTGACACACATCACAATCATCCCTCCAGAAGCTTGG

58

Desalt

TTHA1359 Consensus Position 1 Point Mutation
Probe precursor

ST2_1359_con_p2

GGAATTCGTGCAGAGGTGAAGTGTGACACACATCACAATCATCCCTCCAGAAGCTTGG

58

Desalt

TTHA1359 Consensus Position 2 Point Mutation
Probe Precursor

ST2_1359_con_p3

GGAATTCGTGCAGAGGTGAATGGTGACACACATCACAATCATCCCTCCAGAAGCTTGG

58

Desalt

TTHA1359 Consensus Position 3 Point Mutation
Probe Precursor

ST2_1359_con_p4

GGAATTCGTGCAGAGGTGAATTTTGACACACATCACAATCATCCCTCCAGAAGCTTGG

58

Desalt

TTHA1359 Consensus Position 4 Point Mutation
Probe Precursor

ST2_1359_con_p5

GGAATTCGTGCAGAGGTGAATTGGGACACACATCACAATCATCCCTCCAGAAGCTTGG

58

Desalt

TTHA1359 Consensus Position 5 Point Mutation
Probe Precursor

ST2_1359_con_p6

GGAATTCGTGCAGAGGTGAATTGTTACACACATCACAATCATCCCTCCAGAAGCTTGG

58

Desalt

TTHA1359 Consensus Position 6 Point Mutation
Probe Precursor

ST2_1359_con_p7

GGAATTCGTGCAGAGGTGAATTGTGGCACACATCACAATCATCCCTCCAGAAGCTTGG

58

Desalt

TTHA1359 Consensus Position 7 Point Mutation
Probe Precursor

ST2_1359_con_s5

GGAATTCGTGCAGAGGTGAATTGTGACACACTCACAATCATCCCTCCAGAAGCTTGG

57

Desalt

TTHA1359 Shortened Spacer Consensus Mutation
Probe Precursor

ST2_1359_con_s7

GGAATTCGTGCAGAGGTGAATTGTGACACACACTCACAATCATCCCTCCAGAAGCTTGG

59

Desalt

TTHA1359 Lengthened Spacer Consensus Mutation
Probe Precursor

ST2_CRP_Ec

GGAATTCGTGCAGAGGTGAAATGTGATCTAGATCACATTTCATCCCTCCAGAAGCTTGG

59

Desalt

E. coli CRP Consensus Probe Precursor

Length is reported in nucleotides (nt).
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APPENDIX B: ADDITIONAL BLI ASSOCIATION AND DISSOCIATION STEP RAW DATA PLOTS OF TTHA1359-DNA
BINDING
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Figure B1. Additional BLI association and dissociation step raw data plots of TTHA1359-DNA binding. Graphs depict raw association and
dissociation step data measured during BLI experiments with TTHA1359 and (A) ST2_1359_con_p1, (B) ST2_1359_con_p2, (C)
ST2_1359_con_p3, (D) ST2_1359_con_p4, (E) ST2_1359_con_p5, (F) ST2_1359_con_p6, and (G) ST2_1359_con_p7 biotinylated DNAs.
These DNAs correspond to TTHA1359-binding consensus sequences containing single point mutations at position 1, 2, 3, 4, 5, 6, and 7
respectively. Graphs also depict the raw step data measured during BLI experiments with TTHA1359 and (H) ST2_1359_con_s5 and (I)

ST2_1359_con_s7 biotinylated DNAs. These DNAs correspond to TTHA1359-binding consensus sequences containing 5- and 7-bp spacer
sequences respectively instead of the 6-bp spacer of the wild-type TTHA1359-binding consensus. Dots represent raw data points, and solid lines
depict the calculated best-fit lines for these raw data points. Line colors pink, green, orange, and blue indicate different concentrations of
TTHA1359 protein corresponding to 5.7, 17, 51, and 153 nM TTHA1359 dimer.
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APPENDIX C: BIOINFORMATICALLY CHARACTERIZED TTHA1359-BINDING
SITES WITHIN THE T. THERMOPHILUS HB8 GENOME EXCLUDED FROM
ANALYSIS
1. Chromosome, compl. (917451...917992); TTHA0974

13. Chromosome, compl. (612877...613418); TTHA0644

GGAGGCGGCCCTCCTCGAGGCCCTGGCCCGCTTCCTCTACGGCACGGGCCTCCGCATCTCCG
AGGCCCTCTCCCTGAAGGGGCGGAACGTGGTCCTCGAGGGAGGAAGCCCCGTGGCGGTGCGG
GTGGTGGGCAAGGGGAACAAGGAAAGGCTCGTGCCGCTCTCCAAGACGGCCCGGGAGGTCCT
GGAGGCCTTGGGACGGCCGCAGGGAAATGTGAACATATTCACTTTCTCGCAGGGGCGGCGCA
AAGGCCACGTCCCCTCGGCCCGCTGGGTGGAGGCCAAGTTCCGGGAGGCCGCCCTCAGGGCG
GGCCTGGACCCCAGGCGCTTCACCCCCCACAAGCTCCGCCACGCCTACGCCACCCTCCTCGT
GGAGCGGGGCGTGGAGCTGGACGCGGTAAAGGACCTCCTGGGGCACGAGTCCATCGCCACCA
CCCAGATCTACCTCCACGCCTCCCGGGAGCGCCTTCGGGAGGCGGCCTCGAGGCTCCCCGAG
CTCTGAACCCCGCCCCAAGCGGGCTTGGGCCGGCGTGGAGGTTCCG

CATAGCCACAGGCCTGCACCTGTACTCGTTAGTAAGCGGATTTGAGGGATTTTATCCCCTAG
CCTCGGGGGCAGACGATCGCTTTTATCATTGGGCTGCCGTTTCCCTAGTCCAATCAGGGACC
CCAGAAAATCTTCCGAACGCCTATCCTTATCTCCTCGCTTGGATTTACCAATTCGTGGGACC
GTCCTTGATGTGGGGGAAAATCGTCAATGTCCTTTTAAGCTCAATTGCAGTCTACTATGGGG
TGCTCCTGGCCTACGAGCTTTCCAGGGCAAAGGCCAGGTTGTGGCGGCTTTCCTCCGCTCCA
AACCTGGCGGGCCTTCTTCTCGTCGCCTATCCTTCGGGTTTGTTTTATGGTGGCCAGCTCCT
CAAGGATCCGGCAGTCTTGGCTTTGGGGATGGCCTCTCTTTACTGGTCTGCAAAACTACTTT
GGAAACCCCGCTTAAGGGAAACTATTTTCCTCGTCATAGGGCTGGTAGGGCTTTACCAGTTT
AGAGGATATGCATCTGTAGCCTTGCTGGGAGCACTTTCGGTATATG

3. Miniplasmid pTT8 (1293...1834); TTHC001

15. Chromosome (1507570...1508111); TTHA1584

GGCACAAACCCCAAAAATGTGCCCCAAGCTGGTGGCTATCAGGGTATACAGGCGGGGGTGCG
GGGGTGCAACCCCCGCCAGCCCCGAAGGGGCTGTATTGGAGAACCTAGAGAGTCTCCTTAGC
GTAGTTGACGGCTAAAGTCCCCCTTCTTTTTCCTGGAAGCCGCAAAAATTTTGTTTTTCTTG
GGGTAGACACCTTGAGATCCGAGAGAAAGTGAGATAACTCACATATTTACCCCGCCCGCACG
CAATTTTCATCGTCCAGGACGGCAAAAACACTGATTTTCCCCCTCGAGGACCGCCCCTAAAA
CGGCTTTTAAGGCGGGGGGTGGGCGGGGGGCACCAATCCCACCCCTCCCCCCGCCCCCCGGC
CTTCTAGGGGCCTTAGGACGGGTGAGAGGGTCCTTCTGGGGGCAGGGTCCGGAGCCCGCTCT
GGCCCGGGGGCTGGACCGGCCCTCGGGCGCTCAAGCGTAGACAGGGAGAACCCCTCCATAGC
CGGCCTGGGTTACGGGGCGCTCACCAGAGCCTTGGCGCGCTTCTTC

GAGCTTAACCCACTTCCAGACTTGTACGACCACTATTGGAAGCCCAACGGGAACACCCTTCA
CTTTCCAGATTTTGAAACTTTCTTCGACCAGTGGTGGGAGAAGCGCCTCCGGCCCCTAAACG
AGTTTATTCGCAAGTATTTTTGGGGATGTTCCTATGAATTTGTCCGTCTCGGCTTAGAAGCG
AGGCTCTACCGGACCGCTGTTTCCATTTGGACGCAATTTCACTTTTGCTATCGCTGGAACGC
CTCTTGTCAACTTCGCTTGACGGCCACCTGGGAGTTGGACGCCCAGGGGATAGATGCACAAA
TTCAAGCAGAAGACCGCCTGATAGGCATTCAGATAAAAAAGGAAACCTATCGCTCGGAAGCC
CGGGAGGGAAACCGCTTCCTAAGAAGGCGCGAACATTCCGCCCTCCTGGAAGTTCCCTACAC
GCTGCAAAGCCCAGAGGAACTCGAAAGAAAAGCCCAGCGTGCCCGAACCAGAGAAGAAGCCT
ACCGCTTGTGGGTCAAAATCGCCCACCATCTAGAACGGCTTCCCAA

5. Chromosome, compl. (808810...809351); TTHA0843

16. Megaplasmid, compl. (249070...249611); TTHB244 and TTHB243

GGACATCAACTACCGCAAGGTGGCCCTCTACGGCTCGGACTCCGACCCCCGGGCCTTCAACT
TTGACGGGGAGCTCAACATCGCCAACCGGGGGATCGTGGAGTTCATTGAGATCCTCAAGCTG
GACGTGGCCTTCCTCTACGATCTCCTCACCGCAAGCCAAGAGCACAAGATCAAGTCCAAGAA
GTTCGCCCAGACGGACATAGACGAAATTGTGCTGGGCCACACAAATGAGCCTGAATACAGAA
AACTCCAGGCCAACGAGTACATGGAGGCCCTGCGGGACCGCACCATCAAGATTGACGTCCCC
TACATCCTCCGGGTCTCCGACGAGGTGAGGATCTACCAGAGGGACTTCGCCAAGGTGCGGGG
CAAGCACATCGCCCCCCACACCCTGGAGATGGCCGCCACCTGGGCCGTGCTCACCCGCCTCG
AGCCCCCGAAGCGGGCGGGCCTCACCCTCATGCAGAAGCTCAAGCTCTACGACGGCAAGCTC
CTCCCCGGCTGGACGGAGGAGGCGGTGAGGGAGCTCATGGGGGAGG

CCCAGGAGGGGCTGGAGATCGCCTTTGAGGAGCGGGCGGGGGTGCCCCTCCTGAAGGGGGCC
CTGGCCCAGGTGGCGGCCCGGGTGGTGGCGGTCTACCCCGGGGGGGACCACACCCTCTTCCT
GGGGGAGGTGGAGTACCTCTCCTGGCGGGAAGGGAGGCCCCTCCTCTACTACGCGGGCCGGT
ACGGCCGGCTGGGAGAGTGGGGTTAAATGTGGCTTAGGGCGCAAAAGGAGGTGAGGAAGCGG
CCATGATGAGGCCATGGAAAAGGGCTGGGACCTTTCCCCTCCCCGCTGCGACCTCTGCGGGC
GGGCCCTCACCTGGCGGGAAGGGCGGGACCACCTCTACTACTACACCGCCGCGGGGCACACG
GGGCTCCTTATGGTCTGCTCCCGCTGCCGTGCGGAGGCGGAGGAGCTTCTTCCCCCCAACCT
GCACAGGGCCCTTCCTCCCTGGGGGGGCCTGGCCTACCTCTACAGCCGCAGGCGGGCCTGAG
AGGGGGTGGGGCTAGTGGGGGCCTGGGTCCTCCTGGCCCTCTTAGC

7. Chromosome, compl. (752303...752844); TTHA0785 and TTHA0784

18. Chromosome (1718740...1719281); TTHA1836

TCCTCGCCATGGTCCCGGCAAGCCTGGTGGGCGCCCACACCCACCTGCGCCTGGGGAACGTG
GACCAGGACCTCGCCCTAGGCCTCGTGCCCGGGGTCCTGGTGGGCACCTTCCTAGGGGGGGA
GCTCGCCCACGTCCTCCCGGAAGGCGCCTTGCGGCTCGTCTTCGCCGCCGTGCTCGTCTGGA
CGGGGTGGCGGTACGCCCGTCCGGGAAGGTAACTTCAAACACTTTCTCGCGGGCTCAAACGG
CTCCACGGGGAAAGTGGGTGAAGGCCTATGCGGAAGTGGCAGGACTGGGCCAACCTGGTCTT
GGGCCTTTGGCTCGTCCTCTCCCCCTGGATCCTGGGGTTCAGCGGCACGTCCAGCGCCACCT
GGAACGCGGTCATCCTCGGGCTCCTGGTGGGCCTCCTCGCCCTGAGCGTGGCCCGCGAGAAG
CCCAAGACGGCCTAACCCCGCGCCCGGGCTCCCCGCCCGAGGCCCTCCTCGGGCGGGGTTCC
CCTTGCCGGGACGGGGCAGGGGGTGTAAGGTAGGGGTGGCCTTTAA

CGGCTGGCAGGTGGCCGCCGACGCCAACCTGGCCTGGCAGACCTACCCCGACCAGTCCCTCT
ATCCCTACAACTCCGTGCCCCAGATCGTGAAGCGCATCAACAACGCCCTCATGCGGGCCGAC
CAGGTGGAGCGGATTGAAGGCCGGGTGACCCGGGACTGGTACGTGCCCATCGTGGCCGACGC
CGAGGCGGGCTTCGGCGGGGCCCTCAACGTGTTTGAGCTCACCAAGGCCATGATTGAGGCAG
GGGCCGCCGGGATCCACTACGAGGACCAGCTCGCCAGCGAGAAGAAGTGCGGCCACCTGGGC
GGCAAGGTCCTGGTGCCCACGGGCCAGCACATCCGCACCCTCCAGGCGGCCAGGCTCGCCGC
GGACGTGATGGGCGTGCCCACGGTGATCATCGCCCGCACCGACGCCGAGGCCGCCACCCTCA
TCACCAGCGACATTGACGAGCGGGACAAGCCCTTCATCCTCCCGGACGAGCGCACACCCGAG
GGCTTCTACCGCTTCAAGAACGGGATTGAGGCCGGCATCGCCCGGG

11. Chromosome (932321....932862); TTHA0987 and TTHA0988

19. Chromosome, compl. (890582...891123); TTHA0943 and TTHA0942

CCAACGGCGGCGCCATCGCCCTGGGCCACCCCCTGGGGGCCTCCGGGGCCCGCATCCTCACC
ACCCTGGTCCACGAGATGCGGCGGCGAAAGGTCCAGTTCGGCCTCGCCACCATGTGCATCGG
CGTGGGCCAGGGCATCGCCGTGGTGGTGGAGGGGATGGGCTGAGTCTTAGGCCCCTCCCCGG
GGGCTGAAGGGGGTTCTTTGGCCATCTTGTACTTTTATTCACGATTTCACCCACTCGTGAAG
TGTATCTCCACACCAGGCCGGGCCTGCCCCAGGAGCCAGAGGTCCCGGGGGTCCACCAGGGC
GGGCTTGGCGTACCCCCCGAGGCTCCCCTTGTCGGCGAGGAGCACCAGGGGCCTCCCCGAGG
GGGGCACCTGGACCCCGCCGAGGGGGGTGGGCTCGGAAAGCCCCTCCCCGCCAGGGACCTCC
GGCCCCAAAAGCTCCACCCCCACCCGGTCCGCCCGCGCTACCCGGAAGGGGCCGGAGCAAAG
GGCCCTAAAGGCCTCCCCCGCAAACTGGGGCCCGGGGAGGAGGCGG

CCAGTTAACGGTAAGGGCCTTTGTCCTTGGCCTAAACGGGGGGCTGTATGCCGCCGCGGTGC
TCCTAGTGCTCTACTGGGTGAGCGGCATTTCCTTCCAACCCTCCTGGTGGTGGCCGCTTGGT
GTGTTGGCCTTCTTTCCAATAAACCTCGGCTTAGCTTTCCTCATGGGATCCTTGGGACTTCT
CTTTAGGCGGGTAGATAACCTTTTTATTGTGCTCAATTTCATACTGCTCCCCTACTTTCTTT
CCCTCACCCAATGGCAGCCCTACATGGCCTACCTCCCCTTCGCCCCAGGGGCCCACCTGGTG
CGGCTTGGGCTCACGGGCGGGGAGTTTGACCGGGAGATCTTCCTCCTGGCCCTCCTCCAGGG
CCTCCTCCTCTTCGGGGCGGGCCTTTGGGCCATGGCCTACATGTACCGCCTAGTCCGCAGGC
GGGGTATATTGGGGAGGTTCTAGGGGGCATGGTGCTCTGGCAGCTCTGGAGCGAAATCCTTC
TTGACTGGAGCCTTACCAAGCGCTACTGGTTTGACACCCTGGCGGG

12. Chromosome (871545...872086); TTHA0910 and TTHA0911

20. Chromosome (32491...33032); TTHA0030

ACACCATCTACTTCGGCGAGTGGACCCCCAAGGAGCCCGAGGAGCCCCGCCCGGAGAGGACC
CGGGCCCGCAAAAAGCGGCGCCGCTAAGGCTTCCGCAAGCCCCTGGGGGGGCTGGCAGCGCT
CCAGGCCCAGCGCCTGGAGGCTGCCCTCTTGGGACGGGGGCGCTGCGCCCCCTTTTACTTCT
GGCGGTAGAGCGGGCCTTTGCTATACTTGTCAGCAAAATTACGATGCAACTGGCTTTCTTTG
GGCTTTGAAAAACAAAGCTCAGTCCGGTAGCCCCTTCCTCGCCGAAATTTTGACCTGGCCCA
ACGTTGCGGTGTGTGCTATACTCCCCCTAACCCGGACCTCCGGGTGGGGACCTTGAAAGCCA
GTTTTTCCCTTGCGGAAGGCGAATATGCGCTTTTTCTTTTCATCGCCCCTTCCTCCTGTGGC
TTTGCATCGGCATAAACCCCCGAAAACCCCCGTTATTCGCCGTGTGCATATTCCAAGCTTCA
TCTTTCTCACAAACCCCCCTCTGGCGGCGCCGTCCAGGACGGGGTT

CATGTGCCCGTTGCCCGACGGTAGGGTGCTCATTTCCGAATTCTGGGGCAACCGCATACGAG
AGATTTCCGCAGGAGGTGAGGCCGAAAAGGCCCCTGTCTTTTTGGATGGTCTAATTCGGCCC
TACAGCCTAGCGGCTCTAGGGAAGGTGCACGTAAGAATTTTTGCCGTGGCTTCCAAGGAACC
CACGGCCTTTCGTGATGTTGCAGGGGCTGTGTACGAAATTACAACTGGCACTCCAGAAATCT
TCATTGATCAAATACCAACTCATCGCTCACCTGGTCTAGAAGGTCTAGCCCCCAGTTGGTCT
TGGAAAAGCGAGGACTGGTCGGCGTATGCCAGCGGGTGTAGCAAAACTTCTTGGATAGACGA
TGGAGGGGGAGGTGGAGGCGGCGGAGGAAAGCTTCTAGCTATAGCTGCAAGCAGCTTAGGCA
GGGTTTTGCTCTACCCTGTTGGCGAAGGAAAGAAGGACCTTCTTTCCGTAGCTCTTAATTAC
ACGCTAGCCTTGGATGTTGGCGAAATGGGGGGCATCAAAACCCATC
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21a. Chromosome, compl. (1622223...1622764); TTHA1730 and TTHA1729

27. Chromosome, compl. (455872...456413); TTHA0486

GCCCAGGTAGACCAGGAAGGCCAAAAGGGCCAGGAAGAGGAGCATGTTGAAAAGCCCGAAGA
AGCCTCCGAAGCCGCCCATTCCACCCCAACCCATCATGCCCATCGTTCACCTCCACCTATAC
CCTAGCCCGGTATTGTTAAGCTTGCGTAAAGCGCGCTTAGTCCGGGCTTACCGGGGCCGGAG
TATGGTGGAGGCGTGCTTTGGCGAAAACGTCTTTTTGCCCACCTTTACCCCGGCCTTTCCGC
CCGGCACGAGGCGTTGGTGGCGGAAAGGAAGCGGGCCCTTTTTCGGGAGGCCCTTAGGCGGG
CGCGGCCGGAAAGGGTTCTGGAGATCGGTCCCGGGCCCGGAACCAATCTGGCCCACCTGCCC
GAGGGGGTGGCGTACCTGGCCCTCGAGCCCAACCCTTTCTTCCACCCCCGCCTAAGGGAGGA
GGCGAGGAAGCGGGGCCTCGCCCTTACCCTGCTCCCCGGGCGGGCCGAGGCCATTCCCCTCC
CCGGGGGAAGCGTGGACCTGGTGGTGGCCACCCTGGTCCTCTGCTC

CGCCGCCCTCTCCGGGGCGGGCTGGATCGGGAAAAGCGGCTACTTCCTCTCCCAAGCCTTCG
GGGTCCACGCCTTTATCGGCGTCCTCCTCACCCCCCTGGAGGTGGAGGCCGCCCCCCTCCAC
CCTAGCCGCTGCGGCCGCTGCGCCCGCTGCCTTTCCGCCTGCCCCACGGAAGCCCTCCTCGG
GGACGGCACCCTGGACGCCCGTGCCTGCGTGAGCTACCTCACCATTGAGCACAAGGGCCCCA
TCCCCCCCTCCCTCTGGCCGGGAATCGGGGACTGGCTTTTCGGCTGCGACCTCTGCGGGGAA
GCCTGCCCCTGGGAGAGGTTCGGCAAGGTCTGGAAGGCCTTAAGGCCCGAGCCCGAGCTCGC
CCACCCGGACCTCCTGGACTTCTTCCGCCTCTCGGGGCGGGCCTTCGGGAGGAAGTACGCGG
GCACCGCCTTCCTCCGGGCGGGAAGGGCCCGCATGGCCCGGAACGCCCTCATCGTCCTCTTC
AACCTGGGCCTGGGGGAGGCCCTCTTCCTGGAGGCGACCCGGGACC

21b. Chromosome (1622322...1622864); TTHA1729 and TTHA1730

28. Chromosome, compl. (326070...326611); TTHA0345 and TTHA0344

TTCCTCGCCTCCTCCCTTAGGCGGGGGTGGAAGAAAGGGTTGGGCTCGAGGGCCAGGTACGC
CACCCCCTCGGGCAGGTGGGCCAGATTGGTTCCGGGCCCGGGACCGATCTCCAGAACCCTTT
CCGGCCGCGCCCGCCTAAGGGCCTCCCGAAAAAGGGCCCGCTTCCTTTCCGCCACCAACGCC
TCGTGCCGGGCGGAAAGGCCGGGGTAAAGGTGGGCAAAAAGACGTTTTCGCCAAAGCACGCC
TCCACCATACTCCGGCCCCGGTAAGCCCGGACTAAGCGCGCTTTACGCAAGCTTAACAATAC
CGGGCTAGGGTATAGGTGGAGGTGAACGATGGGCATGATGGGTTGGGGTGGAATGGGCGGCT
TCGGAGGCTTCTTCGGGCTTTTCAACATGCTCCTCTTCCTGGCCCTTTTGGCCTTCCTGGTC
TACCTGGGCTTCAGGGCCCTGGAGCGGTGGGAGGGCCGCAAGGGAAAGGACGAGGCCTTGGA
AGCCCTTAGGCTCCGCTACGCTAAAGGAGAGCTGGCCGAGGAGACCT

GGCCCGGGACGTCCTGGAGCAGGGCGGGCGGGAGATCCTCGCCCAAATCCGATAGGTTTACT
GGAGTTTTGCTCCCCCGTGGGGTATAGTGGGGGTGATGGCGCTGAAGCGTCTTACCCGCCAG
CGCAAGGCCATCCTCGAGGTGGTGCGGCAGGCCCGGCACCACCCGGACGCCGCCTGGATCTA
CCAGGAGGTGCGCAAGCGGGTGCCCAAGGTGAGCCTAGGCACCATCTACCGCAACCTCGAGG
CCTTGGTGGCCGAAGGCTACCTCGTCCCCATCACCAAGGCGGGGGAGGCCACCCGCTACGAC
GCCAACCTCCACCCCCACCACCACCTGGTCTGTGAGGCCTGCGGGGCCATCGTGGACCTGGA
GGTGGACCTCCCCGACCTCCGCGCCCTCGCCCGGGAGGCCCACCCCGGGGTGGAGGTGCGGG
AGGCCGAGGTGACCTTCAAGGGGCTCTGCCCCGCCTGCAAGGCCGCCCTCAAGGGCTAGATG
GACCCCCTCTCCTGGCTCTACGCCCGGCAGGGCCGCTTTGCCCCGG

22. Chromosome, compl. (884821...885362); TTHA0937 and TTHA0936

29a. Chromosome, compl. (1464682...1465223); TTHA1538 and TTHA1537

CGCGCCCACGAGGTTCTGGAAGGAGGAGAGGCCCTACCGGGCTTCCGGTTGCCCTTGGAGGC
CCTTTTCGGCCAGTAAGCCTGGGGAGCGCACTTTAGGTGCGCCAGTTGCGCATTATGTCGGG
GGCTTGGGGAGAGCGTTCGGGCTGTCTAGTTACTATCAGTCTTATAAGTGATGCTCAACTGT
CAACAATACACTTGACATTAGGCCAACAGTAACCCATCATGCACTTATGAGAGCGCCCTTGG
CCCGGACCCCGGTCCTGCGGGACCTCATGCGCACCGATCTCGTGGTGGTAGGGCCCCAGGTG
CCCCTGGGGCAGGCCCACCGCCTTCTGGTCCAGACGGGGGTGCGCTACCTGCCCGTGGTGGA
CGGGGGCCGTTACCGGGGCATGGTGGGGGAGAGGTACCTCCGCCCCTTCCTCGCCCCTTGGG
CCCCCGCTTCGGTGCAGGCCCAGTGGGAAGCTCCTGTGGCCCGCTTCCTCCAGGAGTTCCCC
AAAGCCCACCCGGAGGAGTCTCCCGAGGAGGCGGCCTTCCGCATGG

CCTCCTCCACGAAGCCCAGGATGGGGTTGTGGTCGGGGGTCATCTCGTAGTAGCCCCACCAG
CTGGCCCTTCGGTCCAGGGAAAGCCCCTCCAGGAAGGGGAAGCGGGCGAGGCCCGCCTCGAG
GGTGGGCCCAAGCCAGCCCCAGTCCATCCCCTCCCGGAAGCCCGGGGGCTCCTCGGGGTTGG
AGCGGCCGAAGAGGAGGTGCAAACAGTTGGGAAATAGCGCACATTACTTCACCCCAACGCTC
GTACGTCCCCGCTTCCCGCCACCTCACCCCAGCGAGCCCCCGCGACATACGAAAAGCCCCGA
AGCGCTATACTCCCCCACAGGAGGCCACAGGTGAAGGCCAAGCCTAAGGCCACGCGCAAGCG
TACCTCGCAGAAGAGGGCGAAAGCCTTCACCGGAGTCCAGGCTCTTCTCCTCTTCCCTTCCG
GAGAAGACCACAAGGCCACCCTGGACCTCATGCGCCGCTTCTCCGCCGCCCCGCGCTACGCC
TACAACCGCTTGCTTGAGGGATGGAGCCGGGAAGCCCTCAAACGGG

23. Chromosome, compl. (891012...891553); TTHA0943

29b. Chromosome (1464782...1465323); TTHA1537 and TTHA1538

CAATTGTGGGCAGAATTCGGGCTGCGTCCACAACACCAAGCTTTGGTAGCTGAGGCCTAGGT
AAGGAGGCCAAGGTAGCCTGCGCAGCGAAGAAGTCAAGGCACCTTGGCCTCACACTCCGGAA
TAAAGCGATGAACCGGTTCCAGTGGTTGGCCGAAGTAAGGTTGATGTTGGAGCACTACAAGC
TATATTGGCTCAACTTCCTCTCCGGAATGTTGGCAGATGTACTGTTTTTCTATGCCATCTTA
ATCGGCTTGAAAAGCGTAACGAAGACATCTTTATCAGACCTAGACCTAGGCTCTCTGCTCGC
CTTATACGGTGTCTCCGAATTCGCAGGGGCCCTTTGGCGAACATTTGCTTTGAATATTTTGA
ACGAGAGCATGCTTGGGACCATAGAGCACCTCTCTCTAGCAAGAGGAGGGCTACTTACCCAG
TTAACGGTAAGGGCCTTTGTCCTTGGCCTAAACGGGGGGCTGTATGCCGCCGCGGTGCTCCT
AGTGCTCTACTGGGTGAGCGGCATTTCCTTCCAACCCTCCTGGTGG

GTCTTCTCCGGAAGGGAAGAGGAGAAGAGCCTGGACTCCGGTGAAGGCTTTCGCCCTCTTCT
GCGAGGTACGCTTGCGCGTGGCCTTAGGCTTGGCCTTCACCTGTGGCCTCCTGTGGGGGAGT
ATAGCGCTTCGGGGCTTTTCGTATGTCGCGGGGGCTCGCTGGGGTGAGGTGGCGGGAAGCGG
GGACGTACGAGCGTTGGGGTGAAGTAATGTGCGCTATTTCCCAACTGTTTGCACCTCCTCTT
CGGCCGCTCCAACCCCGAGGAGCCCCCGGGCTTCCGGGAGGGGATGGACTGGGGCTGGCTTG
GGCCCACCCTCGAGGCGGGCCTCGCCCGCTTCCCCTTCCTGGAGGGGCTTTCCCTGGACCGA
AGGGCCAGCTGGTGGGGCTACTACGAGATGACCCCCGACCACAACCCCATCCTGGGCTTCGT
GGAGGAGGGGCTTCTCGTGGCCGCGGGCTTCTCGGGGCACGGGGTGCAGCAGGCGGCCATGG
TAGGCCGCCTCATGGCGGAGGAGGTGGCCTTCGGAAAGGCGCAAAG

24. Chromosome (1161778...1162319); TTHA1222 and TTHA1223

30. Megaplasmid, compl. (100927...101468); TTHB114 and TTHB113

GGAGCTCCTTATTGTGATGGTCTTGCTGGGCCTCTTCCTGACTCTCTCCTATTTCCCTACGG
CTACAGCCCGTAAAAAGGCTAACCTCGCGGCCGGGCAAAGCTACGTCCGGAACGTGGCCCTA
GCCCTGGAAGCCCAGCGGGACCCCTCCACGGGAGCCCTCCCCACCCATCTTACCGATTGCCT
GAGTGGCTTTGGCCAGCGCCCCAAGACTGTAACGGCGTGCACCATCACCTATCTCAATGCCC
TGGACTACGTTATAGAGGCTTCACTAGACGGGGCCGCGCTAAAAAAAGTGGTTTACAAGAGC
TCAGACGGAACGCTTACAAGTCTTCCGTAAGCCATGGGTTGGACGGGGGAGAGTCTACCCAC
TGGAGCAGGAAGCCCCGGTGAAGCACGAGCTGGTGGAAGGCTTCCCCCACGCCATGGCCACA
GCGGGCGACCGGGCGGCGCTGAACCTGGCCCTTCCGGGCCTGGATAGGGCGCCGCCCTTCCC
CACCCCCCGCCCCCAACCTGTGCTACCTTGAGGGCAATGACCACGG

GCCGCGCCCTTGGGGGAGGAGGCCACCTTTCACTTCCACGTGGAGTTCTACCCCCCGAGGCG
CACCCGGGACAAGCTCAAATTCCTGGCGGGGACGGAGCTCGGGGCGGGGACGTTCGTGGTGG
ACGCCCTGCCCGAGGAGACCGCGAAGGCCCTTAGGGCGGCGTTGCCGTGACGGCCAAAGCCC
AGGCGTGGGGCGTCCTGGGGTGGGGACTTTGCCCTAAGGTACAAACCCGTTCTTCGTGAAAC
ATAGAATGCAAAGGGTGAAAGCGGCTCCGAAGGCGCTCCTCCCGTGGCTCGCGTTGCTCAGC
GCCCTGGCGACAGTCGCGGTAAACGCCGCCGCCAACGCCCTTCCCCTGAACGGCCTTAAGAC
CGGGGAGATCTCCGACCGGTTTGCGGTGTACTTCGTCCCGGCGGGGTACGTCTTTGCGGTGT
GGGGCCTGATTTACGTGGGGATCCTGGCGTTCTCCGTTTACCAGCTCCGCCCCGCGGTGAGG
GAGGACCCCAGGCTGGCCGGGGTGCGCCCCTGGTTCCTCGCCTCCA

25. Chromosome, compl. (1173772...1174313); TTHA1237 and TTHA1236

31a. Chromosome, compl. (54213...54754); TTHA0056 and TTHA0055

GCGCCTTCTTCCTCGCCCTGGGGTATGCTCTTAGCCGGAGGAGGTTATGAGGCGGATTGCGG
TGTTGCTCCTGCTCGTCGCGGTGGTGCTCCTCGGGTGGCTTTGGCTTCGGCCCAAGGCGCCT
TCGGGCGCGGGCACCCTTTACTTCCTCAACTGGGCCGACTACATCCCCGAGGAGCTTATCCA
GAAGTTTGAGGCGGAGACCGGGGCCAAGGTGGTCCTGGACACCTTTGAGTCCCCCGAGGCCA
TGCTGGCGAAGCTCAAGGCGGGGGCGGACCAGGAGTTCTCCCTGGTGGTGGCCCCCGACTAC
TACGTCCTGCAGATGGCCCGGGACGGCCTCATCGCCCCCTTGGACAAGGGGAAGCTGAAGAA
CCTCGCCAACCTGGACCCCTTCTTCCTAGACCCTCCCTACGACCCCGGCCTGCAGTACTCCG
TGCCCTACCTCTGGGGCACCACGGGGATCGCCTACCGGGAGGACCTGGTGACGGGCCCCGTG
GACTCCTACGCCGTCTTCTTTGCTCCGGAGGCCCAGGTGGGGCCCT

TGTCCGCCCCGTCTACCCCCTCCGCCAGGGCCAGTCCCGATAAACCTAGGGCCGCGATGCCG
TTGAGGGTTCCTTTCCGCATCCTCCACCCCCTTAGGGCCAAGGGTAGAGGATGGGATGCAAA
ATGTCAATAGATCCTGCGACAAATTGCAATAGCTATCCGAACGTTACAAGAAGACTTGCTGA
CTTATCTTGCTAAGTGTTCCGCGAAAATGGCACGTATGTCACTGATTTATTGAACAAACCTG
CGACCGAGCCCCTCCCTCTTCTCCCCGGACGCCCCGTAAACTGGGCCCCGTGACGTGGGAGG
AGCTGGAGGAACGCCTGGCCCGGGGGCAGGACGAGCGCACCCTCTTCCTGCCCCAGGACATC
TCCCCCGAGGACCTGGCCCGCTACGCCGCGGGCCTCGCCAACCACAAGGGGGGCACCCTCTT
CCTGGGCGTGAGCCCCGAGGGCAAGGTCCTGGGCGCCCAGGACCTCCACCCCCTGCAGGTGA
CCCACGCCCTCTTTGAGCTCACCCAAGGGCTCCTCCTCCCCTACGT

26. Chromosome (1104088...1104629); TTHA1158

31b. Chromosome (54313...54854); TTHA0055 and TTHA0056

GGGCCTGAGGCTCACCCCGGAGCGGGCCGCCTTGAACACCGTCTTCCTCATGGCCCTCCTCA
TCCTCCTGCAGGAGGCCTGGCGGGCCTGGAGGAGCGGGGCGGGGGTGGGTTTCGGGCTCCTC
AAGGGGGGAAGGCTTCTCCTAGAGGGCCTCGAGGCGGGGGCGAGGGGCATGGTGGGCATCGC
CCTGGCCACGGCCTCCGCCGGCGTCATCGTGGGCATCGTCACCATGACGGGCATCGGCTTCG
GGCTCACGGACATCGTGGAGAGGCTTTCCGGGGGGAACCTCCTCTTGGTCCTCCTCCTCGCC
CAGCTCACGAGCCTCCTCCTCGGCATGGGCCTCCCCACCACCGCCAACTACATCGTCATGGC
CTCCTTGGTGGTGCCGGTGATCCTGAACCTGGCGGAGAAGGCGGGGTACGCCGTGCCCCCGG
TGGCGGCCCACATGTTCGCCTTCTACTTCGGCATCATGGCCGACTCCACGCCCCCCGTGGCC
CTCGCCGCCTACGCCGCGAGCGCCATCGCCCGCTCCGACTTCTGGA

CGCCCAGGAAGAGGGTGCCCCCCTTGTGGTTGGCGAGGCCCGCGGCGTAGCGGGCCAGGTCC
TCGGGGGAGATGTCCTGGGGCAGGAAGAGGGTGCGCTCGTCCTGCCCCCGGGCCAGGCGTTC
CTCCAGCTCCTCCCACGTCACGGGGCCCAGTTTACGGGGCGTCCGGGGAGAAGAGGGAGGGG
CTCGGTCGCAGGTTTGTTCAATAAATCAGTGACATACGTGCCATTTTCGCGGAACACTTAGC
AAGATAAGTCAGCAAGTCTTCTTGTAACGTTCGGATAGCTATTGCAATTTGTCGCAGGATCT
ATTGACATTTTGCATCCCATCCTCTACCCTTGGCCCTAAGGGGGTGGAGGATGCGGAAAGGA
ACCCTCAACGGCATCGCGGCCCTAGGTTTATCGGGACTGGCCCTGGCGGAGGGGGTAGACGG
GGCGGACACGGCCTGGATGCTGGTCTCCACGGCCCTGGTCCTCCTCATGACCCCGGCCCTGG
CCTTCTTCTACGGGGGGCTCGTCCGGAGCAAGAACGCCTTGAACAC
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32. Chromosome, compl. (1241025...1241566); TTHA1301

38. Megaplasmid, compl. (171372...171913); TTHB177

CTGGTGCGCTGGATCAACGCCTGGTACGACCCGGCCAAGGCCCGGGAGGCCACGGAGGCCCT
CCTCGCCCAAGGGGCGGACGTCTTCGCCTTCACCGAGGACACCCCCACGGTGATCCAGACCG
CCGCCCGCAAGGGGGCCTATTCCTTCGGCCACTACACCCCCATGCTCAAGTTCGCCCCCGAC
CACGTGGTCTCGGGCCAGATCGTCCACTGGGACGTCATCTACATTGACTTCCTCAAGAAGGT
GAAGGAAGGGGTCTACACCCCCAAGAACCTGGAGAACGTGGACTACTTCTGGCTCCTCCAGC
ACGGGGCCGTGGAGATGGGGGCGGACTACGGCGTCCCCATCAACCCCAAGCACGTTCCCCTG
CTGAAGGCCGCCCAGATGAGCGTGGAGGGCAAGAAGGTTCCGGTCTACGACCGGATCATGTC
CCTTCTTGGGGCGATGAAGCGCCCGAACCCCACCTTTGACCCCTTCACCGGCCCCATCAAGG
ACCGCAAGGGGGTGGTGCGCATCCCCGCCGGGCGCAAGGCGACCCT

TAAACTTGGCCTTGCCCAATAAGGAGGTGGGAGCCATGCGGCGAGCGATCCTGTGGTTTGTG
GCTTTGGCGATAGCCTCGGTCCTGGCCCAGCAGTCCCGGCCTGCCTCGGACCCGCAGGTGGT
GGAGGCGGCGCGGAAAGAAGGGCGCCTCATCATCTACTCCTCCACGGATCAATCCAGCGCCC
AGGCCCTTCTGGACGATTTCCGCAAACTTTATCCCTTTATACAGATTGAATACAATGATCTG
GGTACCCAAGCCATCTACGACCGCTTCGTGAGCGAGACTGCAGCCGGAGCCTCCAGCGCAGA
CCTTCTCTGGTCCAGCGCCATGGAGCTCCAGGTCAAGCTTGCGAGCGAGGGCTACGCCCTGC
CCTACGACTCCCCCGAGGCCAAGAACTGGCCCGCCAACGCCCGCCTGGGGAACCTGGCTTAC
AGCACCACTCTCGAGCCCGCGGTCGTCGTTTACAACAAGCGCTTCCTCAAGCCCGAGGAGGT
GCCCACCACCCGGGAAGGGCTCGCCCGGCTCCTCCAGGAGCCCCGG

33. Chromosome (1732919...1733460); TTHA1848

39. Chromosome (1507126...1507667); TTHA1583 and TTHA1584

GAACGCCGATGCCCCTGCGGAGACGGCCGGGACACAGGATGTCGTCGCGTTCCTTGTGGACA
TGGATCTGAACCTGATCGCGGCCCGCAAGGAAACGCTTAGCATCGCCAACGGAGGGAACTAC
ACGATTACCTTTGCGGCAGGGGACGACAGCTTCACTACAGCCACGCTCCCTGACTTTACGGC
CCCTGCGGGCATGGCCAAGTACTGGATTGTGAGCGGAGCCACGAGCGGCGGAACCGTCTTTC
TGGCCTCCAAGCTGCGTGAGGTTGCGTACTACCAACTTCCTTTCGCCTCGGTCTACGCCTTC
CAGGCCTTTGCGGTCCAGGAGTCCTCCGAGCCTTACGACGAACTTGTGTACCAAGAAACCCG
CGCCGCCAGCGACGGCCCGCCCCCAAGCGTTAACCTTCCCAGTGTTCTAGACGTCACCGTGG
ATGGCAATCCACCCCAAGTTGGAAACCTCAGCCTAGCCGCGGACACGCTACTCTTCGGCCTG
AACCTGGATTGGAGCGTTGACAGCACGCAATATACGATTCAGGCCG

GCCTTTGGATGCCCAAGGAAAGGGCCAAGGAGCTTAGGGACTTCTACGCCACGCCCCACTTG
GTGGTGGCCCACACTAAGGGCACCAAGGTGGTAGCCGCTTGGGACGAGAAGGCCTACCCGTG
GAGAGAAGAGTTCCACCTTCTGCCCAAGGAGGGTGTGGAACTAGACCCCTTGTTTCTGGTAG
AGTGGTTAAACTCCGATAAGATACAAGAGTATGTCAAAACCCTTTACAGGGACTTTGTTCCT
CACTTGACGCTTAGAATGTTGGAGCGGATACCTGCGTTGCTTCCCCGAAAGGGGAACACCGA
GAGGAGGAAACATGGCCCCTACACAAGCCCAGAAAGTGCTGGAAGCTTTTGAGGATTTTCTG
AAGTGTTTGGACCTCGAGAGCTACCAAGAAAAATACCGCCCCATCAAAACAGTAGAGCAAGA
CCTACCTAGAGAGCTTAACCCACTTCCAGACTTGTACGACCACTATTGGAAGCCCAACGGGA
ACACCCTTCACTTTCCAGATTTTGAAACTTTCTTCGACCAGTGGTG

34a. Chromosome, compl. (1292149...1292690); TTHA1352

41. Chromosome (83523...84064); TTHA0083 and TTHA0084

GGCGGACGACCACGCCCTTTTCCGCCAGGGGCTGAAAAGCCTCCTGGAGGCCGAGGGGGACT
TCCGGGTGGTGGGGGAGGCCAAGGACGGATGGGAGGCCATGCGCCACGCCCTGGAGACCAAG
CCCGACGTGATCCTCATGGACATCCAGATGCCGGGCCTGGACGGGGTGCAGGCCACCCAGGC
CATCCTCAAGGAGTGGCCCCAGGCCAAGGTCATCATGCTCACCATGTACCGCCAGGACGCCT
ACGTCTTTGAGGCGGTGAAGGCGGGGGCCCGGGGCTACCTCCTCAAGGACGTGGACGCGAGG
GAGCTGGTGGACGCCATCCGCCGCGTCCACGCAGGGGAGGTGCTTCTGGACGCGGAGCTTGC
CGGGCACATCATCCAGGACTTCCGCGCCAAGAAGGAGGCCAGCCAGCCCCTCCACGCCGAGC
TTTCCGAGCGCGAGGTCCAGATCCTGAGGCTGGTGGCCCAGGGGTACACCAACCAGGAGATC
GCCGCCGAGCTCCAGCTTTCCGAGAAGACGGTGCGCAACCGCCTTT

CTGGGCCTCCCCCCTAGGGTGCGGGCCGAGGAGCTGGACCTCGAGGCCTTCCGCCGGCTGAG
GGAGGGCCTCGAGGGGGCGGTGTAGGCCCGCCTCCCTTCCCTACACCGTCCCTTCTCCTTCT
GTGTAGCCCACCCCCCTTGCGCCCCACCCCGGGGTGATAAGATGGGCGGGAAATGAGGCCGG
CCCCTTTGGGGCTTTGGGGACCGGCTTCGTGAAGAAAGGCACGAAAGGAGGGGACCTTGGCG
CCGATCCAAGAGTACGTGGGCACGCTGATCTACGTGGGGGTGGCCCTCTTTATTGGGGTGGC
GGCCCTTTTGGTGGGGGCCCTCCTCGGCCCCAAGAAGCCGGGGCGGGCCAAGCTCATGCCCT
ACGAGTCGGGGAACGACCCCGCCGGGGAGGTGAAGCGCTTTCCCGTCCACTTCTACGTGGTG
GCCATGCTCTTCATCCTCTTTGACGTGGAGGTGGCCTTCCTCTGGCCCTACGCCGTGAGCGC
GGGCGGGCTTGGCCTCTATGGCTTCCTCGGGGTCCTCGCCTTCACC

34b. Chromosome (1292249...1292790); TTHA1352 and TTHA1353

42a. Chromosome, compl. (290509...291050); TTHA0304 and TTHA0303

CTCGGAAAGCTCGGCGTGGAGGGGCTGGCTGGCCTCCTTCTTGGCGCGGAAGTCCTGGATGA
TGTGCCCGGCAAGCTCCGCGTCCAGAAGCACCTCCCCTGCGTGGACGCGGCGGATGGCGTCC
ACCAGCTCCCTCGCGTCCACGTCCTTGAGGAGGTAGCCCCGGGCCCCCGCCTTCACCGCCTC
AAAGACGTAGGCGTCCTGGCGGTACATGGTGAGCATGATGACCTTGGCCTGGGGCCACTCCT
TGAGGATGGCCTGGGTGGCCTGCACCCCGTCCAGGCCCGGCATCTGGATGTCCATGAGGATC
ACGTCGGGCTTGGTCTCCAGGGCGTGGCGCATGGCCTCCCATCCGTCCTTGGCCTCCCCCAC
CACCCGGAAGTCCCCCTCGGCCTCCAGGAGGCTTTTCAGCCCCTGGCGGAAAAGGGCGTGGT
CGTCCGCCAGAAGAACCCGGATCACCCTTCCATCATAGCGCCAAAGGGGCTAGGGTAGAGGC
GTGCTGACCTTTCGCGTGGAGAAACTGGTGCCCGGGGGGTACGGCC

AGCCCAGGCTCCGCTGGTTGGTGACCCCCATGACCAGGGCCTTTTTGCCCGAAAGGTCCACG
GTGAGCATGGGGGGATTATACCGAAGGCGAAGGGCCCAACACGAAAACGTCTTCCAAGAACT
TCCAAAGCCCAGGGCCGGGCTGAGGCGAGCCACGGGCCCCGGCTTTGGGCCTCGCTCCGTAT
TGGCGGAGGCTTTCTCGGCTAGTTTATAGTGAGGTATGGTCCGGTTGGAAGACTACGGCACC
TGGGACGAGGCCCTAAAGCGGCTCGAGGCGAGCCGCAAGGCCCTCCTCGCCCTGCTTCGGGA
GGCGGACCCCGCTTGGCTTTCCGCCCCCTTGCGGGAGGGGGCCTGGACCCCCCTCATGGTGG
CGGAGCACGTCGCCTTGGTGGAGGACTCCACCGCCCGGGTCCTGAGGCGCTTGAGGCGCCTT
GCGGCCGGGGAGAACCTTCCCCCTGTTCCCGTGAAGCCCGGGGAGTTCAAGGACGGCAAGCC
CCAGGCCCCCGAGGGGGTGCGGCCCAAAGGGGGCCTTTCCCTGGAG

35b. Chromosome (471990...472531); TTHA0506 and TTHA0507

42b. Chromosome (290609...291150); TTHA0303 and TTHA0304

CGGCCTTGTACCGCTCCCAAAGCGCTTGACGCCGCTCCAGGAGGGCCTTGCGCACCGGGTTG
AACTCCCGGTGCAGCGCCACCACGAACCTCAGGGCCTCCTCCGTCAGGACCTCCTTCAGGAG
GGGGTGGTCTTTCCGGATCTCCACGCCCTTCATGGTGGTCCGAGCTTACGGGAGGCGGGGCG
GGATTGTCAAGAAGCAAAAAGATTTTTTGTATCTTGAAAAACAGGGCCGCCCCCGTTACCCT
AAGCGGCATGGCGCGTCCTCGGGAGAAGCCGCCCCAGGCGGTGAAGACCCTGGAGAGGGGGC
TTCGGGTCCTCGAGGCCCTGGCCCAGGCGGGGGAAAGCCCCTTGGGCCCCTTGGCCGAACGG
GTGGGCCTCGCCAAGAGCACCCTCTACCGCCTCCTCAGGGCCCTGGCCCAGGCGGGCTTCGT
GGAGGAGGAGGGCGGGGTCTACCGGGTGGGGCCCAAGGCCTTCGCCGTGGGCCAGGCCTACC
CCAAGCGTTCGCTTTCCCAGGCGGTCCGCCCCGAGATGGAGGCCTT

CCGGCCGCAAGGCGCCTCAAGCGCCTCAGGACCCGGGCGGTGGAGTCCTCCACCAAGGCGAC
GTGCTCCGCCACCATGAGGGGGGTCCAGGCCCCCTCCCGCAAGGGGGCGGAAAGCCAAGCGG
GGTCCGCCTCCCGAAGCAGGGCGAGGAGGGCCTTGCGGCTCGCCTCGAGCCGCTTTAGGGCC
TCGTCCCAGGTGCCGTAGTCTTCCAACCGGACCATACCTCACTATAAACTAGCCGAGAAAGC
CTCCGCCAATACGGAGCGAGGCCCAAAGCCGGGGCCCGTGGCTCGCCTCAGCCCGGCCCTGG
GCTTTGGAAGTTCTTGGAAGACGTTTTCGTGTTGGGCCCTTCGCCTTCGGTATAATCCCCCC
ATGCTCACCGTGGACCTTTCGGGCAAAAAGGCCCTGGTCATGGGGGTCACCAACCAGCGGAG
CCTGGGCTTTGCCATCGCGGCCAAGCTCAAGGAGGCGGGAGCGGAGGTGGCCTTAAGCTACC
AGGCGGAAAGGCTCCGCCCAGAGGCGGAAAAGCTCGCCGAGGCCCT

36a. Chromosome, compl. (550450...550991); TTHA0584 and TTHA0583

43. Chromosome (1075724...1076265); TTHA1134 and TTHA1135

CAGTCCACCCAGGAGAGGCCCGCAGGCTCCAGGAGCCACCTGGAGTCGTCCGCCCCCTGCCA
CTGGGAACAGGCGGCGAGGCCCAAGAAGGGCAGCCACAGGATCTTTTTCACCGTACTCACCC
TGCCTTTCGTGCGGCGCGGGAGCGGAAACCCAGAACGGCCTTCCTTGAGTCGGGATGGCTTA
AGGGTACCCCCGCCCTGCCCGGGGAAAAGGGGGCCAGGGCACTTTTCCGGCTACCATGGAGG
CATGGAGGGCATCCGGCGCGCGGCGCAGCGGGCCGCGGAAGAGTTTCTTCAGGCCTTCCCCA
TGGCGCCCGGGAGCCTCTTCGTCCTCGGGGGCTCCACCAGCGAGGTCCTGGGGGAGAGGGTG
GGGACGAGGCCGAGCCTCGAGGCCGCCCACGCCGTCCTGGAAGGCCTCCTCCCGCCCCTCCT
GGAAAGGGGGGTCCACGTGGCCGTCCAGGCCTGCGAGCACCTGAACCGGGCCCTGGTGGTGG
AGCGGGAGACCGCCCGGGCCTTTGGCCTGGAGGAGGTCGCCGTCTT

CATCGCCTACACCCTGGCCACCCACACCGCCGGGGTCATTCCCGCCGGAAAGCTTGAGCGCG
TGGACCCCACCACGGTAAGGCAGGAAGGCCCCTGGGCCGACCCGGCCCAAGCGGTGGTGCAG
ACCGGCCCCAACCAGTACACGGTCTACGTCCTGGCCTTCGCCTTCGGCTACCAGCCGAACCC
CATTGAGGTGCCCCAAGGGGCGGAGATCGTCTTCAAGATCACGAGCCCGGACGTGATCCACG
GCTTTCACGTGGAGGGCACCAACATCAACGTGGAGGTGCTCCCGGGCGAGGTCTCCACCGTG
CGCTACACCTTCAAAAGGCCCGGGGAGTACCGCATCATCTGCAACCAGTACTGCGGCCTAGG
CCACCAGAACATGTTCGGCACGATCGTGGTGAAGGAGTGAACCATGGCGGTGCGCGCAAGCG
AGATTAGCCGGGTCTACGAGGCCTATCCGGAGAAGAAGGCGACCCTCTACTTCCTGGTCCTG
GGCTTCCTCGCCCTCATCGTGGGGAGCCTCTTCGGCCCCTTCCAGG

37a. Megaplasmid, compl. (79293...79834); TTHB089 and TTHB088

44. Chromosome (1265433...1265974); TTHA1325 and TTHA1326

GACGTCCACCGCCGGGGCGTCGGGGGAGAGGTGGGCCACCCGCACCATGGCGCCTTGGCCCA
GGGCCAGGCCGGCCAGGGCCGCCAGAACCAGAACAAAAAGGCCTCGTTTCATCTTTTCACCT
CCACGGGAAAAGCCTAGAGGGAGGCCTGCCCGTCAAAATGGGCGCAGGCCACATAAACCTCC
CGCCAAGGTAGCCTGGACCACACCCAGGGTGAGGGGGAGCACATTCTCGGGGGACCTTCGGC
CCTAGCATCCTCCCAAAGGAGGTAAGGGCATGGACCGCAGGCGTTTTCTCACCGGTGCGGGG
CTTTTTTTGGCGGCGGGAGGCCTTCCCTTGGGCCGGGCCCAGGGGCGCGCGCCCAAGGGGGT
GAACGGGGGCGGCTTTTACCGCTTCCGGGTAGGGGGGATCCAGGCGGTGGTCCTCTCCGACG
GCCAGTCCCCTCCAGGCCCCCTCCTCCCCAACTGGGGGGCGAACCCGGAGCTCCAGGAGGCC
TTCCGCAGGACGCTCGTGGAGCACTTCCTGGACCCGGAGGCCACCC

AAGAGCTTCGGCTGGGTTCGCTGGCAGGCCACCTTGTACCTGCGCCCTGGGGAACACGAGGT
CATGGCCCGGGCCTGGGACGCCGTGGGCCGCAGCCAGCCCCTGGACGGCAACATCGCCTGGA
ACGAACGGGGTTACGAGTACAACGGGGTCATGCGGGTCAAGTTCACCGTGGCCTAAAGGGCT
TGGCCCCGGCCTTAGGGCCGGGGCCTTTGTGGGCCAGCTCCCTATACCCAGCTAGGGTACGC
CCCACACTGAGACCTGAGATGAAGCGCATCCTTTTACCCCCAGCCCTTCTCCTGGGCCTTGG
CGCCCTCCTGGCCCTGAGCCAGACCACCCTCCCCGAGGGCCCGGGCAAGGAGCTGGTGCTGG
CCAAGTGCCAAACCTGCCACGACATCGGCTTTGTCGCTAGGGAGAGGCTCTCCCGGGAAAGG
TGGGACGTGGTCCTGAGCGAGATGGTCATGCGGGGACTCCAGGTCACCCCCGAGGAGCGCGG
CCGCATCCTGGACTACCTGGCCACCTACCTGGGCACGGAACCCCCG

81

45. Chromosome (508481...509022); TTHA0543 and TTHA0544

52. Chromosome, compl. (495444...495985); TTHA0533 and TTHA0532

GCGCATTGTCCTCAAGCTCAAGCCCCAGCTCGCCCCCATCAAGGTGGCGGTGATCCCCCTGG
TGAAGAACCGCCCGGAGATCACCGAGTACGCCAAGCGCCTCAAGGCCAGGCTCCTCGCCTTG
GGCCTGGGGCGGGTGCTCTACGAGGACACCGGCAACATCGGCAAGGCCTACCGCCGCCACGA
CGAGGTGGGCACGCCCTTCGCCGTCACCGTGGACTACGACACCATCGGCCAGAGCAAGGACG
GCACCACCCGGCTCAAGGACACGGTCACGGTGCGGGACCGGGACACCATGGAGCAGATAAGG
CTCCACGTGGACGAGCTGGAGGGCTTCCTTCGGGAGAGGCTTAGGTGGTAGGCTGGAGGAAC
GATCAGTTCTTGAGGGACCCGAAGTGGCGCAAAACCGGAAGCACTGGAAGGAGGTTCTGGCT
CAGCTGGAGGCGCGAATAGAGGAGCATTGGCGGAAGATCCGGGAAGAGGAAGCTAGACTTCA
ACCCAACTGGGGCGTCATCGCTCACTGGGAGCGGGAGATCCGGGCA

GCCCGAGGGGGTCCGCGGCCGGCAGGTCCTGGACCTGGGGGCGGGCTATGGGGCCCTGACCC
TGCCCCTCGCCCGGATGGGGGCGGAGGTGGTGGGGGTGGAGGACGACCTGGCCTCCGTCCTC
TCCCTGCAAAAGGGCCTCGAGGCCAACGCCCTGAAGGCCCAGGCCCTCCACTCCGACGTGGA
CGAGGCCTTGACAGAAGAGGCCCGGTTTGACATCATAGTTACGAACCCCCCCTTTCACGTGG
GGGGTGCGGTCATTCTGGATGTGGCCCAGGCGTTCGTGAACGTGGCGGCGGCCCGGCTCAGG
CCGGGTGGCGTGTTTTTCCTCGTGTCCAACCCGTTCCTGAAGTACGAGCCTTTGCTGGAGGA
GAAGTTCGGCGCCTTCCAGACCCTCAAGGTGGCCGAATACAAGGTCCTGTTCGCGGAAAAGC
GAGGGAGGTGAGCCTTGAAGAAGAGCAAGCGCAAGAACGCCCAGGCCCAGGAGGCCCAGGAG
ACCGAGGTCCTGGTCCAGGAGGAGGCGGAGGAACTCCCCGAGTTCC

46. Chromosome, compl. (612160...612701); TTHA0644 and TTHA0643

53. Chromosome, (32203...32744); TTHA0030

CGTAGACATTTCTTTGGATTTCTCCAATCCGATAGCTTTCCTGATAAGCTATGCGTACAGCT
TCGCCACAGTTCTATTAGGGCCCCTGCCTTGGCAAGTCAAGAGTCCTATCGTGGCTATCGCC
TTAGTTGAGGCTGTTCCTATGTGGTTTCTTTTAGCAACGGTTTGGCTACGCAACTCTTTTCG
GTGCGCTGATCGAAGGGCAACTTTTTTGGTAATCTTTGTCTTAATTTACATCGGTGGTCTAG
CTCTGATCAGTGACAATATTGGGGCCAACACTCGTTTGCGACTCCTACCGTGGTCCACTCTG
CTTGTTTGGATAGCTCTCCAGCTAGAAATCCAGCTAGAAAGAAGGAGAAAGCATGCGCCTCC
TCTACCTCATCACTCGCGCTGAACCCGGGGGAGCCCAGGTCCACCTCCTGGAACTCCTCCGA
GGCTTCCGGGACCGGGCGGAGCTCCACCTGGGGGTGGGGGAGGACCAAGACGGCTTCCTGGT
GGAGGAAGCCCGCGCCCTGGGGGTGAGGGTCCACCTCCTTAGGCAC

TTCCACGTAACCTCCGCGTAACCTCCCCCCTGCTACCCTGGGGCTAACCCGTAAGGGGGTGA
AGGAGATGCTCAAGGAAGTGCAGGAGGTCAAGGTCGGCGGCCGGACGCGGCGGGTCTACGTG
AGGCCCTTCGCCTGGAACCTGCACGCGCCCACCCACATGGAGTGGACCCCAGACGGCAGGCT
CCTGGTGGTGGAGCGCACCACGGGCAAGGTGAAGGACGTCACCAAGGGTGGGGACATGGAGG
AGGCCAAGCCCTTCGCCTGGGGGCTCCAGGGGCCCTCCAGCATGTGCCCGTTGCCCGACGGT
AGGGTGCTCATTTCCGAATTCTGGGGCAACCGCATACGAGAGATTTCCGCAGGAGGTGAGGC
CGAAAAGGCCCCTGTCTTTTTGGATGGTCTAATTCGGCCCTACAGCCTAGCGGCTCTAGGGA
AGGTGCACGTAAGAATTTTTGCCGTGGCTTCCAAGGAACCCACGGCCTTTCGTGATGTTGCA
GGGGCTGTGTACGAAATTACAACTGGCACTCCAGAAATCTTCATTG

47. Chromosome, compl. (1545917...1546458); TTHA1632

54. Chromosome, (37497...38038); TTHA0036

GCTTTGGCGGGTCTTCTCCTGGGTGCTCTACTACGGGGTCTTGTACCTCGCGGTCTCCGTGG
CCTGGACCTTGGCGGCGGAGGGGATCCGGGCGGGAAGCCTATGGGGCTACCTGGGCTTCGGC
CTCGTCCTGGCCCTCGCCCTTTGGGCCGCCTGGTTCGGGCTTAGGGGGGAGATCCGCCTGGA
CCTGGACGTGGCCATAAGCCGCCTCATTGACTTTATGCTCACCATCCCCACCCTCCCCCTCC
TCTTGGTGCTCTCCGCCCTCCTGCGGGACCCCGAGGTGGCGGTGGGGCGCTGGGCTCAGGGG
GTGTTTGGGGACGCCGCCAGCGTGTTCATCATCATCACCATCCTCGTTTTCTTTGGCTGGCT
GGGGACGGCAAGGCTCGTGCGGGGGAGCATCCTCTCCCTGAGGGAGATGGACTACGCCACCG
CCGCCCAGGCCCTGGGGGCCACGGACTTCCGCATCATGTTCCGCCACCTGGTGCCCAACACC
ATGGCCCCCCTCATCGTCCAGGCCACCTTGCAGGTGGGCCAGGCCA

TTCCACGTAACCTCCGCGTAACCTCCCCCCTGCTACCCTGGGGCTAACCCGTAAGGGGGTGA
AGGAGATGCTCAAGGAAGTGCAGGAGGTCAAGGTCGGCGGCCGGACGCGGCGGGTTCACGTG
AGGCCCTTCGCCTGGAACCTGCACGCGCCCACCCACATGGAGTGGACCCCAGACGGCAGGCT
CCTGGTGGTGGAGCGCACCACGGGCAAGGTGAAGGACGTCACCAAGGGCGGGGACATGGAGG
AGGCTAAGCCCTTCGCCTGGGGGCTCCAGGGGCCCTCCAGCATGTGCCCACTGCCGGATGGT
CGGATCCTGATTACCGAGTTCTGGGGAGGCAGGATTCGGGACATCAGCGTAGGTGGTCCCTC
GGAAAAGTTGGCCATCTACGCTGAGGACTTGAGCAAGCCGTATAGCTTGGCTTTAGATGCTC
TGGGAAGATTGTTAGTAACCGAGCATCTAGGACATGGAGTTGGGCGAATAAGCATACTTGCC
TCGGGAAAGGCCGTACCCTTAGTGCAAGGAGTTCCATCTGTAGAAA

48. Chromosome, (871578 ...872119); TTHA0910

56a. Chromosome, compl. (1332099..1332640); TTHA1399 and TTHA1398

AGCCCGAGGAGCCCCGCCCGGAGAGGACCCGGGCCCGCAAAAAGCGGCGCCGCTAAGGCTTC
CGCAAGCCCCTGGGGGGGCTGGCAGCGCTCCAGGCCCAGCGCCTGGAGGCTGCCCTCTTGGG
ACGGGGGCGCTGCGCCCCCTTTTACTTCTGGCGGTAGAGCGGGCCTTTGCTATACTTGTCAG
CAAAATTACGATGCAACTGGCTTTCTTTGGGCTTTGAAAAACAAAGCTCAGTCCGGTAGCCC
CTTCCTCGCCGAAATTTTGACCTGGCCCAACGTTGCGGTGTGTGCTATACTCCCCCTAACCC
GGACCTCCGGGTGGGGACCTTGAAAGCCAGTTTTTCCCTTGCGGAAGGCGAATATGCGCTTT
TTCTTTTCATCGCCCCTTCCTCCTGTGGCTTTGCATCGGCATAAACCCCCGAAAACCCCCGT
TATTCGCCGTGTGCATATTCCAAGCTTCATCTTTCTCACAAACCCCCCTCTGGCGGCGCCGT
CCAGGACGGGGTTCTTTGGGGGGTACCGTTGCAAGGGATTGAGCCC

CCTTGTGGCCGAGCTCCTGGAACTGGCGCATCTTCCTCAGGACCACCGCGTGGCCCAGGTGC
AGGTCGGGCCTCGTGGGGTCGGCTCCGAGCTTGACCGTGAGGGGCCGCCCCTCCTTGAGCTT
GGCGAGAAGCTCTTCCTCGGGGACGATCTCCTCGGCCCCCCGCTTGAGGAGGGCCAGGGCCT
CTTCCGGGGTGTGGCCGGTGCCCGCCATGTGCCCAAGTATACTTAGGCCAATGCGGACCCTG
CTCTTTCTGGCCCTGGCGGCCCTGGGCCTCTACTGGTACGCCGAGCGGTACGGCCTGGCCGT
GGGCTACCCCCCCTTCCTCCCCGTCTTCTACTGGAAGTACACGGGGGAGGCGGAGTACCCCG
TCCGGGTCACGGGCCTCTACGACGCCTTGAAGGTGAAGGTCTCGGGGAGGCTGGAGGAGGGG
AGGCTCAGGGTCGTCCTGTTGCGGGACGGCCGCAAGGTGGGCGAGCGGACCTACGGCGGCGC
CTTCCAGGACGAGGTGCGCTTCGGCGTGAGCCCCGGGGCGTACCTT

49. Chromosome, compl. (612153...612694); TTHA0644 and TTHA0643

57a. Chromosome, compl. (202704...203245); TTHA0206 and TTHA0205

ATTTCTTTGGATTTCTCCAATCCGATAGCTTTCCTGATAAGCTATGCGTACAGCTTCGCCAC
AGTTCTATTAGGGCCCCTGCCTTGGCAAGTCAAGAGTCCTATCGTGGCTATCGCCTTAGTTG
AGGCTGTTCCTATGTGGTTTCTTTTAGCAACGGTTTGGCTACGCAACTCTTTTCGGTGCGCT
GATCGAAGGGCAACTTTTTTGGTAATCTTTGTCTTAATTTACATCGGTGGTCTAGCTCTGAT
CAGTGACAATATTGGGGCCAACACTCGTTTGCGACTCCTACCGTGGTCCACTCTGCTTGTTT
GGATAGCTCTCCAGCTAGAAATCCAGCTAGAAAGAAGGAGAAAGCATGCGCCTCCTCTACCT
CATCACTCGCGCTGAACCCGGGGGAGCCCAGGTCCACCTCCTGGAACTCCTCCGAGGCTTCC
GGGACCGGGCGGAGCTCCACCTGGGGGTGGGGGAGGACCAAGACGGCTTCCTGGTGGAGGAA
GCCCGCGCCCTGGGGGTGAGGGTCCACCTCCTTAGGCACCTCGTGC

CCACCCGCACCCGGGCCCCGCCTTTCACCAGGCGGGCCACCACCTCGGGCACCAGGGCCACC
CTCCTTTCCCCTGGGGCCCTTTCCTTGGGAACCGCGACGGTCACCATAGGCGCCTCCTTCGG
GGGAAGTATACCAGCGCGGGGTGGGGCGTCCGTCCCCGGGTTTTCCCTTGGGCTACACTACT
TTGACGCTTCCCGGAAGGCTTCCCTTGTGTAAAAATGCGCACCATGCGCCCCCCGGGGTGGA
AGATCGCCGCCGTCCTTCTCGTGGGCATCCTGGCCATAAGCTTCGGGAGCATCCTGGTGCGC
CTGGCCCTTCGGGCCTCCGGGGACCAAAGCCTCGCCTTCAGCCTGGTGATGAGCGCGGGGCG
CCTGGCCTTGGCCGCCCTCCTCCTCGCCCCCGGCTGGACGCGGCCCTTGGAGGGCAGGGCGG
GGCTGCCCTTCGCCTTGGCCGCCGGGGGGTTTCTCGCCCTCCACTTCGCCTTCTGGATCACC
TCCCTCTCCTACACCTCCGTGGCGGCGAGCACCGCCCTCGTCACCA

50. Chromosome, compl. (1021896...1022437); TTHA1074, TTHA1073, TTHA1072
GCGCTTTCCCTCCTTAGGGGCGTCTGGCCCAGGCGGCGCTGGCGGAGGCTTCCCCCGGGGTG
AGGAGGCCTTGCCCTTAGGGGTTCACCCCCTGTACACTAAAAGGTGGCTTGCGCACGGCCAA
GACCGTGCGAAGAAGGAGGCGAACGTGAAGGAAGGCATCCATCCCAAGTTGGTTCCCGCCCG
CATCATCTGCGGTTGCGGCAACGTCATTGAGACCTACTCCACCAAGCCCGAGATCTACGTGG
AGGTCTGCTCCAAGTGCCACCCCTTCTACACGGGGCAGCAGCGCTTCGTGGACACCGAGGGG
CGGGTGGAGCGGTTCCAGCGGCGCTACGGCGACTCTTACCGCAAGGGGCGCTAGGCCCTCTG
GTCTAGGGCGGGGGATGGCCCCGCCCGCTTTCCTTTAGGAGGCGGCGTGGATCGGGTGCTTC
CCTTTCGCTTCGCGGAGGAGGAGGGGGTCTTCTGGCTTTTGGACCAGAGGCGCCTGCCCCAG
GAGGAGGTCTACGTCCCGGTGCGCACCGCCCGGGAGATGGCCCAGG

Figure C1. Bioinformatically characterized potential TTHA1359-binding sites within the T.
thermophilus HB8 genome excluded from analysis. Sequences depict the genomic context of
potential binding sites, -210/+310 bp, identified by FIMO which were excluded from further
analysis. Blue, red, green, and black nucleotides represent genes oriented 5’→ 3’, overlapping
genes oriented 5’→ 3’, genes oriented 5’→ 3’ on the complementary strand, and intergenic
regions respectively. Cyan, yellow, and green highlighting represent predicted core promoter
elements, potential TTHA1359-binding sites, and potential TTHA1359-binding sites overlapping
core promoter elements respectively. Underlined nucleotides indicate translation start sites.
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